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Abstract 
Cordycepin (3഻-deoxyadenosine) is a medicinal bioactive component of the 
caterpillar fungi (Cordyceps and Ophicordyceps). It is reported to have 
nephroprotective, antiapoptotic, anti-metastatic, hepatoprotective (Yue et al. 
2013), inflammatory effects, antioxidant, anti-tumor, immunomodulatory  and 
vasorelaxation activities.  Cordycepin is well known to terminate and inhibit 
polyadenylation, both in vitro and in vivo. Other proposed mechanisms of action of 
cordycepin include activation of adenosine receptors, activation of AMP dependent 
kinase (AMPK) and inhibition of PARP1. 
The purpose of this study is to elucidate the biological and pharmacological effects 
of cordycepin on cancer cell lines such as MCF-7 cells. In this study I found that 
cordycepin reduces the cell proliferation in all examined cell lines without always 
exerting an effect on 4EBP phosphorylation and protein synthesis rates. Therefore, 
the effects on protein synthesis via inhibition of mTOR, which were previously 
reported, are not only the sole reason for the effect of cordycepin on cell 
proliferation. Knockdown of poly (A) polymerases reduces cell proliferation and 
survival, indicating that poly (A) polymerases are potential targets of cordycepin.      
I studied different adenosine analogues and found that 8 aminoadenosine, the only 
one that also consistently inhibits polyadenylation, also reduces levels of P-4EBP.     
It also inhibits the expression of specific genes indicating that the effects on 
polyadenylation, mTOR signalling and gene expression are linked. Also consistent 
with polyadenylation inhibition as the major mode of action is the fact that the 
effects of cordycepin on gene expression are predominantly post-transcriptional.                             
However, knockdown of poly (A) polymerases did not have the same effects on 
gene expression or on polyadenylation, indicating that cordycepin may act as a 
dominant negative rather than as a null mutant. This is consistent with the fact that 
cordycepin is known to arrest a normally transient polyadenylation complex.  
We performed microarray analysis of cordycepin treated MCF-7 cells and found that 
the downregulated mRNAs were predominantly involved in transcriptional 
regulation, cell proliferation, cell cycle and cell migration. These data show that 
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cordycepin is a promising new drug for cancer and indicates that the mode of action 
it is likely to be through the inhibition of polyadenylation.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
iv 
 
Acknowledgements 
Firstly, I would like to thank to my supervisor Dr Cornelia H. de Moor for her great 
support, time, encouragement and co operation throughout my studies. It would 
not be possible for me to finish off my work without her understanding of my 
responsibilities being a mother and a student. I do not have enough words to 
convey my deepest thanks to her.  
I would also like to thank to Keith Spriggs for his advice and guidance during my 
studies and especially to Catherine Jopling for helping me to carry out my radiation 
work safely and efficiently in a friendly manner. I also liked to convey my deepest 
thanks to Anne Willis and her team (MRC Toxicology unit, Leicester) for her support 
in performing microarray analysis for this project.  I would also like to thank to all of 
the past and present members of the RNA biology and gene regulation group, for 
their support and making my time enjoyable during the work particularly Hannah 
Parker, Hughes Alexandra and Andrew Lewis for their support, enjoyable chats and 
help during the work. Special thanks to Alexander Kondrashov for not only helping 
me in experimental work with great experience and expertise over the past three 
years but also for his conceptual guidance. 
I would like to thank to my family especially to my father for being supportive, 
encouraging and for having faith in my capabilities. I would always remain thankful 
to my late grandmother for her kindness, care and love which will always remain in 
my heart. Thanks to University of Nottingham for funding support. Lastly, love to 
my daughters Ayra and Arfa who always reminds me a cheerful and enjoyable face 
of life with her love, hug and endurable smiles which not only gives me strength but 
also boost up my energy after many sleepless nights especially during my final 
stages of research work. 
 
 
 
v 
 
Table of content 
Declaration ........................................................................................................... i 
Abstract ............................................................................................................... ii 
Acknowledgements ............................................................................................. iv 
Table of content .................................................................................................. v 
List of Figures ...................................................................................................... xi 
List of Tables ...................................................................................................... xiii 
List of Abbreviations .......................................................................................... xiv 
1 Introduction ................................................................................................. 1 
1.1 Breast cancer ......................................................................................... 1 
1.1.1 Molecular subtypes of breast cancer ..................................................... 1 
1.1.2 Role of receptors in Breast cancer ......................................................... 2 
1.1.2.1 HER2 ................................................................................................ 2 
1.1.2.2 Hormone receptors......................................................................... 3 
1.1.3 Breast cancer treatment ........................................................................ 3 
1.1.3.1 HER2
+
 treatment ............................................................................. 4 
1.1.3.2 Endocrine therapy .......................................................................... 4 
1.1.3.3 Chemotherapy ................................................................................ 5 
1.1.4 Molecular mechanisms of breast cancer ............................................... 7 
1.1.5 Breast cancer hallmarks ......................................................................... 8 
1.1.5.1 Sustaining proliferative signaling .................................................... 8 
1.1.5.2 Evading growth suppressors ........................................................... 8 
1.1.5.3 Capable of replicative immortality ................................................. 9 
1.1.5.4 Activating invasion and metastasis ................................................. 9 
1.1.5.5 Inducing angiogenesis ................................................................... 10 
1.1.5.6 Resisting cell death ....................................................................... 10 
1.1.6 Mutational analysis of human breast cancers: Role of tumour 
suppressor and oncogenes ................................................................................. 11 
1.1.6.1 Breast cancer mutations ............................................................... 12 
1.2 Signal transduction by the insulin and growth factor pathways in breast 
cancer 13 
1.2.1 Role of tyrosine kinase receptors ........................................................ 13 
1.2.1.1 EGFR signaling in breast cancer .................................................... 14 
vi 
 
1.2.1.1.1 Types of EGFR ............................................................................ 14 
1.2.1.1.2 Types of EGFR ligands ................................................................ 15 
1.2.1.1.3 Mode of receptor activation ..................................................... 15 
1.2.1.1.4 EGFR mutations in breast cancer .............................................. 16 
1.2.1.1.4.1 Role of HER2 ........................................................................ 16 
1.2.1.2 Downstream signaling of EGFR ..................................................... 17 
1.2.1.2.1 The PI3K/AKT/mTOR pathway ................................................... 19 
1.2.1.2.1.1 What is mTOR ..................................................................... 19 
1.2.1.2.1.2 Multi-protein complexes of mTOR ..................................... 19 
1.2.1.2.1.2.1 mTORC2 ........................................................................ 20 
1.2.1.2.1.2.2 mTORC1 ........................................................................ 20 
1.2.1.2.1.3 Phosphatidylinositol 2-kinases ........................................... 20 
1.2.1.2.1.4 Regulation of mTORC1 by upstream kinases ...................... 21 
1.2.1.2.1.4.1 TSC mediated RHEB pathway ....................................... 21 
1.2.1.2.1.4.2 AKT: A positive regulator of mTORC1 activity .............. 22 
1.2.1.2.1.4.3 AMPK:  A negative regulator of mTORC1 activity ........ 23 
1.2.1.2.1.5 Downstream signaling of mTOR ......................................... 24 
1.2.1.2.1.5.1 eIF4E/4E-BP .................................................................. 25 
1.2.1.2.2 Raf/MEK/Erk1/2 pathway (MAPK) ............................................ 26 
1.2.1.2.2.1 Role of MAPK (ERK1/2) ....................................................... 26 
1.2.1.2.2.2 ERK signaling cascade ......................................................... 27 
1.2.1.2.2.3 Downstream signaling events of ERKs ................................ 27 
1.2.1.2.2.4 AMPK: attenuates MAPK signaling ..................................... 28 
1.2.1.2.3 Genetic alterations in downstream signaling pathways ........... 29 
1.2.1.2.3.1 Mutation analysis of mTOR................................................. 29 
1.2.1.2.3.2 Mutational analysis of MAPK pathway ............................... 30 
1.2.1.2.4 Interference between PI3K and ERK pathway........................... 31 
1.2.1.2.5 Therapeutic strategies of breast cancer .................................... 31 
1.2.1.2.5.1 PI3K/mTOR/AKT inhibitors .................................................. 32 
1.2.1.2.5.1.1 PI3K inhibitors .............................................................. 32 
1.2.1.2.5.1.2 AKT inhibitors ............................................................... 32 
1.2.1.2.5.1.3 mTOR inhibitors ........................................................... 32 
vii 
 
1.2.1.2.5.1.3.1 Rapamycin ............................................................. 32 
1.2.1.2.5.1.3.2 mTORC1/2 inhibitors ............................................. 33 
1.2.1.2.5.1.3.3 PI3K/mTOR dual inhibitors .................................... 33 
1.2.1.2.5.2 MAPK pathway inhibitors ................................................... 33 
1.2.1.2.5.3 Activating AMPK: a negative regulator of PI3K and MAPK 
pathway 34 
1.3 Eukaryotic polyadenylation .................................................................. 34 
1.3.1 Mechanism of nuclear polyadenylation .............................................. 35 
1.3.1.1 Cis acting Sequence elements ...................................................... 35 
1.3.1.2 Trans acting protein factors .......................................................... 36 
1.3.2 Regulation of gene expression by co-transcriptional processing of the 
 ? ?ĞŶĚŽĨĂŶŵZE .............................................................................................. 41 
1.3.3 Alternative polyadenylation ................................................................. 45 
1.3.3.1 Alterations in trans-acting factors ................................................ 47 
1.3.4 Mechanism of cytoplasmic polyadenylation ....................................... 47 
1.4 Role of Poly (A) polymerases in polyadenylation .................................. 50 
1.4.1 General characteristics of poly (A) Polymerase ................................... 50 
1.4.2 Structure of poly (A) polymerases ....................................................... 50 
1.4.3 Types of PAPs ....................................................................................... 51 
1.5 Role of polyadenylation in cancer ......................................................... 54 
1.5.1 Polyadenylation in cancer .................................................................... 54 
1.5.1.1 Role of Poly (A) polymerases in cancer ........................................ 55 
1.5.2 Alternative polyadenylation ................................................................. 56 
1.6 Role of the Poly(A) tail in the life of an mRNA ....................................... 56 
1.6.1 Poly(A) tails in mRNA stability .............................................................. 56 
1.6.1.1 Deadenylation dependent decay of an mRNA ............................. 56 
1.6.2 Poly(A) tails in translation .................................................................... 58 
1.6.2.1 Translational regulation: ............................................................... 58 
1.6.2.1.1 ůŽƐĞĚůŽŽƉĨŽƌŵĂƚŝŽŶďǇƚŚĞ ? ?ĐĂƉĂŶĚ ? ?ƉŽůǇ ? ?ƚĂŝů............. 58 
1.6.2.1.2 Role of cytoplasmic polyadenylation in translational reactivation
 60 
1.6.2.2 Role of deadenylation: translational repression .......................... 61 
1.6.2.2.1 AU-Rich elements (ARE) ............................................................ 61 
1.7 Cordycepin: highly prized traditional Chinese medicine ........................ 63 
viii 
 
1.7.1 History and habitat of the caterpillar fungi ......................................... 63 
1.7.2 Structure of cordycepin ....................................................................... 64 
1.7.3 Cordycepin as a cancer drug ................................................................ 64 
1.7.3.1 Role of cordycepin in cancer cell survival and proliferation ........ 64 
1.7.3.2 The effect of cordycepin on DNA damage repair ......................... 66 
1.7.3.3 Cordycepin activates AMPK and inhibits PI3K/AKT and MAPK 
signaling pathways .......................................................................................... 67 
1.7.4 Molecular functions of cordycepin ...................................................... 67 
1.7.5 Effect of cordycepin on adenosine receptors ...................................... 68 
1.7.6 Pharmacokinetics of adenosine and cordycepin ................................. 70 
1.7.7 Mode of action of C-8 substituted adenosine analogues .................... 71 
1.7.7.1 8-Chloro adenosine analogue ....................................................... 73 
1.8 Aims of the project............................................................................... 74 
2 Materials and Methods: .............................................................................. 75 
2.1 General reagents .................................................................................. 75 
2.1.1 Reagent and equipment suppliers ....................................................... 75 
2.1.2 Chemicals ............................................................................................. 75 
2.2 Tissue culture techniques ..................................................................... 76 
2.2.1 Solutions and reagents ......................................................................... 76 
2.2.2 Cell Lines ............................................................................................... 76 
2.2.3 Culturing and Maintenance of cell lines .............................................. 76 
2.2.4 Isolation and quantification of total RNA from Tissue culture cells .... 77 
2.3 Molecular Biology Techniques .............................................................. 77 
2.3.1 Buffers and solutions ........................................................................... 77 
2.3.2 Separation of Nuclear /Cytoplasmic fractions ..................................... 78 
2.3.3 Quantitative PCR .................................................................................. 79 
2.3.3.1 Human primer sequences for RT-qPCR ........................................ 79 
2.3.4 siRNA Transfections ............................................................................. 81 
2.3.5 Protein synthesis assay by 
35
 S Methionine Incorporation .................. 82 
2.3.6 In cell-enzyme linked immunosorbent assay (ELISA) for phospho 4E-BP 
as a cordycepin bioassay .................................................................................... 82 
2.3.7  ? ?-End labeling of mRNA with 32WƉƉ ?ǇƚŝĚŝŶĞ ? ? ? ? ?-ďŝƐƉŚŽƐƉŚĂƚĞ ? ? ?-
32
P)) 83 
2.3.8 Proliferation Assay ............................................................................... 84 
2.3.9 Immunohistochemistry of MCF-7 cells ................................................ 84 
ix 
 
2.4 Microarray profiling ............................................................................. 85 
3 Characterizing the effects of cordycepin on different cell lines ..................... 86 
3.1 Dose response effect of cordycepin on protein synthesis by 
35
S and ELISA 
on different cell lines ...................................................................................... 86 
3.2 The effects overtime of combining cordycepin with a stabilizing drug in 
MCF-7 cells ..................................................................................................... 89 
3.3 Pentostatin stabilizes cordycepin in HELA cells over time ...................... 91 
3.4 A minimal dose of pentostatin is still effective ...................................... 93 
3.5 Cell proliferation and survival are affected by cordycepin in different cell 
lines 95 
3.6 Effects of low dose of pentostatin on cell proliferation ......................... 98 
3.7 Minimal doses of pentostatin are still effective at lower doses of 
cordycepin ..................................................................................................... 99 
3.8 Discussion ........................................................................................... 100 
4 Effects of cordycepin on gene expression, polyadenylation and cell adhesion 
in MCF7 cells .................................................................................................... 102 
4.1 Inflammatory mRNAs affected by cordycepin ...................................... 102 
4.2 Cordycepin acts as a polyadenylation inhibitor .................................... 103 
4.3 Polyadenylation is affected by cordycepin over time ........................... 105 
4.4 Effects on cell adhesion by cordycepin in MCF-7 cells .......................... 107 
4.5 Discussion ........................................................................................... 107 
5 Investigating the mechanism of action of cordycepin in MCF-7 ................... 108 
5.1 The effects of adenosine analogues on polyadenylation ...................... 111 
5.2 Other adenosine analogues as alternative polyadenylation inhibitors.. 113 
5.3 The effects of adenosine analogues on cell proliferation ...................... 114 
5.4 PAP knockdown by SiRNAs .................................................................. 115 
5.5 Combination PAP knockdowns affects cell proliferation ...................... 116 
5.6 The effects of PAP knockdowns on polyadenylation ............................ 118 
5.7 The effects of PAP knock down on the level of selected mRNAs ........... 120 
5.8 Effects of adenosine analogues on inflammatory mRNAs ..................... 122 
5.9 Effects on cordycepin sensitive mRNAs are post-transcriptional .......... 123 
5.10 Investigation of the cordycepin sensitivity of mRNAs in cancer and mTOR 
related pathways .......................................................................................... 125 
x 
 
5.11 Discussion ........................................................................................... 126 
6 Identifying cordycepin sensitive mRNAs in MCF7 cells ................................ 128 
6.1 Functional clustering of significant genes in microarray analysis .......... 128 
6.2 Validation of selected candidates of microarray analysis ..................... 135 
6.3 The effect of adenosine analogues on four cordycepin targeted mRNAs
 139 
6.4 The effects of PAP knockdowns on four cordycepin targeted mRNAs ... 141 
6.5 Combination PAP knockdowns does not affect JUNB mRNA expression
 142 
6.6 Post transcriptional effects of cordycepin on its target mRNAs ............ 143 
6.7 Discussion ........................................................................................... 144 
7 Discussion and Conclusion ......................................................................... 146 
8 References ................................................................................................. 152 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xi 
 
List of Figures 
Figure 1.1: The signal transduction cascade downstream of receptor tyrosine kinase 
with AMPK as a negative regulator: ........................................................................... 18 
Figure 1.2: Schematic representation of factors involved in cleavage process: ....... 38 
Figure 1.3: Process of nuclear cleavage and polyadenylation in eukaryotes: ........... 41 
Figure 1.4: Mechanism of transcriptional coupled polyadenylation: ........................ 45 
Figure 1.5: Diagrammatic representation of a gene containing cis-acting elements 
with APAs. .................................................................................................................. 46 
Figure 1.6: Regulation of poly (A) tail length by cytoplasmic polyadenylation: ........ 49 
Figure 1.7: Structural organization of types of RNA specific nucleotidyl transferases:
 .................................................................................................................................... 52 
Figure 1.8: Schematic representation of deadenylation dependent decay of an 
mRNA: ........................................................................................................................ 58 
Figure 1.9: Role of PABP1 in translation initiation: .................................................... 60 
Figure 1.10: Regulation of deadenylation by AU-Rich elements: .............................. 63 
Figure 1.11: Chemical structures of adenosine, cordycepin and pentostatin. .......... 64 
Figure 1.12: Deamination of adenosine into hypoxanthinosine. .............................. 70 
Figure 1.13: Chemical structure of C-8 substituted adenosine analogue. ................ 72 
Figure 3.1: The sensitivity of cordycepin varies among different cell lines: .............. 88 
Figure 3.2: Effects of cordycepin and pentostatin on the rate of protein synthesis 
over time: ................................................................................................................... 90 
Figure 3.3: Pentostatin stabilizes cordycepin levels over time in MCF-7 cells: ......... 91 
Figure 3.4: Pentostatin increases the effect of Cordycepin in HELA: ........................ 93 
Figure 3.5: Concentration titration of pentostatin in combination with cordycepin:94 
Figure 3.6: Pentostatin enhances the long-term effects of cordycepin: ................... 97 
Figure 3.7: Dose response effects of pentostatin with cordycepin on cell 
proliferation: .............................................................................................................. 98 
Figure 3.8: Effects of low doses of cordycepin and pentostatin on cell proliferation in 
MCF-7: ...................................................................................................................... 100 
Figure 4.1: Levels of inflammatory mRNAs affected by cordycepin: ....................... 103 
Figure 4.2: Dose response effect of cordycepin on total poly (A) tail length in MCF-7:
 .................................................................................................................................. 104 
Figure 4.3: Effects of cordycepin on total poly (A) tail length over time in MCF-7: 106 
Figure 4.4: Immunohistochemistry of MCF-7 cells treated with cordycepin: ......... 107 
Figure 5.1: The effects of Adenosine analogues at 50µM on total poly (A) tail length:
 .................................................................................................................................. 112 
Figure 5.2: The effects of adenosine analogues on MCF-7 and HELA cells: ............ 114 
Figure 5.3: The effects on MCF-7 cells by different compounds on cell proliferation:
 .................................................................................................................................. 115 
Figure 5.4: PAP knockdown by SiRNAs: ................................................................... 116 
xii 
 
Figure 5.5: Cell proliferation is affected by combination PAP knockdowns in MCF-7 
cells: .......................................................................................................................... 117 
Figure 5.6: The effects of PAP knockdowns on total poly (A) tail length in MCF-7: 120 
Figure 5.7: The effects of PAP knockdown on MCF-7 cells: ..................................... 121 
Figure 5.8: Adenosine analogues inhibit expression of inflammatory mRNAs in MCF-
7: ............................................................................................................................... 123 
Figure 5.9: Nascent and mature inflammatory mRNAs affected by cordycepin: .... 124 
Figure 5.10: Cordycepin does not affect expression levels of mTOR and cancer 
mRNAs: ..................................................................................................................... 126 
Figure 6.1: Validation of candidates from microarray analysis: .............................. 139 
Figure 6.2: Effects of adenosine analogues treatment on selected mRNAs from 
microarray analysis: ................................................................................................. 140 
Figure 6.3: Effects of PAP knockdowns on selected mRNAs from microarray analysis:
 .................................................................................................................................. 141 
Figure 6.4: The effects of combination PAP knockdowns on JUNB expression: ..... 143 
Figure 6.5: Post transcriptional effects of cordycepin: ............................................ 144 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xiii 
 
List of Tables 
Table 1: Tumour Biology of breast cancer ................................................................... 6 
Table 2: Genetic alterations of the PI3K/AKT/mTOR pathway in breast cancer 
subtypes ..................................................................................................................... 30 
dĂďůĞ ? P>ŝƐƚŽĨĨĂĐƚŽƌƐŝŶǀŽůǀĞĚŝŶŵĂŵŵĂůŝĂŶ ? ?ĞŶĚĐůĞĂǀĂŐĞĂŶĚƉŽůǇĂĚĞŶǇůĂƚŝŽŶ
 .................................................................................................................................... 37 
Table 4: Types of mammalian poly (A) polymerases ................................................. 53 
Table 5: Decription of Cell lines ................................................................................. 76 
Table 6: Primers sequences for RT-qPCR: .................................................................. 79 
Table 7: Summary of rate of protein synthesis and levels of P-4EBP by in cell ELISA 
on various cell lines: ................................................................................................... 89 
Table 8: Description of adenosine analogues and related compounds: ................. 109 
Table 9: List of significantly up regulated genes: ..................................................... 129 
Table 10: List of significantly down regulated genes: .............................................. 131 
Table 11: Functional clustering of 289 significantly down regulated genes:........... 135 
Table 12: List of selected validated mRNAs: ............................................................ 137 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xiv 
 
List of Abbreviations 
4E-BP eIF4E-binding proteins 
18S rRNA 18S ribosomal RNA 
 ? ?hdZ  ? ?ƵŶƚƌĂŶƐůĂƚĞĚƌĞŐŝŽŶ 
35
S Sulphur-35 
5'-[
32
P]pCp
 
 Cytidine-3',5'-bis-phosphate 
A549 Human alveolar adenocarcinoma cell line 
ACTB Actin, beta 
Ado Adenosine 
ADP Adenosine diphosphate 
AGTR2 Angiotensin II receptor, type 2 
AICAR 5-aminoimidazole 4-carboxamide riboside 
AMPK Adenosine monophosphate dependent protein kinase 
APA Alternative cleavage and polyadenylation 
APS Ammonium persulphate 
ARE AU rich element 
ASM Primary human airway smooth muscle cells 
ATF4 Activating transcription factor 4 
ATP  ĚĞŶŽƐŝŶĞ ? ?- triphosphate 
AUF1 AU-rich binding factor 1 
BRCA1 Breast cancer type 1 susceptibility protein 
BRF1 Butyrate response factor 1 
BSA Bovine Serum Albumin 
BTG1  B-cell translocation gene 1 
CASP8 Caspase 8, apoptosis-related cysteine protease 
CATSPER2  Cation channel, sperm associated 2 
CBFB Core-binding factor subunit beta 
CCL2 Chemokine (C-C motif) ligand 2 
CCR4 Carbon catabolite repression 4 
CD36 Thrombospondin receptor 
CDH1 Cadherin-1 
Cdk Cyclin dependent kinase 
CDKA Cyclin dependent kinase A 
CDKN1A  Cyclin-dependent kinase inhibitor 1A (p21) 
CDKN1B Cyclin-dependent kinase inhibitor 1B (p27, Kip1) 
cDNA Complementary deoxyribonucleic acid 
CDS Coding sequence 
CF I Cleavage factor I 
CF II  Cleavage factor II 
CK Cytokeratin 
xv 
 
CM Cordyceps Militaris 
CNOT4  CCR4-NOT transcription complex, subunit 4 
COX2 (PTGS2) Cyclooxygenase 
CPE Cytoplasmic Polyadenylation Element 
CPE  Carboxypeptidase E 
CPEB Cytoplasmic Polyadenylation Element Binding Protein 
CPSF Cleavage and Polyadenylation Specificity Factor 
CS Cordyceps Sinensis 
CstF1  Cleavage stimulation factor, 3' pre-RNA, subunit 1 
CTD C terminal domain 
CTSL1 Cathepsin L1 
CXCL1 Chemokine (C-X-C motif) ligand 1 
CXCL8 or (IL8) Interleukin 8  
dATP ĞŽǆǇĂĚĞŶŽƐŝŶĞ ? ?-tripohosphate 
DAVID Database for Annotation, Visualisation and Integrated Discovery 
DCP1A  Decapping enzyme homolog A 
dCTP ĞŽǆǇĐǇƚŝĚŝŶĞ ? ?-triphosphate 
DDR DNA damage response 
Deptor DEP-domain containing mTOR-interacting protein 
dGTP ĞŽǆǇŐƵĂŶŽƐŝŶĞ ? ?-triphosphate 
DMEM ƵůďĞĐĐŽ ?ƐDŽĚŝĨŝĞĚĂŐůĞƐDĞĚŝƵŵ 
DMSO Dimethyl sulfoxide 
DNA
 
Deoxyribonucleic acid 
DNase Deoxyribonuclease 
dNTP ĞŽǆǇƌŝďŽŶƵĐůĞŽƚŝĚĞ ? ?-triphosphate 
DRB 5,6-Dichloro-1-ɴ-D-ribofuranosylbenzimidazole 
DSE Downstream sequence elements 
DSIF DRB- sensitivity inducing factor 
dsRNA Double stranded RNA 
DTT Dithiothreitol 
ECL Enhanced Chemiluminescence 
EDTA Ethylene Diamine Tetraacetic Acid 
eEF2 Eukaryotic translation elongation factor 2 
eEF2K Eukaryotic translation elongation factor 2 kinase 
EGR1  Early growth response 1 
EGTA Ethylene glycol tetraacetic acid 
eIF (4A,4E,4G) Eukaryotic translation initiation factors (4A,4E,4G) 
ELISA Enzyme-linked immunosorbent assay 
ER Estrogen receptor 
ErbB Erythroblastic leukemia viral oncogene 
ERK Extracellular signal-regulated kinase 
xvi 
 
ERRB2 ERRB2 estrogen-related receptor beta-2 
FAT FAT-carboxy terminal domain 
FATC  FRAP-ATM-TTRAP domain 
FBS Foetal Bovine serum 
FBXW7  F-box and WD repeat domain containing 7 
FCS Foetal calf serum 
FOXA1 Forkhead box protein A1 
FRB FKBP12-rapamycin binding domain 
GAB2 Grb2-associated binding protein 2 
GAPDH Glyceraldehyde 3-phosphate dehydrogenase 
GATA3 Trans-acting T-cell-specific transcription factor/GATA-binding 
factor 3 
GNAI3  Guanine nucleotide binding protein (G protein), alpha inhibiting 
activity polypeptide 3 
GRB7 Growth factor receptor-bound protein 7 
GTFs General transcription fcators 
GTP Guanosine triphosphate 
HCl Hydrogen chloride 
HCT116  Human colorectal carcinoma cells 
HEAT Huntingtin-Elongation factor 3-regulatory subunit A of PP2A-
TOR1 
Hela Human cervical epithelial carcinoma cells 
Hepes N-2-Hydroxyethylpiperazine-E ?-2-Ethanesulphonic Acid 
HER2 Human epidermal growth factor receptor 2 
HIF1A Hypoxia inducible factor 1, alpha subunit 
HRP Horseradish peroxidase 
HT29 Human colorectal adenocarcinoma cells 
IGF-1R Insulin-like growth factor receptor 1 
IHC Immunohistochemistry 
IL6 Interleukin 6 
IRS1  Insulin receptor substrate 1 
IRS2 Insulin receptor substrate 2 
kDa Kilodalton 
KHSRP KH-type splicing regulatory protein 
KRAS Kirsten rat sarcoma viral oncogene 
LDLRAP1 Low density lipoprotein receptor adaptor protein 1 
LIF Leukemia inhibitory factor 
LKB1 Liver kinase B1 
MAP3K1 Mitogen-activated protein kinase kinase kinase 1 or MAPK/ERK 
kinase kinase 1 
MAP3K13 Mitogen-activated protein kinase kinase kinase 13 
xvii 
 
MAPK Mitogen-activated protein kinase 
MCF-7 Michigan Cancer Foundation - 7 
MCL1  Myeloid cell leukemia sequence 1 
MED13L  Mediator complex subunit 13-like 
MED26 Mediator complex subunit 26 
MED9  Mediator complex subunit 9 
MEK Raf/mitogen-activated and extracellular signal-regulated kinase 
kinase 
MEK1/2 Map or ERK kinase 1 or 2 
MgCl2 Magnesium chloride 
miRISC miRNA induced silencing complex 
miRNA MicroRNA 
mLST8 Mammalian lethal with SEC Thirteen 8 
mRNA Messenger ribonucleic acid 
mSIN1 Mammalian stress-activated protein kinase interacting protein 1 
MTA  ? ?-Deoxy- ? ?-(methylthio)adenosine 
mTOR Mammalian target of rapamycin 
mTORC1 mTOR complex 1 
mTORC2 mTOR complex 2 
MTPAP (papd1) Mitochondrial poly(A) polymerase 
MYC v-myc avian myelocytomatosis viral oncogene homolog 
MYH9 Myosin heavy chain 9 
NaCL Sodium chloride 
NCOR1 Nuclear receptor corepressor 1 
NEK6  NIMA (never in mitosis gene a) related kinase 6 
NELF Negative elongation factor 
NFKBIA  Nuclear factor of kappa light polypeptide gene enhancer in B-
cells inhibitor, alpha 
NIH3T3 Primary mouse embryonic fibroblast cells "3-day transfer, 
inoculum 3 x 10
5
 cells 
Nt Nucleotide 
NTP Nucleoside triphosphate 
NUDT21 Nucleoside diphosphate linked moiety X)-type motif 21 
P-4EBP Phosphorylated-eIF4E-binding proteins 
PABN1 Nuclear poly (A)- binding protein 1 
PABP Poly-A Binding Protein 
PABPC Cytoplasmic  poly (A)- binding protein 
PAGE Polyacrylamide gel electrophoresis 
PAIP PABP interacting protein 1 
PAN Poly (A) nuclease 
PAP Poly(A) polymerase 
xviii 
 
PAPD2 PAP-associated domain-containing 2 
PAPD4  PAP associated domain containing 4  
PAPd5   PAP associated domain containing 5 
PAPd7  PAP associated domain containing 7 
PAPOLA  Poly(A) polymerase alpha 
PAPOLB  Poly(A) polymerase beta 
PAPOLG Poly(A) polymerase gamma 
PARN Poly (A)- specific ribonuclease 
PBS Phosphate buffered saline 
PCR  Polymerase Chain Reaction 
PDCD4 Programmed cell death 4 
PDK1 Phosphoinositide-dependent protein kinase 1 
PHAS-I Phosphorylated heat and stable protein, insulin stimulated 
PI3K Phosphoinositide 3-kinase 
PIC Preinitiation complex 
PIK3CA Phosphoinositide-3-kinase, catalytic, alpha polypeptide 
PIK3CB  Phosphoinositide-3-kinase, catalytic, beta polypeptide 
PIK3CD  Phosphoinositide-3-kinase, catalytic, delta polypeptide 
PIP2 Phosphatidylinositol (4,5)-biphosphate 
PIP3 PtdIns(3,4,5)P3), phosphatidylinositol (3,4,5)- trisphosphate 
PLK2  Polo-like kinase 2 
Pol II RNA Polymerase II 
PR/PgR Progesterone receptor 
PRAS40 Proline rich AKT substrate 40 kDa 
Protor-1 Protein observed with Rictor-1 
P-TEFb Positive transcription  elongation factor b 
PTEN Phosphatase and tensin homolog or phosphatidylinositol 3,4,5-
trisphosphate 3-phosphatase and dual-specificity protein 
phosphatase 
PTN Pleiotrophin 
q-PCR quantitative real time polymerase chain reaction 
Raptor Regulatory associated protein of mTOR 
RB1 Retinoblastoma 1 
Rheb Ras homolog enriched in brain 
Rictor Rapamycin-insensitive component of mTOR 
RN18S  18S ribosomal RNA 
RNA Ribonucleic acid 
RNase Ribonucleic acid hydrolase 
RNPS Ribo-nucleo proteins 
RPL10A Ribosomal protein L10a 
RPs Ribosomal  proteins 
xix 
 
rRNA Ribosomal RNA 
RUNX1 Runt-related transcription factor 1 
S6K1 Ribosomal S6 protein kinase 1 
SDS Sodium Dodecyl Sulphate 
Se13 Secret 13 compund 
SF3B1 Splicing factor 3b, subunit 1 
siRNA Silencing ribonucleic acid 
SMARCD1 SWI/SNF-related matrix-associated actin-dependent regulator 
of chromatin subfamily D member 1 
SNAI3 Snail family zinc finger 3 
ssRNA Single stranded RNA 
STMN2 Stathmin-2 
SUN1  Sad1 and UNC84 domain containing 1 
TAE Tris acetic acid  EDTA buffer 
TBE Tris-borate EDTA buffer 
TBS Tris buffered saline 
TBST Tris Buffered Saline Tween 
TBX3 T-box transcription factor 
TE Tris-EDTA 
TEMED Tetramethylethylenediamine 
TFPI Tissue factor pathway inhibitor 
TKIs Tyrosine kinase inhibitors 
TOS TOR signaling motif 
TP53  Tumor protein p53 
Trf4 Topoisomerase I-related protein 
tRNA Transfer RNA 
TSC1 and TSC2 Tuberous sclerosis complex 1 and 2 
TTP Tristetraproline 
uORF Upstream open  reading frame 
USE Upstream sequence elements 
UTR Untranslated Region 
ZFP36  Zinc finger protein 36, C3H type 
ZFP36L1  Zinc finger protein 36, C3H type-like 1 
 
 
 
1 
 
1 Introduction 
1.1 Breast cancer  
Approximately 13% of all worldwide deaths in 2008 are related to different types 
of cancer, representing 7.6 million deaths (Gutschner and Diederichs 2012).      In 
general cancer affects 1 in 3 people in the duration of their lifetime  (Kaye 1999). 
In USA the average age of breast cancer identification is 61 years              
(Roskoski 2014). Known risk factors for breast cancer include smoking, tobacco, 
infections, excessive weight gain and radiation. Breast cancer is the development 
of abnormal cells that keep growing beyond the normal boundaries of tissue 
repair (Hanahan and Weinberg 2011). Somatic alterations in human genome are 
involved in developing cancer such as translocations, single base substitutions 
and copy number alterations. Investigation of these alterations provides insights 
into the cellular defects (Beroukhim et al. 2010). Among women, breast cancer is 
the most commonly diagnosed form of cancer especially in USA and Europe and 
the main cause of death related to cancer worldwide (Eroles et al. 2012). In 
2008, 182,640 women and 1,990 men were diagnosed with breast cancer 
(Meacham et al. 2009).  
1.1.1 Molecular subtypes of breast cancer 
Breast cancer is a heterogeneous, complicated and diversified disease rather 
than a simple single disease. It comprises a mixture of various subtypes, which 
were first analyzed by high throughput gene expression profile by Perou in 2000 
into four subtypes and a year later further divided into luminal subtypes A and B 
by Sorlie in 2001 (Perou et al. 2000, Sasaki et al. 2013). Breast cancer can be 
divided into six molecular subtypes: HER2-enriched (hormone receptor 
negative/HER2 positive), Basal- like (hormone receptor negative/HER2 negative), 
normal breast cancer (hormone receptor negative/HER2 negative), luminal A 
(hormone receptor positive/HER2 negative), luminal B (hormone receptor /HER2 
positive) and claudin-low (hormone receptor/HER2 negative). All are linked with 
distinct prognosis (Eroles et al. 2012, Previati et al. 2013).  
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Normal and basal subtypes of breast cancer are negative for all three key 
receptors (ER, PgR, HER2) but they differ in expression pattern of CK5 and EGFR 
which are positive for basal-like while negative for normal subtype. The  claudin-
low subtype is also predominantly ER/PgR/HER2 negative but 20% of these 
tumours are hormone receptor positive, in contrast with basal-like which are 
100% negative for ER/PgR/HER2 (Eroles et al. 2012).  Basal-like and HER2 subtype 
are found to be the most commonly diagnosed breast tumours in young women. 
They are characterized by high levels of EGFR, a familiar marker of basal-like 
breast tumours, which are most agressive. The basal-like subtype of breast 
cancer, also known as triple negative, has been defined by 
immunohistochemistry. Characteristic features of molecular subtypes of breast 
cancer, based on their clinical and gene expression pattern, have been 
summarized in table 1. Both subtypes of luminal are defined by expression of 
hormone receptors gene. Luminal A posses greater levels of estrogen receptors 
compared to luminal B. The key marker of identification between these two 
subtypes relate to the high expression of KI67 and cyclin B proliferation genes 
(Eroles et al. 2012).  
1.1.2 Role of receptors in Breast cancer 
Breast cancer involves deregulation of the growth factor and hormone receptors 
that are also used to classify them. Key receptors of breast cancer are HER2, 
estrogen receptor and progesterone receptor used as a biomarker play crucial 
role in identification and treatment of various sub types and grades of breast 
cancer (Sekar et al. 2011).  
1.1.2.1 HER2  
Alterations in the HER2 receptor pathway result in a loss of maintenance of 
proliferative signalling in breast cancer. HER2 is an oncoprotein linked with 
subfamily of HER (human epidermal receptor) family and associated with EGFR 
(epidermal growth factor receptor) family. HER2 can formeither homo or 
heterodimers in the presence of ligand, which leads to activation of tyrosine 
kinase function inside the cell. 10% -30% of breast tumours have amplification of 
HER2(Cornejo et al. 2014). The signalling pathways which are mainly effected by 
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these receptors are PI3K/AKT/mTOR and Ras/Ref/MAPK. These pathways are 
major regulators of cell growth, proliferation and survival, metabolism, division 
and apoptosis   (Eroles et al. 2012). 
1.1.2.2 Hormone receptors 
Steroid hormone receptors (estrogen receptor (ER) and progesterone receptor 
(PR)) interact with hormones and act in the nucleus. Progesterone receptors 
serve as an indicative marker in determining the status of estrogen levels. This 
helps to determine the choice and response of therapy among patients, as levels 
of ER serves as crucial role in PR expression. Breast cancer patients with 
progesterone receptor expression (PR
+
) in their tumours have better rates of 
survival compared to those who are are PR
- 
(Cornejo et al. 2014). 
  
Estrogen receptors are the major players of endocrine signaling. There are two 
isoforms: ZɲĂŶĚZɴ ?Zɲhas a crucial role in advancement of breast cancers 
as around 70- ? ?A? ŽĨ ďƌĞĂƐƚ ĐĂŶĐĞƌ ĂƌĞ ĞƐƚƌŽŐĞŶ ƌĞĐĞƉƚŽƌ ɲ ƉŽƐŝƚŝǀĞ ?Zɲ+) 
(Ciruelos Gil 2014). One of the ER
+ 
cell lines of breast cancer which is used 
extensively in research is MCF-7. Estrogen receptors bind to estrogen, a steroid 
hormone, which plays a critical role in the female reproductive cycle. The 
association of estrogen to its receptor not only affects the function of targeted 
genes, but also growth and differentiation. Estrogen receptors modulate gene 
expression by serving as a ligand mediated transcription factors. The binding of 
ligand stimulates changes in receptor conformation and results in dimer 
formation, DNA binding, addition of co-activator molecules in addition with 
other transcription factors and release of co-repressors. ERs transfer to the 
nucleus upon binding to estrogen, which enhances the expression of targeted 
genes either through the interaction of the ER with the ERE (estrogen response 
element) or  by association with a co-activator molecule  (Xu et al. 2013). 
1.1.3 Breast cancer treatment  
Hormone receptor positive subtypes of breast tumour, such as luminal A and B, 
are generally treated by endocrine therapy, as detailed below. In addition, 
chemotherapy is also required for the efficient treatment of luminal B subtype. 
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HER2 positive subtype (36%) and basal-like (43%) are highly sensitive to 
chemotherapy compared with luminal A (7%) and B (17%) (Eroles et al. 2012). 
For basal-like subtype of breast cancer, PARP1 inhibitors are used in combination 
with DNA damage inducing chemotherapeutic agents such as platinum salts (e.g: 
carboplatin, cisplatin) (Anders and Carey 2009). Effective treatments for each 
subtype of breast cancer are summarized in table1. 
1.1.3.1 HER2+ treatment 
The HER2
+
 subtypes of breast cancer are characterized by increased expression 
of the HER2 gene or the genes related to the HER2 pathway found on 17q12 
chromosome. The breast cancer shows resistance towards endocrine therapy 
but are effectively cured by anti-HER2 treatment such as trastuzumab 
(Genentech, Inc., San Francisco) a monoclonal antibody and lapatinib 
(GlaxoSmithKline, King of Prussia, Pennsylvania). Anti-HER2 treatment is found to 
be more efficient when used in combination with chemotherapy, which reduces 
the  relapse rate to 50% and enhances the survival rate to 33% (Cornejo et al. 
2014).  
1.1.3.2 Endocrine therapy 
Endocrine therapy is a direct targeted therapy proposed for ER and PgR positive 
subtypes of breast tumour, which inhibits the growth enhancing effects of 
estrogen through estrogen receptors. The effective response length of endocrine 
therapy is 8-14 months for 20-40% ER positive patients.  Types of endocrine 
therapy include selective estrogen receptor modulators (SERMS), such as 
tamoxifen, which block ligand binding to ER. Others regulate the transcription of 
ERs in a tissue specific manner, by downregulating the ER expression (such as 
fulvestrant), while some block the synthesis of estrogen such as analogs of 
gonadotropin-releasing hormone. Aromatase inhibitors (AI) inhibit the activity of 
the aromatase enzyme which converts androgens into estrogen  (like letrozole, 
exemestane) (Ciruelos Gil 2014). Tamoxifen treatment is effective for most 
women independent of menopausal status, compared to AI which is more useful 
in post menopausal women. WĂƚŝĞŶƚƐǁŝƚŚŚŝŐŚ ůĞǀĞůƐŽĨZɲƌĞƐƉŽŶd better to 
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ĞŶĚŽĐƌŝŶĞƚŚĞƌĂƉǇĐŽŵƉĂƌĞĚƚŽƚŚĞƉĂƚŝĞŶƚƐǁŝƚŚůŽǁƚŽŶĞŐůŝŐŝďůĞůĞǀĞůƐŽĨZɲ, 
which react better to chemotherapy (Xu et al. 2013). Tumours in patients with 
high levels of HER2 have greater resistance towards SERMS compared to 
estrogen reduction therapy (AI)  (Cornejo et al. 2014).  
1.1.3.3 Chemotherapy 
Chemotherapy is one of the most popular options for breast cancer treatment. It 
gives better outcomes with enhanced rates of disease-free survival especially 
when used in combination with endocrine therapy. Chemotherapy reduces 
mortality rate by 33% with 45% decline in recurrence rate when used in 
combination with endocrine therapy. The major limitation of chemotherapy for 
breast cancer treatment is drug resistance.  For luminal B, HER2
+
 and basal like 
subtypes of breast cancer, chemotherapy is preferred. The molecular mechanism 
behind chemotherapy resistanĐĞ ŝŶ Zɲ ƉŽƐŝƚŝǀĞ ƉĂƚŝĞŶƚƐ ŝƐ Ɛƚŝůů ƵŶŬŶŽǁŶ. A 
reduced rate of proliferation in MCF-7 breast cancer lines has been reported, 
when chemotherapeutic agents (paclitaxel, 5-fluorouracil) are used in 
combination with endocrine therapy (AI and SERMS) (Xu et al. 2013).  
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Table 1: Tumour Biology of breast cancer 
M
o
le
cu
la
r 
S
u
b
ty
p
e
s 
R
e
ce
p
to
rs
 
(E
R
/P
R
/H
E
R
2
) 
F
re
q
u
e
n
cy
 
H
is
to
lo
g
ic
a
l 
g
ra
d
e
 
P
ro
g
n
o
si
s 
P
ro
li
fe
ra
ti
o
n
 
G
e
n
e
s 
 (
K
i6
7
) 
M
o
le
cu
la
r 
p
a
th
w
a
y
s 
R
e
la
p
se
 r
a
te
 
S
it
e
 o
f 
o
ri
g
in
 
M
a
rk
e
rs
 
id
e
n
ti
fi
e
d
 b
y
 
IH
C
 
T
re
a
tm
e
n
t 
HER2 (or 
ERRB2) 
enriched 
ER
-
/PR
-
/HER2
+
 15-20% high bad high 
HER2 genes, 
mutations in 
TP53 
_ 
Epithelium 
of breast 
duct 
HER2, GRB7 
Chemotherapy
,anti-HER2
+
 
therapy 
Basal-like 
OR 
Triple 
negative     
(TN) 
 
ER
-
/PR
-
/HER2
-
 10-20% 
high 
 
(gradeIII/ 
highly 
aggressive) 
bad high 
High rate of 
TP53 
mutations 
(44%), 
BRCA1 
Initial 3 
years 
Myoepitheli
al breast 
cells 
CK5
+
, CK6
+
, 
CK17
+
,CK14
+
,E
GFR
+  
(HER1
+
),CD44
+
, caveolin 1
+
, 
P-cadherin
+
 
Chemotherapy
, PARP 
inhibitors, 
cytotoxic 
agents e.g 
platinum salts 
Normal-like ER
-
/PR
-
/HER2
-
 5-10% low middle low _ _ 
Adipose 
tissue 
PTN, CD36 
EGFR
-
, CK5
-
 
Poor response 
to 
chemotherapy
, U-I 
Luminal A 
ER
3+
/PR
3+
/HER
2
-
 
50-60% low good low 
ER sensitive 
genes 
27.8% 
Luminal 
epithelium 
of mammary 
ducts 
CK8
+
, CK18
+
, 
GATA3
+
 
Endocrine 
therapy 
Luminal B 
ER
+
/PR
+/-
/HER2
-/+
 
10-20% 
intermediat
e 
Bad/ 
middle 
high 
ER sensitive 
genes, 
mutations in 
TP53 
1.6 
years 
Luminal 
epithelium 
of mammary 
ducts 
CK8
+
, CK18
+
, 
GATA3
+ 
 
Endocrine 
therapy, 
chemotherapy 
Claudin low ER
-
/PR
-
/HER2
-
 12-14% high bad high _ _ _ SNAI3 
Poor response 
to 
chemotherapy
, U-I 
7 
 
Abbreviations: CK: cytokeratin, PR: progesterone receptor, ER: estrogen receptor, GATA3: 
GATA binding protein 3, HER2: human epithermal receptor protein-2,                           
IHC: immunohistochemistry, CD36: thrombospondin receptor, GRB7: growth factor receptor-
bound protein 7, SNAI3: snail family zinc finger 3, PTN: pleiotrophin, ERRB2: estrogen-
related receptor beta-2, U-I: under-investigation 
Adapted from: (Earp et al. 2003, Anders and Carey 2009, Eroles et al. 2012, Cornejo et al. 
2014). 
 
1.1.4 Molecular mechanisms of breast cancer  
The cellular and molecular pathways in the development of breast cancer involve 
several important mechanisms, such as the proliferative response of breast cells 
toward several peptide growth factors or involvement of the estrogen receptor (ER) 
and IGF (Insulin-like growth factor) pathways. IGF was found to play an important 
role in breast cancer progression by transforming normal cells to acquire 
tumorigenic characteristics, which consist of a chain of several components. These 
include insulin, IGF-1, IGF-2 and IGF-1 receptor (IGF1R), which are involved in 
mediating growth, metabolic and nutritional processes of cells (Oh et al. 2008, 
Werner and Bruchim 2012). IGF-IR exerts its action as an inhibitor of apoptosis and 
regulates the activities of insulin and IGF (IGF-1, IGF-2) (Jalving et al. 2010). High 
levels of IGF1R expression are found in aggressive types of breast cancer compared 
to benign tumor oruntransformed breast epithelial cells (Lee et al. 1998, Werner 
and Bruchim 2012).  
Inactivating mutations in BRCA1 and BRCA2 have a pronounced effect on breast 
cancer development (King et al. 2003). BRCA1 genes are ŽĨƚĞŶŬŶŽǁŶĂƐ ‘ĐĂƌĞƚĂŬĞƌs 
ŽĨƚŚĞŐĞŶŽŵĞ ?and play a vital role in identifying DNA damage and mediating DNA 
repair processes (Anders and Carey 2009). Under normal conditions BRCA1 and 
BRCA2 are involved in the DNA repair mechanism by homologous recombination 
(Earp et al. 2003). In breast cancer, inactive BRCA1 or BRCA2 leads to the collection 
of DNA strand breaks, which aids the growth of tumours. Cancerous cells with 
mutated BRCA1 or BRCA2 genes are more sensitive to DNA damage agents in 
combination with the drugs that inhibit the activity of enzymes involved in DNA 
damage repair, such as PARP (Poly (ADP-ribose) polymerase) (Vogelstein et al. 
2013). PARP plays crucial role in repairing DNA single strands break after DNA 
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damage, while its lack of activity leads to collections of double strand DNA breaks, 
causing cell death. Therefore PARP inhibitors are used extensively in treating BRCA 
deficient cancer (Anders and Carey 2009, Frizzell and Kraus 2009, Kim et al. 2011).  
1.1.5 Breast cancer hallmarks 
There are some basic hallmarks of breast cancers (Hanahan and Weinberg 2000) 
which normal cells have to acquire in several stages in order to become 
tumorigenic. These are as follows: 
1.1.5.1 Sustaining proliferative signaling 
In general, normal or healthy cells manage to control the balance between growth 
inhibiting and promoting signals. In contrast, cancerous cells continue to proliferate 
endlessly without the need of any stimuli, as the cells become independent of 
growth signals and often have deregulated signaling pathways. Oncogenic 
mutations that enhance growth factor signaling include the activating mutations in 
the RAS and PI3K (PIK3CA) oncogenes and inactivation of the PTEN tumour 
suppressor. These activating mutations lead to growth factor signaling in the 
absence of growth factors. In other cases, mutations or overexpression of 
transcription factors that are normally induced by growth factors, such as FOS and 
MYC, leads to reduced dependence on growth factors for proliferation. Many novel 
cancer drugs target the growth factor signaling, but feedback regulation can lead to 
drug resistance. An example of such type of feedback mechanism involved in cancer 
is the mTOR pathway, which plays important roles in cell metabolism and growth. 
Activated mTOR inhibits PI3K signaling through negative feedback. Therefore, after 
inhibition of mTOR, PI3K signaling frequently is increased. This unltimately reduces 
the antiproliferative properties of inhibitors of this pathway (Hanahan and 
Weinberg 2011).  
1.1.5.2 Evading growth suppressors 
Tumor cells also have an ability to maintain proliferative signals by escaping from 
growth inhibiting factors. These factors normally induce several tumor suppressor 
genes and lead to apoptosis or an arrest in cell cycle progression. Inactivation of 
tumour suppressor genes such as Tp53 and Rb, either by mutation or by gene 
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regulation, therefore play a critical role in tumour progression. More than 50% of all 
human cancer has mutated Tp53 and in individuals where only one functional copy 
of the Tp53 is inherited, there is a higher chance of cancer (Gutschner and 
Diederichs 2012).  
1.1.5.3 Capable of replicative immortality 
Unlike normal cells in which the number of cell divisions is restricted, cancerous 
cells have a potential to replicate endlessly. In normal cells, senescence or cell cycle 
arrest limits the replicative potential. This may be due to DNA damage or the 
shortening of telomere lengthening enzyme telomerase after each cycle of cell 
division (Gutschner and Diederichs 2012). As cancerous cells become immortalized, 
about 90% of human tumor expresses the telomere lengthening enzyme 
telomerase at high levels. This type of DNA polymerase is responsible for adding 
telomeric hexanucleotide repeats at the end of each chromosome. The remaining 
10% of tumor cells undergo ALT (alternative lengthening  of telomeres) which 
involves the transfer of hexanucleotide repeats among chromatids               
(Gutschner and Diederichs 2012).  
1.1.5.4 Activating invasion and metastasis 
The major characteristic of cancer is its ability to spread or metastasize to other 
parts of a body. Most solid tumours are carcinomas, which arise from epithelial 
cells.  Metastasized carcinomas are oftenmore aggressive and higher grade than the 
original tumour. They metastasize rapidly to distant organs by developing changes 
in their shape and their connections to ECM (extracellular matrix) and to other cells 
in a process, which is called the epithelial to mesenchymal transition (EMT) 
(Hanahan and Weinberg 2000, Gutschner and Diederichs 2012). Carcinoma cells 
lose a key cell matrix interacting molecule known as E-cadherin, which plays a 
crucial role in assembling epithelial cell layers by providing cell to cell adhesion 
support.  Over-expression of E-cadherin blocks metastasis and invasion, therefore in 
cancerous cells, the expression of E-cadherin found to be downregulated 
(Gutschner and Diederichs 2012). The gene expression changes associated with the 
EMT also inhibit programmed cell death (Hanahan and Weinberg 2011).  
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1.1.5.5 Inducing angiogenesis 
Cancerous cells like normal cells also need oxygen and nutrients and need to 
excrete carbon dioxide and metabolic waste to proliferate. The process of 
angiogenesis and vasculogenesis (formation of new endothelial cells and their 
assembly into a tube), normally happens during the process of embryogenesis, in 
adults during wound healing and in the female reproductive cycle. In normal tissues 
the process of vasculogenesis becomes inactivated once the tissue is fully formed. 
In tumors, angiogenesis and vasculogenesis remain active allowing continued 
proliferation of tumor cells (Hanahan and Weinberg 2011). One of the factors 
involved is VEGF-A (vascular endothelial growth factor-A) an angiogenesis activator 
which becomes activated upon oncogenic signals or hypoxia (Ferrara 2009, 
Gutschner and Diederichs 2012). 
1.1.5.6 Resisting cell death    
Cancer cells usually experience stresses which would normally induce cell death due 
to imbalanced signaling and damage to the DNA causing a high rate of replication 
(Hanahan and Weinberg 2000). Normal cells possess three main mechanism of cell 
death: apoptosis, autophagy and necrosis.  
Cancer therapy is often targeted to induce apoptosis. Aggressive forms of cancer 
are less responsive towards cancer therapy because of their resistance to cell death 
pathways. Tumor cells also activate the expression of anti-apoptotic proteins like 
Bcl-x and Bcl-2 (Gutschner and Diederichs 2012). 
The apoptotic cascade consists of the intrinsic and the extrinsic pathway. The 
intrinsic pathway processes intracellular signals, such as mitochondrial stress. The 
extrinsic pathway is caused by extracellular signals, such as the Fas ligand binding to 
its receptor. These pathways are responsible for activating caspases (caspases 8 and 
9) which initiate a series of proteolytic events and thus activate the process of 
apoptosis. The intrinsic process of apoptosis is usually co-ordinated by balancing 
pro- and anti-apoptotic members of the Bcl family of proteins, such as   Bcl-2 (Mcl-1, 
Bcl-w). They inhibit apoptosis by inactivation of pro-apoptotic members such as Bak 
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and Bax which cause disruption in the outer mitochondrial membrane (Gutschner 
and Diederichs 2012).   
The second mechanism of cell death is autophagy, which is activated as a response 
to different cellular stresses, such as low levels of nutrients. The mTOR signaling 
pathway, which is down regulated during starvation, is an inhibitor of autophagy. 
The process usually generates energy in order to carry out cellular biosynthesis 
processes by breaking down cell organelles. When autophagy persists, it can also 
cause cell death. The third mechanism involved in cell death is necrosis, which is 
usually referred to as uncontrolled cell death (Gutschner and Diederichs 2012).                                       
1.1.6 Mutational analysis of human breast cancers: Role of tumour 
suppressor and oncogenes  
Breast cancer usually results from a series of genetic alterations, which cause the 
activation of oncogenes and inactivation of tumor suppressor genes. These genetic 
alterations result in genomic instability, increase in cell proliferation, hindrance in 
differentiation and a lack of apoptosis.  Formation of tumours involves translocation 
of chromosomes, mutations, substitutions or deletions. Compared to normal 
growing cells, cancerous cells lack the ability to sustain the wholeness of the 
genome. (Felsher 2004).  
Tumour suppressor genes serve as gatekeeper genes that regulate proliferation 
under normal conditions. Upon DNA damage these genes signal the cells to stop 
dividing further by promoting apoptosis or cell cycle arrest. Mutational inactivation 
of tumour suppressor genes leads to uncontrolled growth of cells. P53, PTEN and Rb 
(Retinoblastoma) are some examples of tumour suppressor genes. Oncogenes play 
important role in cancer progression and have been found to be mutated or 
overexpressed in many tumours. Activation of oncogenes results in rapid cell 
proliferation and causes disruption in the process of apoptosis and cellular 
differentiation, while their inactivation reduces cell proliferation or induced cell 
cycle arrest. RAS, ERK and MYC are some examples of oncogenes (Felsher 2004). 
Breast cancer is usually caused by the accumulation of mutations in genes involved 
in cell growth or cell cycle. Most of these mutations are somatic while some are 
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inherited. These mutations include activating mutations in proto-oncogenes, which 
are dominant, while most inactivating mutations in tumor suppressor genes are 
recessive. Cells involved in breast cancer progression posses a unique ability to 
proliferate, metastasize and survive due to genomic instability which leads to 
further mutations and rearrangements of chromosomes (Eroles et al. 2012).   
Oncogenes play a crucial role in growth factor signalling, including the signal 
transduction machinery  (PIK3CA, AKT, Ras, Raf, Rheb), Tyrosine kinase receptors 
(EGFR/HER2), adaptors proteins (GAB2), intracellular proteins (SRC) and 
transcription factors (MYC, JUN and FOS). The functional loss of tumour suppressor 
genes involved in growth factor signalling, such as TSC1/2, PTEN and LKB1, increases 
cancer progression (Felsher 2004, Ali and Sjoblom 2009, Vogelstein et al. 2013). 
Mutational analysis of breast cancer reveals several gatekeeping mutations that 
provide selective growth to normal cells. The further expansion in cell number as a 
consequence of the second mutation leads to the spread of tumour to distant 
organs (Previati et al. 2013). These types of mutations are termed as driver 
mutations.  The genes which contain driver mutations in breast cancer are TP53, 
PTEN, PIK3CA, CDKN1B and ERBB3 (Liang et al. 2006). In general at chromosomal 
and nucleotide level healthy cells also posses different types of genetic alterations 
upon division, but they are designed to undergo apoptosis when mutations become 
deleterious (Vogelstein et al. 2013). On average one third of cancer genes are 
translocated, mutated or their expression is deregulated. Somatic mutations 
frequently occur in the majority of genes involved in the breast cancer pathway. In 
breast tumours about   33 to 66 genes show somatic mutations, among them 95% 
are single base substitution, while the rest of them are either deletions or insertions                             
(Ali and Sjoblom 2009). 
1.1.6.1 Breast cancer mutations  
Among the diagnosed cases of Breast cancer 93-95% are sporadic while 5-7% are 
familial breast cancer. In familial breast cancer, 25% of cases exhibit germ line 
mutations in BRCA1 and BRCA2 while 5% contain mutations in other high 
susceptibility genes such as Tp53, PTEN and CDH1. Somatic mutations in BRCA1 
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(61%) are mainly found to be associated with Basal-like sporadic breast cancer 
(Anders and Carey 2009).  
Other genes with somatic mutations found in breast cancer are GATA3 (trans-acting 
T-cell-specific transcription factor GATA-3 or GATA-binding factor 3) and TP53. 
Other mutations found in breast cancer are: CDH1 (cadherin-1),                             
RB1 (retinoblastoma 1), MAP3K1 (mitogen-activated protein kinase kinase kinase 1 
or MAPK/ERK kinase kinase 1), SMARCD1 (SWI/SNF-related matrix-associated actin-
dependent regulator of chromatin subfamily D member 1), NCOR1 (nuclear 
receptor corepressor 1), CASP8 (caspase 8, apoptosis-related cysteine protease), 
MAP3K13 (mitogen-activated protein kinase kinase kinase 13), CDKN1B (cyclin-
dependent kinase inhibitor 1B (p27, Kip1), FOXA1 (forkhead box protein A1), TBX3 
(T-box transcription factor), SF3B1 (splicing factor 3b, subunit 1), MYH9 (myosin 
heavy chain 9), AGTR2 (angiotensin II receptor, type 2), LDLRAP1 (low density 
lipoprotein receptor adaptor protein 1), STMN2 (stathmin-2), CBFB (core-binding 
factor subunit beta) with its associated partner RUNX1 (runt-related transcription 
factor 1), PTEN (phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-
specificity protein phosphatise) (Previati et al. 2013, Cornejo et al. 2014). 
 
1.2 Signal transduction by the insulin and growth factor pathways 
in breast cancer 
1.2.1 Role of tyrosine kinase receptors  
Tyrosine kinase receptors play a crucial role in transmitting growth signals to the 
cell and serve as a major determinant of cell destiny (Sasaki et al. 2013). Tyrosine 
kinase receptors are involved in regulation of various cellular functions such as DNA 
replication, cell proliferation, transcription, DNA damage repair, metastasis of 
cancer, apoptosis, cell cycle advancement, development and differentiation 
(Roskoski 2014). Overexpressed and genetically altered forms of tyrosine kinases 
can cause oncogenic transformation in the cell. These mutations are usually found 
in the intracellular domain of growth factor receptors (Masuda et al. 2012).  
Therefore tyrosine kinase inhibitors (TKIs) which usually interact with the ATP 
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binding site of the tyrosine kinase domain are regarded as a promising class of 
cancer drugs (Ali and Sjoblom 2009).  
The pioneering work done by Stanley Cohen in the growth factor field, led to the 
discovery of EGF (epidermal growth factor) and EGFR (epidermal growth factor 
receptor). This resulted in further identification of 14 families of tyrosine kinases 
receptors such as IGF-1R (Mendelsohn and Baselga 2000, Masuda et al. 2012).  The 
IGF-1R and insulin receptor are activated by IGF-1, IGF-2 and insulin respectively 
and play a crucial role in stimulating signaling pathways involved in cell proliferation 
and survival (Werner and Bruchim 2012). EGFR was first identified as a 
transmembrane tyrosine kinase receptor and serves as a potent element in 
epithelial malignancies. It is by far the best examined signalling family in oncology 
(Earp et al. 2003). 
1.2.1.1 EGFR signaling in breast cancer 
Signalling pathways serve a crucial role in the regulation of cause, existence and 
spread of tumour growth. These pathways mediate biological signals to the cell and 
regulate various functions (Santen et al. 2002).  Among other malignancies, breast 
cancer is one of the most complex diseases, with several stages of altered signalling 
pathways (Hadad et al. 2008). Under normal circumstances the level of EGFR is 
strictly regulated according to cell demand in order to maintain the balance of 
cellular functions (Sasaki et al. 2013).  
1.2.1.1.1 Types of EGFR 
The gene family of EGFR also called HER1 (human EGFR receptor 1) and ErbB1 
(erythroblastosis virus) consist of four members: EGFR (ErBb1,HER1), ErBb2 
(HER2,nue), ErBb3 (HER3) and ErBb4 (HER4) (Roskoski 2014). EGFR receptors consist 
of intracellular or cytoplasmic domains, which exhibit tyrosine kinase activity. They 
also have a C terminal tail, which contains several residues of tyrosine that are 
involved in initiation of signaling pathways upon phosphorylation. The extracellular 
or ligand binding domain is connected to the transmembrane hydrophobic domain 
(Roskoski 2014).  The cytoplasmic tyrosine kinase domains of EGFR receptors are 
very similar, except for HER3 which lacks kinase activity, while the extracellular 
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domains are least conserved and have variable ligand binding affinities     
(Normanno et al. 2006).  
1.2.1.1.2 Types of EGFR ligands 
The family of peptide growth factors that bind to EGFR falls into three groups. The 
first group includes EGF, amphiregulin (AR) and transforming growth factor ɲ(TGF-
ɲ), the second group consists of heparin-binding growth factor (HB-EGF), 
betacellulin (BTC) and epiregulin (EPR) and third group contains neuregulins (NRG-1, 
NRG-2, NRG-3 and NRG-4) (Mendelsohn and Baselga 2000). None of these ligands 
binds to HER2, while seven ligands bind to HER1 and HER4 and only two bind to 
HER3 (Roskoski 2014). 
 
 Several possible combinations of interaction exist between the four receptors and 
their 10 ligands, which lead to a diversified role of EGFR in signaling. Activation of 
the same receptors by different ligands induces distinct signaling pathways                
(Mendelsohn and Baselga 2000, Earp et al. 2003). Types of ligands and receptor 
complexes greatly influence the resulting activated signaling pathways       
(Normanno et al. 2006).  
1.2.1.1.3 Mode of receptor activation 
Binding of a ligand to the extracellular domain of EGFR receptors stimulates 
receptor activation, which promotes the formation of homo and heterodimer 
complexes and leads to the activation of tyrosine kinase domain                            
(Gala and Chandarlapaty 2014). This is true for all EGFR receptors except for HER2, 
which only becomes activated when in a complex with another EGFR. Receptor 
activation favours the conformational change in the receptor resulting in the 
phosphorylation of C terminal tyrosine residues (Mendelsohn and Baselga 2000). 
These phosphorylated tyrosine residues provide docking sites for the 
phosphotyrosine binding (PTB) domains and Src homology 2 (SH2) comprising 
proteins. Interaction of these proteins results in the initiation of transduction 
pathways (Normanno et al. 2006). 
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1.2.1.1.4 EGFR mutations in breast cancer  
The initial link between cancer and increased expression of receptors was found to 
be in EGFR (Roskoski 2014). The increased expression of EGFR and EGF is associated 
with many malignancies and they also have the potential to cause oncogenic 
transformation. EGFR is known to be amplified at gene level, while mutations in 
tyrosine kinase domain of EGFR are found to be associated with carcinogenesis 
(Normanno et al. 2006). In cancer EGFR levels are upregulated due to an extended 
yield of ligand or might be due to mutation in EGFR which leads to level of 
continuous production (Sasaki et al. 2013). Around 50% of Basal like subtype cases 
have increased expression of EGFR (Earp et al. 2003, Masuda et al. 2012). 
1.2.1.1.4.1  Role of HER2  
HER2 is overexpressed and amplified at gene level in 20-25% of breast cancers, 
leading to poor prognosis. Therefore HER2 is considered as a well recognized 
therapeutic target for breast cancer treatment (Earp et al. 2003). HER2 activating 
mutations are found in around 1.6% of patients (Roskoski 2014).  
There is no known suitable ligand for HER2, therefore it forms heterodimers with 
other receptors. HER2 is the most active as it occurs in dimer-ready form and 
heterodimerized with other receptors (Earp et al. 2003). HER3 which lacks kinase 
activity prefers HER2 for dimerization, forming a HER2/HER3 complex. This dimer 
receptor complex is one of the strongest in stimulating the signaling cascades of 
PI3K/AKT and Ras/Raf/MAPK pathways (Normanno et al. 2006). HER3 induces 
kinase activity of HER2 by stimulating autophosphorylation of six tyrosine residues 
of C terminus of HER3.The terminus then interacts with p85 subunit of PI3K leading 
to activation of the PI3K signaling cascade, which is involved in carcinogenesis. Thus 
targeting PI3K pathway receptor tyrosine kinases may provide an effective tool in 
breast cancer treatment (Gala and Chandarlapaty 2014).  
The EGFR inhibitors which act primarily by blocking ligand interaction are used as 
the best directed agent against breast cancer treatment. The combined targeting 
with EGFR inhibitors and anti-HER2 (MAbs), provide a more novel approach for the 
treatment of breast cancer (Normanno et al. 2006, Masuda et al. 2012). 
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1.2.1.2 Downstream signaling of EGFR 
The family members of EGFR propagate growth stimulating signals through the 
interaction of EGF (epidermal growth factor) ligand into the cell, stimulating the 
tyrosine kinase function of the receptor and leading to activation of the signaling 
cascade. Thus it leads to the initiation of several biochemical modifications which 
include cell proliferation, transcription and DNA synthesis. The downstream 
signaling pathway activated by EGFR involves the Ras/Raf/mitogen-activated 
protein kinase and the PI3K/mTOR/AKT pathway, the most common altered 
signaling cascade in breast cancer progression as shown in figure 1.1                 
(Sasaki et al. 2013).  
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Figure 1.1: The signal transduction cascade downstream of receptor tyrosine kinase 
with AMPK as a negative regulator: 
The growth factor/insulin stimulated RTKs activate the two most commonly altered signaling 
cascades of breast cancer. The PI3K/AKT and MAPK pathways are shown with their 
associated cellular proteins. Bars indicate inhibition while arrows represent activation. Both 
pathways are stimulated by RTKs through their respective adaptor proteins. The mTORC1 
and mTORC2 a protein complexes of PI3K/AKT pathway mediates downstream signalling 
with the interaction of other protein partners. mTORC1 mediates translation regulation in 
response to amino acid, growth factors and cellular energy levels through phosphorylation of 
4E-BP and S6K1. Upstream regulators of mTORC1 are AKT, AMPK and TSC-Rheb. AKT is 
activated through PI3K signalling, serving as a positive regulator of mTORC1 by inhibiting 
TSC complex and PRAS40 through phosphorylation while AMPK is activated by upstream 
NLQDVHV /.% &$0..ȕ upon deprivation of cellular energy levels/oxygen. AMPK 
downregulates the activity of mTORC1 by stimulating the TSC complex and through Raptor 
phosphorylation. The TSC complex 1/2 act as a GTPase-activating protein for the Rheb, a 
small Ras-related GTPase involves in inhibiting mTORC1 activity by converting Rheb-GTP 
(active) form to Rheb-GDP (inactive) form. RTKs stimulation of of the MAPK pathway 
involvesthe conversion of inactive RAS into active RAS-GTP through SOS. Ras in GTP 
bound form activates Raf which further activates MEK1/2 by phosphorylation. Active MEK 
phosphorylates ERK1/2 which regulates various downstream cellular targets through the 
activation of various genes encoding transcription factors. AMPK inhibits MAPK signaling 
through BRAF phosphorylation. The potential tumour suppressors are highlighted with red 
borders while oncogenes are edged in dark blue.  
Abbreviations: AMPK, adenosine monophosphate-dependent protein kinase; mTOR, 
mammalian target of rapamycin; PDK1, phosphoinositide-dependent protein kinase 1; PI3K, 
phosphoinositide 3-kinase; PRAS40, proline rich AKT substrate 40 kDa; or AKT1S1 (AKT 
substrate 1)); PIP3 (also known as PtdIns(3,4,5)P3), phosphatidylinositol (3,4,5)- 
trisphosphate; PTEN, phosphatase and tensin homolog; Raptor, regulatory associated 
protein of mTOR; Rheb, Ras homolog enriched in brain; Rictor, rapamycin-insensitive 
component of mTOR; S6K1, ribosomal S6 protein kinase 1; TSC1 and TSC2, tuberous 
sclerosis complex 1 and 2, ERK: extracellular signal-regulated kinase. MEK: mitogen-
activated and extracellular signal regulated kinase kinase. 
 
Receptor tyrosine kinases such as EGFR stimulate various growth related cellular 
functions through the interaction of peptide growth factors or EGFR associated 
ligands which leads to the activation of the signal transduction cascade (Normanno 
et al. 2006). In next section I will discuss the roles and links between these signaling 
pathways in breast cancer development, as well as the merit in targeting RTKs and 
signaling components of PI3K/AKT and Ras/MAPK pathways in the treatment of 
breast cancer.  
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1.2.1.2.1 The PI3K/AKT/mTOR pathway 
1.2.1.2.1.1 What is mTOR 
The large protein kinase complex, mammalian (or mechanistic) target of rapamycin 
(mTOR) is an extremely conserved serine-threonine kinase that plays a crucial role 
in many key cellular processes. These include cell proliferation, metabolism, 
differentiation, survival, growth, senescence and progression of metastasis by 
integrating extracellular and intracellular signals and are found to be deregulated in 
several cancers, such as breast cancer (Efeyan et al. 2012, Khan et al. 2013).      
mTOR signaling is inhibited by rapamycin, a macrolide ester, which interacts with 
intracellular cytoplasmic protein receptor FKBP12 (FK506 binding protein 12KDa). 
Upon entering into the cell, rapamycin  forms a rapamycin/FKBP12 complex, which 
is associated with mTOR through FRB (FKBP12 rapamycin binding domain) (Laplante 
and Sabatini 2009). The PI3K/AKT/mTOR pathway, depicted in Fig 1.1, is activated 
by several upstream growth factor tyrosine kinase receptors such as EGFR (HER1), 
IGF-1R, insulin receptor (InsR) and HER2. In addition, it can also be activated 
through non-genomic estrogen signaling (Lauring et al. 2013, Martin et al. 2013). 
Insulin receptor substrate (IRS1-4) serves as an adaptor protein in insulin mediated 
activation of the PI3K signaling cascade (Jalving et al. 2010). 
1.2.1.2.1.2 Multi-protein complexes of mTOR 
mTOR is a kinase that regulates a complex signaling network and functions as a 
multidomain protein in complexes with several other proteins. It regulates 
ribosome biogenesis, protein synthesis and metabolism (Averous and Proud 2006, 
Guertin and Sabatini 2007). mTOR is found in two different multiprotein complexes 
known as mTORC1 (mTOR complex1) and mTORC2 (mTOR complex2)               
(Hadad et al. 2008). mTORC1 consists of mTOR, PRAS40 and Raptor while mTORC2 
contains mTOR, mSIN1, Rictor and Protor1. mLST8 and Deptor are common in both 
complexes. mTOR kinase serves as the catalytic subunit in both protein complexes 
(Averous and Proud 2006, Laplante and Sabatini 2009).  
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1.2.1.2.1.2.1 mTORC2 
The mTOR kinase in the mTORC2 is growth factor sensitive, but not sensitive to 
nutrients (amino acids) and rapamycin. Rictor serves as a scaffolding protein, which 
stimulates assembly and substrate binding to mTORC2 and interacts with Protor-1 
(Wu et al. 2005, Laplante and Sabatini 2012).  Deptor serves as a negative regulator 
of mTORC2 activity while mLST8 knockout is lethal and plays a crucial role in 
mTORC2 activity (Yonezawa 2004). mTORC2 phosphorylates and activates the AKT 
kinases. 
1.2.1.2.1.2.2 mTORC1 
mTORC1 is activated in response to amino acids, growth factors and cellular energy 
levels and is involved in the regulation of protein synthesis, ribosome biogenesis 
and  promotion of cell growth (Dazert and Hall 2011, Laplante and Sabatini 2012). 
The mTOR kinase in mTORC1 is sensitive to the immune suppressive drug 
rapamycin. The rapamycin sensitivity of the complex is dependent on its interaction 
with the scaffolding protein Raptor, which facilitates the recruitment of mTORC1 
substrates through their TOS motif to mTOR. In absence of Raptor, or after 
mutation of the TOS motif, mTOR kinase is unable to phosphorylate its downstream 
translational targets such as 4EBP and p70S6K (Yonezawa 2004, Yang and Guan 
2007, Laplante and Sabatini 2009).  
The mLST8 is not crucial for mTORC1 activity but enhances the interaction of mTOR 
and Raptor through the catalytic domain of mTOR. PRAS40 and Deptor negatively 
regulate mTORC1 activity. PRAS40 interacts with raptor through its TOS motif and 
competes for the binding site with other mTORC1 substrates, repressing the kinase 
activity of mTORC1. Phosphorylation of PRAS40 by mTORC1 on Ser183 demolishes 
the activity of PRAS40, which leads to its dissociation with mTORC1, thus enhancing 
the activity of mTORC1 (Yang and Guan 2007, Laplante and Sabatini 2009).  
1.2.1.2.1.3 Phosphatidylinositol 2-kinases 
mTOR belongs to a large family of proteins called PIKK (phosphoinositide kinase 
related kinases) and shares sequence similarity with the  PI3K (phosphatidylinositol 
3-kinase) lipid kinase family, which respond to growth factors and regulate mTOR 
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activity (Chiang and Abraham 2007, Hadad et al. 2008).  The family of PI3K consists 
of three classes among which PI3K class 1A isoforms are mostly found to be 
involved in carcinogenesis. PI3K, a heterodimer enzyme, consists of a p110 catalytic 
and p85 regulatory subunits which exist ŝŶƉ ? ? ?ɲ ?Ɖ ? ? ?ɴ ?Ɖ ? ? ?ɷand Ɖ ? ?ɲ ?Ɖ ? ?ɲ ?
Ɖ ? ?ɶ ?Ɖ ? ?ɲĂŶĚƉ ? ?ɴisoforms respectively. /ƐŽĨŽƌŵƐƉ ? ? ?ɲ ?Ɖ ? ? ?ɴĂŶĚ Ɖ ? ? ?ɷĂƌĞ
encoded by PI3KCA, PI3KCB and PI3KCD and are most widely expressed                    
(Miller et al. 2011). 
Growth factors activate PI3K (phosphatidyl inositol-3-kinase) to mediate the 
phosphorylation of lipid messenger PIP2 (phosphatidylinositol-4,5-bisphosphate or 
PtdIns(3,4)P2) to PIP3 (phosphatidyl inositol-3,4,5-triphosphate or PtdIns(3,4,5)P3) 
(Yang and Guan 2007, Lauring et al. 2013). The function of PI3K is inhibited by PTEN 
(phosphatase and tensin homolog) and INPP4B (Inositol polyphosphate-4- 
phosphatase type II) by dephosphorylating PIP3 and PIP2 (Ciruelos Gil 2014).       
PIP3 acts as a second messenger and initiates downstream signaling through 
recruitment of PDK1 (PI3K dependent serine/threonine kinases) and AKT at the cell 
membrane. This is achieved through an interaction with PH (pleckstrin homology) 
domain of PDK1, which partially activates AKT through phosphorylation at T308 
(threonine 308). The full activation of AKT is mediated by mTORC2 by 
phosphorylation on Ser473, which might be recruited through mSINI (Yang and 
Guan 2007, Yap et al. 2008). AKT (PKB or protein kinase B) is a serine threonine 
kinase involved in the regulation of cell growth, proliferation and apoptosis                             
(Laplante and Sabatini 2009). 
1.2.1.2.1.4 Regulation of mTORC1 by upstream kinases  
mTOR serves as a main controller of growth and proliferation, which conveys signals 
to its downstream targets in response to growth factors and nutrient availability. 
Growth factor mediated inhibition of TSC1/2, which in turn activates Rheb-GTP, 
leads to the initiation of mTORC1 activity (Gingras et al. 2001, Saini et al. 2013). 
1.2.1.2.1.4.1 TSC mediated RHEB pathway 
The Tuberous Sclerosis complex (TSC 1 and TSC 2) serves as a negative regulator of 
mTORC1 activity and plays a crucial role in the regulation of  mTOR signaling  
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through AMPK and AKT (Yonezawa 2004). TSC is a heterodimer which consists of a 
complex of two interacting proteins called TSC1 (hamartin) and TSC2 (tuberin) 
(Dazert and Hall 2011). TSC1/2 is a guanosine triphosphatase or GTPase activating 
protein (GAP) for a small GTPase, Rheb (Ras homolog enriched in brain). Rheb 
activates mTORC1 through its active GTP bound state (Laplante and Sabatini 2009).       
TSC1/2 complex converts active GTP bound Rheb into its inactive GDP bound form 
and thus negatively regulates mTORC1 (Inoki et al. 2012, Laplante and Sabatini 
2012). 
1.2.1.2.1.4.2 AKT: A positive regulator of mTORC1 activity 
AKT is involved in cell survival, inhibition of apoptosis, cell growth and proliferation 
by positively regulating the mTORC1 kinase activity (Gingras et al. 2001, Laplante 
and Sabatini 2009). mTORC2 activates AKT signaling by PI3K  in response to growth 
factors. AKT upstream of mTORC1 is involved in translational regulation of its 
downstream signaling targets in response to nutrients (Guertin and Sabatini 2007, 
Yang and Guan 2007). AKT promotes mTORC1 kinase activity by two independent 
pathways: the TSC-Rheb pathway and the PRAS40-mTORC1 pathway.  
AKT inhibits the activity of the TSC complex through phosphorylation of TSC2 on 
multiple sites leading to upregulation of mTORC1 kinase activity, linking PI3K-AKT to 
TSC-mTORC1 signaling pathways (Laplante and Sabatini 2013). Overexpression of 
AKT leads to hyperphosphorylation of translational targets such as 4EBP and 
p70S6K, through inactivation of TSC1 and TSC2 heterodimer (Yonezawa 2004).  
AKT also positively regulates mTORC1 kinase activity, independent of the TSC-Rheb 
pathway, through directly phosphorylating the PRAS40 (proline-rich Akt substrate 
40 kDa or AKT1S1 (AKT substrate 1)) on T246 near its carboxyl terminal region, 
which decreases its interaction with mTORC1 kinase (Yang and Guan 2007). PRAS40 
suppresses  RHEB-GTP activation of mTORC1 and remains associated with mTORC1 
(Guertin and Sabatini 2007). Thus AKT promotes mTORC1 kinase activity by 
stimulating the activity of RHEB-GTP and releasing the inhibitory effect of PRAS40 
from mTORC1 by phosphorylation (Xu et al. 2012). PRAS40 suppresses the 
phosphorylation of mTORC1 substrates such as 4EBP and S6K1 by competing for the 
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same kinase raptor-mTOR among these substrates. Therefore 
hyperphosphorylation of PRAS40 reduces 4EBP and S6K1 phosphorylation and vice 
versa    (Yang and Guan 2007).  
1.2.1.2.1.4.3 AMPK:  A negative regulator of mTORC1 activity 
mTOR is a ĚŽǁŶƐƚƌĞĂŵ ƚĂƌŐĞƚ ŽĨ DW<  ? ? ?-adenosine monophosphate-activated 
protein kinase) which  regulates cell metabolism, cell growth and proliferation in 
response to signals from the environment such as oxygen, nutrients and energy 
status (Xu et al. 2012) (Inoki et al. 2002, Laplante and Sabatini 2009). The process of 
protein synthesis is highly energy consuming and has to be increased during cell 
growth in response to growth factor signals. However if there are insuffient 
nutrients or inadequate amount of energy, the rate of protein synthesis needs to be 
reduced and cell growth prevented (Xu et al. 2012). AMPK is regulated in response 
to changes in the intracellular ratio of AMP/ATP or due to elevated intracellular 
levels of Ca2+ (Kim and He 2013). Favorable conditions stimulate cell growth 
through mTOR activation by inhibiting AMPK (Inoki et al. 2012).  AMPK consists of 
an ɲĐĂƚĂůǇƚŝĐƐƵďƵŶŝƚ, ǁŚŝůĞɴĂŶĚɶare regulatory subunits.  Upstream kinases such 
as LKB1 (serine/threonine kinase 11), a tumour suppressor, and CaMKKɴ 
(Calcium/calmodulin-dependent protein kinase kinase-b) family kinases play an 
essential role in AMPK activation, by phosphorylating the ĐĂƚĂůǇƚŝĐ ɲ ƐƵďƵŶŝƚ Ăƚ
threonine residue 172 (Thr-172). In mammals, LKB1 is the critical enzyme for AMPK 
activation and thus provides an initial link of AMPK to cancer (Hadad et al. 2008).  
AMPK is involved in regulating the balance of intracellular energy levels through 
modulating the phosphorylation state of its substrate by catabolic or ATP 
generating processes such as fatty acid oxidation and glycolysis. AMPK also 
regulates energy levels through inhibiting anabolic processes to reduce the 
consumption of ATP, such as inhibiting protein and fatty acid synthesis (Shen et al. 
2013).  AMPK becomes activated during cellular stress conditions, including low 
oxygen or hypoxia, which lead to a low ratio of ATP/ADP (Laplante and Sabatini 
2009). The rate of cell growth is therefore highly regulated by mTOR, in relation to 
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the availability of nutrients and energy in co-ordination with AMPK (Chiang and 
Abraham 2007).  
AMPK negatively regulates mTOR by stimulating the activity of the TSC by 
phosphorylating TSC2 on S1345 and T1227 which inhibits the activity of Rheb by 
activating TSC GTPase activity and converting Rheb into its GDP bound state 
(inactive state) (Xu et al. 2012). AMPK also suppresses mTORC1 activity through 
Raptor phosphorylation which may destabilize the complex (Laplante and Sabatini 
2009). Thus mTORC1 efficiently regulates protein synthesis by blocking the 
phosphorylation of 4EBP and S6K1 through AMPK mediated inhibition of mTORC1 
under low energy or stress conditions, mediated by TSC-mTORC1 pathway          
(Yang and Guan 2007). AMPK also mediates the inhibition of mTORC1 in response 
to energy reduction through raptor phosphorylation, which disrupts its association 
with mTOR and thus inhibits substrate binding (Laplante and Sabatini 2009, Inoki et 
al. 2012). 
1.2.1.2.1.5 Downstream signaling of mTOR 
The best characterized function of downstream targets of the mTORC1 signaling 
pathway is the regulation of translation machinery in response to availability of 
nutrients, especially amino acids, through an unidentified mechanism. It acts 
independently of the TSC complex mediated pathway (Laplante and Sabatini 2009, 
Laplante and Sabatini 2012). mTOR not only changes the phosphorylation state of 
translation initiation factors, but also influences levels of components involved in 
the translation process by controlling their rate of synthesis (Gingras et al. 2001). 
The deregulation in FRAP/mTOR signaling pathway due to altered levels of signaling 
components, also leads to translational deregulation, linked with an increase in cell 
growth. Disrupted FRAP/mTOR signaling contributes to translational activation of 
mRNAs involved in cell cycle progression as well as inhibitors of apoptosis     
(Dowling et al. 2007). Deregulation of translational pathways is thought to lead to 
cell transformation, as a result of the altered production of proteins that are 
involved in promoting and suppressing cancer (Clemens 2004). 
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The downstream effectors of mTOR signaling which are directly or indirectly 
phosphorylated by mTOR are 4EBP1 (4E-binding protein), eIF4G and S6K kinases 
(p70 ribosomal protein S6 kinase1 and 2).  S6K kinases then phosphorylate eIF4B, 
eEF2K (Eukaryotic elongation factor-2 kinase) and ribosomal protein 6, thus 
promoting cell growth by enhancing cap dependent translation, elongation and 
ribosome biogenesis (Sonenberg and Hinnebusch 2009, Laplante and Sabatini 
2012).  
 
eIF4G1 is phosphorylated at several sites by mTORC1, which stabilizes the complex 
of eIF4G1-eIF3 and leads to efficient recruitment of the 40S ribosomal subunit.  
However, the direct phopshorylation of eIF4G1 by mTOR is still uncertain       
(Averous and Proud 2006, Mamane et al. 2006, Thoreen 2013). mTORC1 
phosphorylates and activates the p70 S6 kinases (S6K1 and S6K2). The most 
abundant substrate of S6K1 is RpS6 (ribosomal protein 6), a phosphoprotein 
(Hershey 2010, Komelkov 2012 ). S6K1 is also reported to be involved in promoting 
tumour growth and its expression is elevated in several cancers                     
(Mamane et al. 2006). The phosphorylation of eIF4B by S6K1 not only enhances the 
helicase activity of eIF4A but also increases the association of eIF4B with eIF3, thus 
leading to efficient initiation of cap dependent translation by promoting the 
recruitment of the translation initiation complex (Gingras et al. 2001, Sonenberg 
and Hinnebusch 2009). 
1.2.1.2.1.5.1 eIF4E/4E-BP 
In a complex process of protein synthesis, eIF4E is a main regulator during the rate 
limiting step of translation initiation. eIF4E is also involved in tumorigenesis and 
found to be deregulated in a variety of cancers (Mamane et al. 2004, Averous and 
Proud 2006). eIF4E specifically binds to the  ? ? ĐĂƉ ƐƚƌƵĐƚƵƌĞ ŽĨ ĂŶ ŵZE ĂƐ Ă
component of the trimeric complex of eIF4F with eIF4G (a scaffolding protein) and 
eIF4A (an RNA helicase) (Montanaro and Pandolfi 2004). High levels of eIF4E 
enhance the translation of specific mRNAs involved in cell growth (c-myc), cell cycle 
progression (cyclin D1) and in angiogenesis (VEGF). Thus eIF4E is a potential proto-
oncogene (Montanaro and Pandolfi 2004, Thoreen 2013). 
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The availability of functional eIF4E is regulated through the phosphorylation state of 
4EBP (4E-binding proteins) also known as PHAS-I (phosphorylated heat and stable 
protein, insulin stimulated). 4EBP1 acts as a translation repressor in a 
hypophosphorylated state, by inhibiting the assembly of eIF4F complex by 
competing for the binding site with eIF4G on the dorsal face of eIF4E. In this way, it 
inhibits cap dependent translation. 4EBP in its hyperphosphorylated state 
dissociates from eIF4E, allowing eIF4G to effectively interact with eIF4E, which leads 
to translation initiation (Bjornsti and Houghton 2004, Hershey 2010). Consequently, 
mTOR mediates translation regulation by stimulating cap dependent translation 
through 4EBP1 phosphorylation in response to extracellular stimuli (Yang and Guan 
2007). In its hypophosphorylated state, 4EBP acts as a tumor suppressor by 
reducing the levels of functional eIF4E. This leads to downregulation of specific 
mRNAs, which become translationally upregulated due to increased levels of eIF4E 
(Meric and Hunt 2002). Thus high levels of 4EBP revert the oncogenic phenotype of 
transformed cells caused by elevated levels of eIF4E (Hershey 2010). 
1.2.1.2.2 Raf/MEK/Erk1/2 pathway (MAPK) 
1.2.1.2.2.1 Role of MAPK (ERK1/2) 
The MAPK (mitogen-activated protein kinases) is a family of serine threonine 
protein kinases, also known as the ERK pathway. This is an extremely conserved 
signal transduction pathway among eukaryotes that incorporates various 
extracellular signals into the cellular machinery. ERK consist of two isoforms ERK 1 
and 2, which have 85% similarity. However, ERK 2 is the one that is predominantly 
implicated in carcinogenesis (Santen et al. 2002, Deschenes-Simard et al. 2014). 
MAPK mediates signal transduction depending upon stimulus and cell type, 
regulating cellular processes ranging from cell proliferation and survival to 
activating tumor suppressor events, such as apoptosis and cell differentiation 
(Dhillon et al. 2007, Deschenes-Simard et al. 2014). Among the three MAPK 
pathways which are found in humans, the one which consists of MEK 1/2 (MAP/ERK 
kinase) and ERK1/2 (extracellular signal regulated kinases 1 and 2) is heavily 
implicated in breast cancer (Saini et al. 2013). ERK 1 and ERK 2 are localized in 
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various cellular places such as  specific parts of plasma membrane, microtubule 
associated cytoskeleton and nucleus (Santen et al. 2002).  
1.2.1.2.2.2 ERK signaling cascade 
The ERK cascade consists of three sequential series of kinases: Raf1 (MAPKKK), MEK 
1/2 (MAPKK) and ERK 1/2 (MAPK). Growth of estrogen independent breast cancer 
subtypes is dependent on peptide growth factors as major extracellular stimuli, 
which activate ERK signaling through tyrosine kinase receptors, stimulating 
phosphorylation of adaptor proteins such as Shc (Santen et al. 2002). The 
Shc/receptor complex interacts with Grb2 and SOS (son of sevenless). Grb2 acts as 
scaffold protein that connects RTKs to downstream components.  Interaction of 
Grb2 or Shc adaptor proteins to RTKS results in stimulation of Raf/MEK/ERK 
signalling (Adams et al. 2012). SOS is a Ras-guanine nucleotide exchange factor that 
facilitates converstion of GDP-RAS to GTP-RAS. RAS is an oncoprotein that plays 
crucial roles in cellular proliferation and cancer progression and consists of three 
family members KRas, NRas and HRas (Saini et al. 2013). The first kinase effector of 
GTP-RAS is Raf-1, which exists in three isoforms (ARaf, BRaf, CRaf or Raf-1). The 
GTP-RAS mediated phosphorylation activates Raf. Activated Raf phosphorylates a 
second downstream kinase MEK that also exists in two isoforms MEK 1 and 2.  BRaf 
is most effective in activating MEK, followed by Raf-1 and ARaf. MEK activation 
leads to stimulation of ERK through phosphorylating tyrosine and threonine 
residues. Activated ERK 1 and 2 phosphorylate a large number of downstream 
targets that have been linked with gene regulation (Santen et al. 2002).  
1.2.1.2.2.3 Downstream signaling events of ERKs 
ERKs signaling involve the regulation of many downstream cellular events through 
phosphorylation of various key cytoplasm and nuclear players. Targets of ERKs 
signaling include cytoskeleton proteins, kinases, phosphatases and various 
transcription factors. The diverse biological roles of ERK signaling are dependent 
upon the signaling intensity and localization of ERK (Dhillon et al. 2007, Roskoski 
2014).  
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ERKs signaling mediated activation of other protein kinases such as RSK via 
phosphorylation, leads to stimulation of various downstream cellular targets of 
ERKs cascade that are involved in transcriptional regulation (Santen et al. 2002). 
Nuclear translocation of ERKs upon activation plays a crucial role in stimulation of 
several transcription factor encoded genes, including c-fos, c-myc, ATF-2 (activating 
transcription factor 2) and c-jun, which also promote cell proliferation. Activation of 
the ERK cascade also leads to phosphorylation of histone 3 and HMG-14. Thus ERKs 
signaling regulates gene expression and contributes to chromatin remodeling  
(Santen et al. 2002).  
Sustained ERK signaling not only leads to stable activation and high expression of 
proliferation linked transcription factors, but it also stimulates CDKs (cyclin-
dependent kinase) such as cyclin D1. This helps to promote cell cycle progression 
and also inhibits anti-proliferative gene expression (Fowler et al. 2011, Deschenes-
Simard et al. 2014). However, a hyperactive ERK cascade blocks cell cycle 
progression by activating CDKs inhibitors such as p27 and p21 (Dhillon et al. 2007). 
1.2.1.2.2.4 AMPK: attenuates MAPK signaling 
The molecular link between Ras-Raf-MEK-Erk and LKB1-AMPK pathways is 
complicated and still not entirely clear. These two pathways are a major link 
between the regulation of cell growth and proliferation, in response to cellular 
energy status or under metabolic stress (Zheng et al. 2009). BRAF is found to be 
mutated in several malignancies. The amino acid change in the kinase domain of 
BRAF leads to mutant V600E involved in continuous signaling and activation 
downstream of MAPK pathway. The KSR (kinase suppressor of Ras), a scaffold 
protein of MAPK pathway, stimulates RAF mediated MEK phosphorylation. The 
LKB1 mediated activation of AMPK by AICAR leads to phosphorylation of BRAF at 
Ser729, which interrupts the interaction of BRAF-KSR and CRAF, resulting in 
inhibition of MAPK signaling pathway (Shen et al. 2013). The relationship between 
LKB1-AMPK and MAPK signaling pathway is attenuated in cancerous cells harboring 
various genetic aberrations. Conversely, the MAPK signaling cascade reduces AMPK 
signaling through phosphorylation mediated inactivation of the upstream Ser/Thr 
kinase LKB1 at Ser428 by ERK and p90RSK in BRAF mutant V600E cells, providing 
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resistance to metabolic stress. However in cells with wild type BRAF, AICAR induces 
AMPK activation as normal (Esteve-Puig et al. 2009). Phosphorylation of BRAF by 
AMPK also leads to inhibition of cell proliferation by stimulating cell cycle arrest, 
due to elevated levels of cell cycle inhibitors such as p21 (Petti et al. 2012). 
1.2.1.2.3 Genetic alterations in downstream signaling pathways 
Growth factor mediated signalling pathways such as PI3K/AKT/mTOR and 
Raf/MEK/ERK are important in cancer progression, as many key players of signalling 
pathways are found to be deregulated or expressed constitutively in breast cancer 
(Hadad et al. 2008, Saini et al. 2013). Alterations in signals regulated by membrane 
receptors or TRKs are often due to changes in the amount of receptors found on the 
cell surface or to modifications that lead to continuous activation of signalling 
pathways, without the presence of the ligand. Pathways like PI3K/AKT, AMPK, 
mTOR, IGFIR, estrogen receptors and HER2 are under intense investigation as 
therapeutic targets in breast cancer treatment (Eroles et al. 2012, Werner and 
Bruchim 2012).  
1.2.1.2.3.1 Mutation analysis of mTOR  
The PI3K/mTOR pathway is found to be deregulated in 70% of breast cancer (Miller 
et al. 2011, Lauring et al. 2013). Constitutive signaling of this pathway is either due 
to overexpression of RTKs (HER2, IGF-IR), or somatic ĂůƚĞƌĂƚŝŽŶƐŝŶW/< ? ?Ɖ ? ? ?ɲ ? 
and its downstream effectors like AKT, TSC1/2 (Calkhoven et al. 2002, Khan et al. 
2013).  Activation of the mTOR pathway also leads to hyperphosphorylation of 
downstream translational targets such as S6K and 4EBP1, resulting in hyper-
activated translation and growth and proliferation of tumor cells (Gingras et al. 
2001, Martin et al. 2013). The catalytic subunit of PI3K kinase, PI3KCA is found to be 
mutated in 36% of breast cancer, with 80% genetic alteration in the kinase domain 
of the Ɖ ? ? ?ɲƐƵďƵŶŝƚĂŶĚ frequent combination with HER2 overexpression or PTEN 
loss (Ali and Sjoblom 2009, Martin et al. 2013, Saini et al. 2013). The frequency of 
genetic alterations of PI3K signaling pathway in different subtypes of breast cancer 
is summarized in table 2. 
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Table 2: Genetic alterations of the PI3K/AKT/mTOR pathway in breast cancer subtypes 
Type of 
alteration 
Gene 
(Protein) 
Consequence on 
signaling 
Frequency in breast cancer subtypes (%) 
 
ER+ (Luminal) Basal (TN) HER2+ 
Amplification 
or activating 
mutations 
ErbB2 (HER2) 
Hyperactivation 
of HER2 signaling 
(PI3K, MEK) 
10 0 100% 
EGFR 
Hyperactivation 
of EGFR signaling 
(PI3K, MEK) 
- - 0.8 
AKT1 
Hyperactivation 
of AKT 
2.6-3.8 0 0 
AKT2 
Hyperactivation 
of AKT 
2.8 in all subtypes 
PDK1 
Hyperactivation 
of PDK1 
(AKT,mTORC1) 
22 38 22 
PIK3CA 
 ?W ? ? ?ɲW/ ?< ? 
Hyperactivation 
of PI3K signaling 
28-47 8-25 23-33 
IGFIR & INSR 
(IGF-IR, InsR) 
Activates IGF-
IR/InsR signaling 
41-48 42 18-64 
RPS6K1 
(p70S6K) 
unknown 3.8-12.5 in all subtypes 
Loss of 
function 
mutations 
PTEN 
Hyperactivation 
of PI3K signaling 
29-44 67 22 
INPP4B 
Hyperactivation 
of PI3K signaling 
10-33 53 54 
 
Abbreviations: AKT, protein kinase B; EGFR, epidermal growth factor receptor; HER2, 
human epidermal growth factor receptor 2; ER,estrogen receptor; IGF-1R, insulin-like growth 
factor-1 receptor; INPP4B, inositol polyphosphate-4-phosphatase, type II; InsR, insulin 
receptor; MEK, mitogen-activated 
protein kinase kinase; mTOR, mammalian target of rapamycin; mTORC1, mTOR complex 1; 
PDK1, phosphoinositide-dependent kinase 1; PI3K, phosphatidylinositol 3-kinase 
Adapted from: (Miller et al. 2011, Saini et al. 2013, Ciruelos Gil 2014, Cornejo et al. 2014). 
 
1.2.1.2.3.2 Mutational analysis of MAPK pathway 
The MAPK pathway is often over expressed in breast cancer but rarely found to be 
mutated in breast cancer progression (Santen et al. 2002). The basal like subtype of 
breast cancer contains the largest increase in expression of ERK signaling molecules 
(Saini et al. 2013). RAS is the most general human oncogene found to be mutated in 
30% of cancers, while 4-6% of breast cancers contain an activating mutation in 
KRAS, which leads to hyperactivation of ERK signaling (Miller et al. 2011, Deschenes-
Simard et al. 2014). BRAF is found to be mutated in 3% of breast cancers (Saini et al. 
2013). MEK mutation is even more uncommon, while ERK has never been reported 
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as being mutated. Overexpression or activating mutations in tyrosine kinase 
receptors and the continuous production of ligands with activated upstream 
oncogenes (RAS and RAF) leads to constitutive stimulation of ERK signaling and 
promotes breast tumour progression (Dhillon et al. 2007, Saini et al. 2013, 
Deschenes-Simard et al. 2014).  
1.2.1.2.4 Interference between PI3K and ERK pathway 
The cross-talk between the PI3K/mTOR and MAPK pathways is complicated and not 
entirely clear. The PI3K/mTOR pathway is mainly activated through the interaction 
of P85, a regulatory subunit of PI3K with HER2 and EGFR. The Ras/Raf/mitogen-
activated protein kinase (MAPK) pathway is mainly induced by Shc or Grb2 adaptor 
proteins (Normanno et al. 2006). The kinases of these two pathways highly 
influence the functional activity of each other through modulating the 
phosphorylation state. Ras is a key activating molecule of MAPK signaling pathway 
and regulates PI3K activity through various mechanisms. Ras inhibits the activity of 
PTEN, a tumour suppressor gene, thus stimulating PI3K (Saini et al. 2013). Raf (B-Raf 
and Raf-1) the downstream component of MAPK signaling is inhibited by AKT and 
Rheb, which attenuates MAPK signaling. In addition, ERK1/2 mediates the inhibition 
of TSC complex, a negative regulator of mTOR activity (Saini et al. 2013). 
Consequently, in the presence of growth factors, the inhibition of one pathway 
ultimately stimulates the other pathway due to failure of the feedback mechanisms. 
For instance, it has been reported that inhibiting AKT without blocking mTORC1, 
stimulates signaling from RTKs which leads to active PI3K pathway through the S6-
PI3K feedback pathway (Khan et al. 2013). 
1.2.1.2.5 Therapeutic strategies of breast cancer 
Current therapeutic strategies in breast cancer treatment are focused on targetting 
receptor mediated signaling such as hormone receptors or HER2 (Martin et al. 
2013). Therefore TKI (tyrosine kinase inhibitors) for EGFR and HER2 such as 
Lapatinib are considered as a potential agent in HER2+ breast cancer (Martin et al. 
2013, Vogelstein et al. 2013). Breast cancers which contain genetic alterations in 
signaling pathways such as mTOR/AKT and MAPK pathway have resistance for    
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anti-HER2+ and endocrine therapy, therefore targeting either signaling pathway in 
combination with TKIs is considered as a standard therapy in breast cancer 
treatment (Ciruelos Gil 2014).  
1.2.1.2.5.1 PI3K/mTOR/AKT inhibitors 
Several mTOR/AKT pathway inhibitors are considered as potential therapeutic 
agents, which could be used in combination with traditional breast cancer therapy 
such as anti-HER2+, in addition to TKIs (Miller et al. 2011). In ER+ breast tumours, 
elevated levels of PI3K signaling lead to reduced expression of ER resulting in 
resistance to endocrine therapy. Therefore mTOR inhibitors could restore the 
sensitivity to endocrine therapy (Ciruelos Gil 2014). Five main inhibitors targeting 
PI3K pathway at various levels are summarized below:  
1.2.1.2.5.1.1 PI3K inhibitors 
PI3K inhibitors are classified into Pan-PI3K inhibitors and PI3K-isoform inhibitors. 
These inhibitors interact specifically with the ATP pocket and specifically act on 
class1A PI3K members. PI3K-isoform inhibitors act on different isoforms of the 
ĐĂƚĂůǇƚŝĐƐƵďƵŶŝƚƐ ?Ɖ ? ? ?ɲ ?ɴ ?ɶ ?ɷ ? (Khan et al. 2013).  
1.2.1.2.5.1.2 AKT inhibitors 
This class includes ATP-competitive and allosteric AKT inhibitors. ATP-competitive 
inhibitors act towards three isoforms of AKT through competing with the ATP 
binding pocket. Allosteric AKT inhibitors interact with PH domain of AKT to induce a 
conformational change, thus preventing AKT translocation to the plasma membrane 
and inhibiting its activation (Miller et al. 2011).  
1.2.1.2.5.1.3 mTOR inhibitors 
1.2.1.2.5.1.3.1  Rapamycin 
Rapamycin and its analogues (such as everolimus) form complexes with FKBP12 
(FK506 binding protein 12KDa) through FRB (FKBP12 rapamycin binding domain), 
thus inhibiting mTORC1 signaling (Martin et al. 2013). However, there are 
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difficulties with the formulation of rapamycin and its analogs. It is therefore not 
considered a suitable agent for breast cancer treatment (Miller et al. 2011).   
1.2.1.2.5.1.3.2 mTORC1/2 inhibitors 
mTOR kinase inhibitors that bind to the ATP interacting site of the mTOR kinase 
domain target both mTORC1 and 2. RpS6, a downstream product of mTORC1, 
negatively feeds back to IRS1, which in turn diminishes the activity of PI3K. Such 
dual inhibitors of mTOR lead to complete inhibition of PI3K signaling (Lauring et al. 
2013). 
1.2.1.2.5.1.3.3 PI3K/mTOR dual inhibitors 
Blocking mTORC1 signaling eases the negative feedback on PI3K activators. 
Therefore targeting PI3K is a more effective way of blocking PI3K/AKT/mTOR 
signaling. Increased expression of RTKs also stimulates other oncogenic signaling 
cascades such as MAPK pathway. Due to the similarity in kinase domains of PI3K 
and mTOR these agents can act as dual inhibitors. Thus combination treatments of 
TKIs with PI3K/AKT/mTOR inhibitors are expected to have increased effectiveness 
(Miller et al. 2011). 
1.2.1.2.5.2 MAPK pathway inhibitors 
Several drugs have been developed so far as targets of the MAPK pathway at 
various nodes. Currently in clinical trials are non competitive ATP MEK1/2 inhibitors 
(Selumetinib) and inhibitors of BRaf kinase (Sorafinib) (Saini et al. 2013, Deschenes-
Simard et al. 2014).  
The strategy of targeting the two most relevant deregulated cascades of breast 
cancer: PI3K/mTOR and MAPK pathway should provide a better clinical response in 
breast cancer treatment (Saini et al. 2013). Targeting PI3K pathway together with 
the MAPK pathway is more effective in restoring the sensitivity to ER+ breast cancer 
(Ciruelos Gil 2014).  
 
 
34 
 
1.2.1.2.5.3 Activating AMPK: a negative regulator of PI3K and MAPK pathway 
Several activators of AMPK are currently considered as potential anti cancer drugs.  
Active AMPK is involved in the downregulation of crucial signaling pathways, which 
inhibits cell proliferation and survival. MAPK pathway inhibitors in combination with 
AMPK activators could potentially provide a better strategy for inhibiting cell 
proliferation in several cancers. Further investigation into evaluating the role of 
AMPK and MAPK pathways in carcinogenesis could provide better therapeutic 
options for breast cancer treatment (Zheng et al. 2009). Activators of AMPK such as 
metformin and its analogues AICAR  and phenformin, which exerts their action 
through LKB1 kinase, are considered as major activators of AMPK (Hadad et al. 
2008). AMPK activators stimulate apoptosis and reduce cell proliferation in basal-
like and estrogen positive and HER2+ subtypes of breast cancer (Kim and He 2013). 
1.3 Eukaryotic polyadenylation 
In this thesis, I examine the potential of inhibiting polyadenylation as a mechanism 
of action for novel breast cancer drugs. The process of polyadenylation in 
mammalian mRNA was reported in 1970 (Penman et al. 1970, Rose and Jacob 
1978). In mRNA metabolism the poly (A) tail plays an important role (Tian and 
Graber 2012, Goss and Kleiman 2013). As soon as the process of transcription starts, 
the pre-mRNA is processed in several steps. These include capping of an mRNA 
followed by splicing. The termination of transcription is coupled to the cleavage of 
ƚŚĞŵZEĂŶĚƚŚĞ ? ?ĞŶĚŽĨƚŚĞĐůĞĂǀĂŐĞƉƌŽĚƵĐƚŝƐthen polyadenylated (Kuehner 
et al. 2011, Sagawa et al. 2011). 
Almost all of the eukaryotic pre-mRNAs undergo the process of cleavage and 
polyadenylation except histone mRNAs, which are only cleaved (Tian and Manley 
2013). The poly (A) tail, a stretch of adenosine monophosphate residues at the end 
of an mRNA, stimulates translation, stability and localisation of mRNAs (Cappell et 
al. 2010, Cevher et al. 2010, Ozsolak et al. 2010). The addition of a poly A tail is 
considered a default process on the way to mRNA maturation, which is essentially 
the same for all non-histone mRNAs (Mirkin et al. 2008, Sagawa et al. 2011).  
Addition of a poly(A) tail to an mRNA is a two step process: it is first initiated with 
35 
 
an endonucleolytic cleavage followed by the addition of a poly(A) tail (Mirkin et al. 
2008).  
Cleavage and polyadenylation plays a vital regulatory role in mammalian gene 
expression. Besides being the mechanism of  ? ? ĞŶĚ ĨŽƌŵĂƚŝŽŶof mRNA, it is also 
required for the termination of transcription (Guhaniyogi and Brewer 2001, Nunes 
et al. 2010), in export of the mRNA from the nucleus (Huang and Carmichael 1996), 
in translation of the mRNA (Sachs et al. 1997), in removal of the terminal intron 
(Nunes et al. 2010) and in controlling the stability of the mRNA (Guhaniyogi and 
Brewer 2001, Eckmann et al. 2011). 
1.3.1 Mechanism of nuclear polyadenylation 
The initial polyadenylation of an mRNA takes place in the nucleus and is coupled 
with cleavage (Ghoshal and Jacob 1991). There are different cis and trans regulatory 
elements involved in the process of cleavage and polyadenylation, which are tightly 
coupled with transcription and translation (Moore and Proudfoot 2009, Tian and 
Graber 2012). It is generally believed that all polyadenylated mRNAs are appended 
with a tail of 230 adenosine residues at the cleavage site (Penman et al. 1970, 
Darnell et al. 1971).  
1.3.1.1 Cis acting Sequence elements 
The process of  cleavage and polyadenylation is a well co- ordinated stage ŝŶ ? ?ĞŶĚ
processing, involving cis acting elements which are present both upstream and 
downstream of poly (A) signal. The ĨŽƵƌƐĞƋƵĞŶĐĞĞůĞŵĞŶƚƐŝŶ ? ?ĞŶĚƉƌŽĐĞƐƐŝŶŐĂƌĞ
the upstream element (USE, containing U(G/A)UA),  the poly(A) signal, the GU or U 
rich downstream sequence (DSE) and the G rich auxilliary sequence (Zhao et al. 
1999, Charlesworth et al. 2013).  
The core polyadenylation signal (AAUAAA or AUUAAA) is usually present <30 
nucleotides downstream of USE (upstream sequence element) which is identified by 
CPSF (cleavage and polyadenylation specificity factor) as shown in figure 1.3 (Ryan 
et al. 2004, Danckwardt et al. 2007). The canonical hexamer motif (AAUAAA or 
AUUAAA) in humans is 70-80% conserved. However in some cases, the process of 
cleavage and polyadenylation is mediated by a non-canonical poly (A) signal, as 20-
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30% of mammalian genes do not have a conserved canonical poly (A) signal. The 
processes of alternative cleavage and polyadenylation are found to be more 
common in mRNAs containing a non-canonical poly (A) signal  (Nunes et al. 2010). 
About 16% have AUUAAA while 20% contain single base variants A(A/U)UAAA and 
10% of poly (A) signals lack relevant AAUAAA type sequence (Tian and Manley 
2013). The downstream canonical sequence element (DSE) is G/U rich and is 
present <30 nucleotides downstream from the site of cleavage. It is bound by the 
64-kDa subunit of the CstF (cleavage stimulation factor) through its RNA binding 
domain found in the N terminus (Colgan and Manley 1997, Zhao et al. 1999). The 
USE enhances the efficiency of cleavage and polyadenylation but it is not present in 
all mRNAs in which cleavage occurs such as in histone pre-mRNAs (Mandel et al. 
2008). The USE stabilizes RNA interaction between CPSF and CstF, often 
determining the choice of cleavage site. The G-rich downstream auxillary sequence 
element which aids in cleavage site selection still lacks a binding partner 
(Charlesworth et al. 2013). 
1.3.1.2 Trans acting protein factors 
The process of nuclear polyadenylation is a multiple step event that involves several 
protein complexes of multiple subunits (de Klerk et al., 2012, Ghoshal and Jacob, 
1991). Proteomics experiments indicate the cleavage and polyadenylation 
complexes consist of more than 80 proteins in humans (Shi et al. 2009, Nunes et al. 
2010). The main components of these multi protein complexes are highly conserved 
and comprise several protein complexes flanking the cleavage site, including CPSF, 
CstF, cleavage factors I and II (CFIm and CFIIm) and poly (A) polymerases (PAP), as 
summarised in table 3. For the process of cleavage and polyadenylation, the 
assembly of these protein complexes in mammals is initiated by the interaction of 
CPSF and CstF to core sequences on premature mRNAs (Zhao et al. 1999, Takagaki 
and Manley 2000). There are some scaffolding proteins that lack RNA binding 
function and only serve as a binding site for other regulatory elements such as 
symplekin and CstF-3 (Tian and Manley 2013). 
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The h'hE ŵŽƚŝĨ ĨŽƵŶĚ ƵƉƐƚƌĞĂŵ ŽĨ ĐůĞĂǀĂŐĞ ƐŝƚĞ Ăƚ ǀĂƌŝĂďůĞ ĚŝƐƚĂŶĐĞ ŝŶ  ? ?hdZ
recruits an additional heterodimeric core factor, CFIm, which stimulates the process 
of cleavage and polyadenylation in the absence of the conserved AAUAAA hexamer. 
The role of CFIIm is still unknown (Danckwardt et al. 2008, Nunes et al. 2010).  
 
Table 3/LVWRIIDFWRUVLQYROYHGLQPDPPDOLDQ¶HQGFOHDYDJHDQGSRO\DGHQ\ODWLRQ 
Factors 
Subunits 
(KDa) 
HUGO 
Nomenclature 
Features 
CPSF 
(cleavage and 
polyadenylation 
specificity factor) 
160 CPSF 1 
Recognizes the poly (A) signal and interacts with 
CstF-77, PAP and CTD of RNAPII 
100 CPSF 2 /ŶǀŽůǀĞĚŝŶ ? ?ĞŶĚŵZEƉƌŽĐĞƐƐŝŶŐ 
73 CPSF 3 
Endonuclease mediates the cleavage of pre-mRNA 
at 10-30 nucleotides downstream of the poly (A) 
signal 
30 CPSF 4 Binds to U rich elements on pre-mRNA 
Fip1L - 
In vitro, FipL1 is responsible for recruitment of PAP 
thus link CPSF1 and PAP 
CstF 
(cleavage 
stimulating 
factor) 
50 CstF 1 
DĞĚŝĂƚĞƐ ? ?ĞŶĚƉƌŽĐĞƐƐŝŶŐŝŶƚĞƌĂĐƚƐǁŝƚŚdŽĨ
RNAPII thus facilitate assembly of other factors of 
polyadenylation machinery 
64 CstF 2 Interact with G/U or U-rich downstream signals 
77 CstF 3 
Connect CstF-64 and CstF-50 and interacts with 
CPSF1 
CFIm 
(cleavage factor 
Im complex) 
25 
NUDT21 
(CPSF5) Interact with upstream element (USE) containing 
U(G/A)UA, serves cruĐŝĂůƌŽůĞŝŶ ? ?end processing 68 CPSF6 
59 CPSF7 
CFIIm 
(cleavage factor 
IIm complex) 
- PCF11 Unknown 
 
Adapted from: (Colgan and Manley 1997, Zhang et al. 2005, Sagawa et al. 2011, 
Charlesworth et al. 2013). 
 
The most commonly found nucleotide followed next to cleavage site is cytosine 
(Tian and Manley 2013). Upon transcription at the poly (A) site by RNAPII CPSF, 
which was initially linked with the CTD, is recruited to poly (A) signal leading to RNA 
cleavage and termination of transcription (Glover-Cutter et al. 2008). Upon 
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recognition, the recruitment of CPSF and CstF subunits to their respective sequence 
elements on pre-mRNA is assisted by CFIm, together with RNAPII, CF IIm and PAP, 
forming a competent cleavage complex as shown in figure 1.2. After the assembly 
of multi protein complexes to their specific cis acting regulatory sites on pre-mRNA, 
cleavage occurs which is followed by addition of  the poly (A) tail (Zhao et al. 1999). 
 
 
Figure 1.2: Schematic representation of factors involved in cleavage process:  
Recruitment of protein factors of cleavage and polyadenylation machinery at their cognate 
sites on pre-P51$ IRU ¶ HQG SURFHVVLQJ &36) 1(160) specifically recognises poly (A) 
signal which associates with PAP and is involved in connecting CstF 3 (77) and PAP. CstF 
interact with GU rich region by CstF 2 (64). CF Im and CF IIm are also required for efficient 
cleavage process. 
Abbreviations: AAUAAA (poly (A) signal), CstF (cleavage stimulating factor), CPSF 
(cleavage/polyadenylation specificity factor), Pol II (RNA polymerase II), CTD (C-terminal 
domain), CF Im (cleavage factor I), CF IIm (cleavage factor II), PAP (poly(A)-polymerase).  
 
Binding of PAP (poly (A)-polymerase) to RNA is weak and non-specific in the 
presence of Mn
2+
,
 
however in combination with Mg
2+ 
and CPSF, PAP becomes 
specific for AAUAAA and the complex of PAP, CPSF, CstF and RNA is stabilized, 
C
A
CFIIm
CFIm
 ? ?
3 ?
1
AAUAAA
3
3
Cleavage site1
4
2
Competent cleavage
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F
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mediating polyadenylation (Zhao and Manley 1996). Soon after, the endonucleolytic 
cleavage nuclear PAP adds 200-250~ adenosine residues as shown in figure 1.3 
(Zarkower and Wickens 1987, Meijer et al. 2007, Cevher et al. 2010), which is bound 
by PABPN1 (Nuclear poly A binding protein). The first poly(A) polymerase (PAP 
alpha or PAPOLA) isolated from calf thymus, is thought to be the main mediator of 
nuclear polyadenylation by most mRNAs (Bardwell et al. 1990). It has been reported 
that poly(A) polymerase is required for both cleavage and polyadenylation.               
A second canonical poly(A) polymerase, PAP gamma (PAPOLG) has also been linked 
to nuclear polyadenylation  (Ghoshal and Jacob 1991, Zhao and Manley 1996, Zhao 
et al. 1999).  
 
Except for PABP, all protein factors are necessary for in vitro cleavage, but for in 
vitro polyadenylation only CPSF (Fip1L), PAP and PABP are required (Mandel et al. 
2008). Nuclear poly(A) binding protein (PABPN1) controls the final length of the 
poly(A) tail, by disrupting the interaction of CPSF (Fip1L) and PAP, as the ƉŽůǇ ? ?ƚĂŝů
ƌĞĂĐŚĞƐƚŚĞůĞŶŐƚŚŽĨ๝250 nucleotides by an unknown mechanism (de Klerk et al., 
2012., Eckmann et al., 2011; Kuhn et al.,  2009). The association of other proteins 
with polyadenylation machinery, such as nucleophosmin, plays a significant role in 
the regulation of length of poly (A) tail and in export of an mRNA from nucleus to 
cytoplasm (Sagawa et al. 2011). The binding of PABPN1 is weak and it is replaced by 
PABPC1 (cytoplasmic poly (A) binding protein) while still in the nucleus (Hosoda et 
al. 2006). After export, PABPC1 then interacts with eIF4G initiation complex bound 
to the cap of the mRNA, resulting in the formation of the competent closed loop 
complex and initiation of translation (Danckwardt et al. 2008). 
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Figure 1.3: Process of nuclear cleavage and polyadenylation in eukaryotes:  
 
Once the Trans-acting multiprotein complexes are assembled on their respective cis-acting 
RNA sequence elements, the pre-mRNA is cleaved endonucleolytically by CPSF-3 
(CPSF73). This is followed by the addition of adenosine residues by PAP to form poly (A) 
tail, which is initially bound to PABPN1. Upon nuclear export PABPN1 is replaced by 
cytoplasmic PABPC. PABPC forms the closed loop ribonucleoprotein complex upon 
interaction with translation initiation factor eIFG, a part of the translaton initiation complex.  
 
Abbreviations: USE (upstream sequence element), AAUAAA (poly(A) signal), DSE 
(downstream sequence element), CstF (cleavage stimulating factor) (blue complex), CPSF 
(cleavage/polyadenylation specificity factor) (light blue complex), Pol II (RNA polymerase II), 
CF I (cleavage factor I) (green complex), CF II (cleavage factor II), PAP (poly(A)-
polymerase), PABPN1 (nuclear poly(A)-binding protein), PABPC (cytoplasmic poly(A)-
binding protein) 4A, 4E, 4G (translation initiation factors).   
 
1.3.2 Regulation of gene expression by co-transcriptional processing of the 
¶HQGof an mRNA 
Formation of mRNA by RNAPII is linked with the recruitment of essential  ? ? ĞŶĚ
processing factors, located at the place of RNA synthesis in the nucleus (Zhao et al. 
1999, Glover-Cutter et al. 2008). Co-transcriptional recognition of regulatory factors 
involved in the process of cleavage and polyadenylation of nascent pre-mRNA, is 
mediated through interactions with RNAPII during transcription elongation. This 
provides a mechanistic explanation for the cŽƵƉůŝŶŐ ŽĨ ƚƌĂŶƐĐƌŝƉƚŝŽŶ ĂŶĚ  ? ?end 
mRNA processing. The recruitment of polyadenylation factors to RNAPII and the 
type of promoter plays an important role in determining the efficiency of 
polyadenylation (Mapendano et al. 2010, sWang et al. 2010).  
Eukaryotic DNA-dependent RNA polymerase (RNAPII) is initially recruited in a hypo-
phosphorylated state to the promoter. It is composed of up to 12 polypeptides in 
which Rpb1 is the largest subunit and contains the catalytic activity (Hsin and 
Manley 2012). Nuclear polyadenylation is restricted to nascent transcripts of Pol II, 
by the interaction of cleavage and polyadenylation factors with the C  ?terminal 
domain (CTD), a unique feature of RNAPII (Zhao et al. 1999).  The carboxyl terminal 
domain (CTD) of the largest subunit Rbp1 of RNAP II is composed of conserved 52 
heptapeptide repeats (N-Tyr
1
-Ser
2
-Pro
3
-Thr
4
-Ser
5
-Pro
6
-Ser
7
-C) in humans (Proudfoot 
and O'Sullivan 2002, Ryan et al. 2004, Glover-Cutter et al. 2008, Proudfoot 2011, 
Hsin and Manley 2012, Mayer et al. 2012) and each repeat consist of three serine 
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residues reversibly phosphorylated throughout the process of transcription (Moore 
and Proudfoot 2009). The CTD determines the efficiency of all processing steps 
required for the formation of mature RNA, and its function is modulated  by the 
different states of phosphorylation with the aid of kinases and phosphatases (Zhao 
et al. 1999, Hsin and Manley 2012). The CTD interacts with cleavage and 
polyadenylation factors and recruits them to RNAPII, especially if it is Ser 2 
phosphorylated. In this way, RNAPII functions as part of the polyadenylation 
machinery (Yonaha and Proudfoot 2000, Proudfoot 2011, Hsin and Manley 2012). 
The phosphorylation on serine 5 (Ser5P) by TFIIH associated kinase Cdk7 (cyclin 
dependent kinase-7) is involved in early stages of elongation (Moore and Proudfoot 
2009). Phosphorylation on serine 2 (Ser2P) by Cdk9 (Cyclin-Dependent kinase-9) or 
Cdk12 (Davidson et al. 2014) during late stages of transcriptional elongation recruits 
the cleavage and polyadenylation complex to the poly (A) signal through CTD-
interacting domains (CIDs) mediating 3 ?ĞŶĚ formation of mRNAs, while 
polyadenosine binding protein (PABP) binds to the newly formed poly-A sequence 
(Shim et al. 2002, Glover-Cutter et al. 2008, Mapendano et al. 2010, Mayer et al. 
2012). Ser5 is dephosphorylated by phosphatases during transcripton elongation, 
forming a pattern of phosphorylation in which Ser5-P is high at the start of 
transcription, while Ser2-P emerges at later stages of transcription.  
The kinase activity of CDK9 (P-TEFb) and Cyclin T plays a regulatory role in 
transcriptional control of the elongating polymerase (Garriga and Grana 2004, 
Moore and Proudfoot 2009). A component of CFII, Pcf11 in mammals, has a CID 
(CTD interacting domain) and interacts with the Ser-2 phosphorylated CTD. This 
leads to recruitment of the polyadenylation complex, including CPSF1 and PCF11, to 
RNAP II as shown in figure 1.4 (Kuehner et al. 2011, Nagaike and Manley 2011). The 
phosphorylation of TFIIB serine residue 65 is important in the recruitment of CPSF 
and CstF to the promoter, just after the Ser5P phosphorylation of CTD RNAPII and 
before the initiation of transcription (sWang et al. 2010). 
The last stages of co-transcriptional processing of an mRNA are important for 
preventing the formation of abnormal transcripts (Moore and Proudfoot 2009). For 
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efficient transcription, termination by RNAPII cleavage of an mRNA is a necessary 
event (Moore and Proudfoot 2009, Proudfoot 2011). According to the torpedo 
model, endonucleolytic cleavage of pre-mRNA at the poly (A) signal during 
transcription is an essential step required for exonucleases activity of Xrn2 (Rat1 in 
yeast). Xrn2 ŝƐ ƚŚŽƵŐŚƚƚŽĂƚƚĂĐŚƚŽƚŚĞĨƌĞĞ  ? ?ĞŶĚŐĞŶĞƌĂƚĞĚďǇpolyadenylation-
associated cleavage and contacts RNAP II, resulting in conformational changes and 
leading to the dissociation of nascent RNA from Pol II. Thus it leads to arrest of the 
elongation complex of Pol II and favours termination (Rosonina et al. 2006, 
Proudfoot 2011). The ability of polyadenylation factors such as Pcf11 to bind to the 
CTD is indeed a prerequisite for transcription termination (Hsin and Manley 2012).  
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Figure 1.4: Mechanism of transcriptional coupled polyadenylation:  
Polyadenylation factor CPSF is initially recruited to the promoter by TFIIB, a part of PIC, 
which is later transferred to the transcription complex of CTD (Ser5P) RNAP II at elongation 
initiation stage. As elongation proceeds, CstF is transferred to CTD RNAP II. As soon as the 
RNAP II transcribes the poly (A) signal, cleavage and polyadenylation factors are recruited 
on newly transcribed mRNA from the CTD (Ser2P) of RNAPII. Thus upon recognition of the 
poly(A) signal, transcriptional elongation pauses just next to the poly(A) signal, resulting in 
termination of transcription, leading WR WKH FOHDYDJH RI 51$3,, DVVRFLDWHG ¶HQG RI DQ
mRNA. This in turn leads to the addition of poly (A) tail of ~200-250 residues by PAP bound 
by PABP. Assembly of poly (A) complex leads to the cleavage of an mRNA, which expels 
the CTD results in dissociation of pause Pol II from the template.  
Abbreviations: AAUAAA (poly (A) signal), CstF (cleavage stimulating factor), CPSF 
(cleavage/polyadenylation specificity factor), Pol II (RNA polymerase II), PAP (poly (A)-
polymerase), PABP (Poly (A)-binding protein). TFIIB (Transcription factor IIB), CTD (C 
terminal domain).  
 
Two possible mechanisms of transcriptional termination coupled to cleavage and 
polyadenylation have been reported. In most genes, a transcriptional pause site is 
located just next to the poly(A) signal at which cleavage occurs, while Pol II is still 
involved in transcription. (Zhao et al. 1999). Another class of termination occurs in 
the absence of a pause site downstream to the poly(A) signal, causing RNAPII to 
move further down the  ? ?flanking region of an mRNA. An additional  ? ? ĨůĂŶŬŝŶŐ
termination sequence is found further downstream, which is known as the 
cotranscriptional cleavage (CoTC) sequence. The CoTC mediates a downstream 
cleavage event that precedes cleavage of the polyadenylation site. The degradation 
of nascent transcripts by Xrn2 at the  ? ?ĨůĂŶŬŝŶŐƌĞŐŝŽŶƌĞƐƵůƚƐŝŶWŽů//ĚŝƐƐŽĐŝĂƚŝŽŶ
from DNA templates along pre-mRNAs, which are still linked to the CTD via poly(A) 
complexes (Moore and Proudfoot 2009, Proudfoot 2011). 
1.3.3 Alternative polyadenylation 
In alternative polyadenylation (APA) a gene possesses multiple poly(A) sites which 
result in the generation of different mRNAs, usually producing a variety of mRNAs 
ǁŝƚŚĚŝĨĨĞƌĞŶƚ  ? ?hdZs. More than 50% of protein encoding mammalian genes are 
subject to APA (Nunes et al. 2010). Alteration in length of the   ? ?hdZ can change 
the presence of binding sites for miRNA or protein factors involved in maintaining 
the stability of an mRNA and in gene specific regulation as shown in figure 1.5 (de 
Klerk et al; 2012). The efficiency of the cleavage and polyadenylation processes 
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varies and selection of stronger downstream polyadenylation signals is thought to 
result from the ineffficiency of weaker upstream signals (Colgan et al. 1998). 
Shorter  ? ?hdZs, presumably generated through recognition of weak upstream APA 
sites in the presence of higher levels or activity of the polyadenylation machinery, 
have been observed to be enriched in cancer (Sandberg et al. 2008, Mayr and Bartel 
2009) ? dŚĞƐĞ ƐŚŽƌƚĞƌ  ? ?hdZ ĂƌĞ ĐůŽƐĞůǇ ĂƐƐŽĐŝĂƚĞĚ ǁŝƚŚ ŵĂůŝŐŶĂŶƚ ƚƌĂŶƐĨŽƌŵĂƚion 
compared to rates of cellular proliferation (Sagawa et al. 2011).  How APA is 
regulated in cancer is still unclear (Weill et al. 2012, Tian and Manley 2013). The 
machinery of cleavage and polyadenylation, splicing and transcriptional factors, 
have all been implicated in the regulation of APA (de Klerk et al., 2012; Proudfoot, 
2011).  
 
Figure 1.5: Diagrammatic representation of a gene containing cis-acting elements with 
APAs.  
*HQHFRQWDLQLQJ WZRVLWHV IRUDOWHUQDWLYHFOHDYDJHDQGSRO\DGHQ\ODWLRQ ORFDWHGRQ¶PRVW 
H[RQ RI JHQH JHQHUDWHV YDULDEOH ¶ 875 Due to usage of different APAs an mRNA 
generates a transcript with or without the regulatory elements such as miRNA binding sites 
and AU-rich elements. PA: Poly (A) site, CDS: coding sequence, UTR: untranslated region.  
 
Cap 5 ?hdZ CDS
3 ?hdZ
PA PA AREs
miRNA binding sites
Cap AAAAAAAAAAAA
Cap
3 ?hdZ
3 ?hdZ
AAAAAAAAAAAA ? ?hdZ CDS
 ? ?hdZ CDS
Removal of cis-elements
Addition of cis-elements
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The shorter mRNA isoforms are generally much more stable and are well translated. 
In many cases, loss of miRNA binding sites on the  ? ?hdZis probably involved in this 
effect (Mayr and Bartel 2009, Elkon et al. 2012).  
1.3.3.1 Alterations in trans-acting factors 
An example of regulation of APA is alterations in the levels of the CstF 64-kDa 
subunit, which lead to the selection of alternative poly(A) sites. During B cell 
differentiation, CstF-64 regulates the processing of pre-mRNA of the IgM heavy 
chain (µ). Increased levels of CstF-64 upon B-cell activation, results in a change of 
mRNA expression of the membrane bound form (µm) of IgM (µ) heavy chain to the 
secreted form (µs). This is due the selection of the upstream poly (A) site specific for 
µs. Furthermore, a decrease in the levels of CstF 64 in B cells results in cell cycle 
arrest in G0/G1 phase, while its depletion results in apoptotic cell death. The 
process of alternative polyadenylation also affects many mRNAs in LPS stimulated 
macrophages and this also is a consequence of upregulation of CstF-64 expression. 
The amount of CstF-64 in cells not only involves in regulation of alternative 
polyadenylation but also plays an important role on level of RNA by modulating the 
gene expression (Takagaki and Manley 1998, Danckwardt et al. 2008).  
PABPNI (poly A binding protein nuclear 1) not only plays an important role in the 
basal polyadenylation but changes in PABPNI expression also result in the selection 
of different alternative polyadenylation sites. The low levels of functional PABPN1 in 
OPMD (Oculopharyngeal muscular dystrophy), a muscular disorder, is caused by 
alternative polyadenylation site selection, which leads to altered gene expression 
(de Klerk et al. 2012).  
1.3.4 Mechanism of cytoplasmic polyadenylation 
 During oogenesis and early development in animals, maternal mRNAs are stored in 
the cytoplasm of the oocyte in an under-adenylated state and become 
translationally activated by cytoplasmic polyadenylation at later stages of 
development (Weill et al. 2012). Therfore cytoplasmic regulation of polyadenylation 
requires particular factors involved in the shortening of poly(A) tail and in 
translation repression, in addition to the specific factors required for the induction 
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of cytoplasmic polyadenylation (Kojima et al. 2012, Charlesworth et al. 2013).  The 
mechanism of cytoplasmic polyadenylation has been well studied in Xenopus 
oocytes. The best studied cases show that cytoplasmic polyadenylation requires 
tǁŽĞůĞŵĞŶƚƐŽŶŝƚƐ ? ?hdZ ?the poly(A) signal bound by a cytoplasmic CPSF complex 
lacking the 73 kDa subunit, and a U-rich conserved cytoplasmic polyadenylation 
element (CPE) (UUUUUAU) bound to CPE-binding protein (CPEB1). Other 
cytoplasmic polyadenylation factors also exist (Fox et al. 1989, McGrew and Richter 
1990, Gebauer and Richter 1996, Charlesworth et al. 2013).  
Symplekin is a scaffold protein that binds CPSF, the non-canonical poly(A) 
polymerase Gld2 and CPEB. PARN, an enzyme that removes poly(A) tails, is also part 
of the CPEB complex (Zhang et al. 2010), as depicted in Figure 1.6. Cytoplasmic 
polyadenylation is induced by phosphorylation of CPEB1 by Aurora A (Richter 2007). 
This results in the expulsion of PARN from the complex (CPSF, Gld2 and symplekin), 
allowing Gld2 to elongate poly(A) tails and activates the process of translation 
(Novoa et al. 2010, Kojima et al. 2012). In oocytes, the poly(A) tail is bound by 
embryonic poly(A) binding protein (ePAB) (Zhang et al. 2010).  
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Figure 1.6: Regulation of poly (A) tail length by cytoplasmic polyadenylation:  
Process of cytoplasmic polyadenylation involves the recognition of cis acting elements at 
¶875 VXFK DV &3( DQG $$8$$$ 3$ VLJQDO E\ WUDQV-acting factors CPEB and CPSF 
respectively. Complex of CPEB contains PARN and Gld2 which plays crucial role in poly (A) 
tail length regulation. By default mRNAs gets longer poly (A) tail in nucleus. The length of 
poly (A) tail after nuclear polyadenylation gets shorter upon cytoplasmic export due to 
deadenylation by PARN. CPEB, CPSF, PARN and Gld2 are associated together in mRNP 
complex assembled by the scaffold protein symplekin. Gld2 remains inactive until the 
progression of meiotic cell division or upon oocytes maturation which phosphorylates CPEB 
leads to dissociation of PARN from CPEB complex. Gld2 remains no longer restricted leads 
to the elongation of poly (A) tail followed by translation of specific mRNAs.  
Abbreviations: CPE: cytoplasmic polyadenylation element, CPEB: CPE- binding protein, 
CPSF: cleavage-polyadenylation and specificity factor, Gld2: Germline development 2, 
PARN: Poly (A)-specific ribonucleases, ePAB: Embryonic poly (A) binding, mRNP: protein 
ribonucleoprotein.  
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1.4 Role of Poly (A) polymerases in polyadenylation 
1.4.1 General characteristics of poly (A) Polymerase 
The first poly(A) polymerase (PAP) was isolated from calf thymus in the beginning of 
the  ? ? ? ? ?Ɛ(Edmonds and Abrams 1960, Mandel et al. 2008). PAP is the enzyme that 
ĐŽǀĂůĞŶƚůǇĂĚĚƐƚŚĞ ? ?ƉŽůǇ(A) tail of mRNAs (Zhao and Manley 1996, Martin et al. 
2008). PAP activity can be mediated by a variety of enzymes and is present in 
prokaryotes as well in eukaryotes. In eukaryotes it is present in mitochondria, 
nucleus, RNPs (ribonucleoprotein particles) and ribosomes (Jacob et al. 1989).  PAPs 
play diverse roles from marking aberrant nuclear transcripts to stabilizing the small 
non coding RNAs (miRNAs) in cytoplasm (Katoh et al. 2009, Shcherbik et al. 2010). 
Addition of the ƉŽůǇ ? ?ƚĂŝůƚŽ ? ?ĞŶĚs of an mRNA by PAPɲ in the nucleus is carried 
out in a processive manner until it reaches a length of ~250 residues (Martin et al. 
2004). 
1.4.2 Structure of poly (A) polymerases 
PAPs belong to the superfamily of the template-independent RNA specific 
nucleotidyl transferases (rNTrs), which are responsible for the covalent addition of 
ƌŝďŽŶƵĐůĞŽƚŝĚĞƐ ĂƐ ƉĂƌƚ ŽĨ  ? ?ĞŶĚ ŵZE ƉƌŽĐĞƐƐŝŶŐ ? DĞŵďĞƌƐ ŽĨ ƌEdƌƐ and PAPs 
share a similar active site structure with that of the template dependent DNA 
ƉŽůǇŵĞƌĂƐĞɴ ?WŽůɴ ?, a DNA repair enzyme, and have sequence similarity to other 
enzymes in their catalytic domains, such as RNA and DNA polymerases (Martin and 
Keller 1996, Zhao et al. 1999, Martin et al. 2004, Martin and Keller 2007, Schmidt 
and Norbury 2010). The nucleotide substrates of rNTRs are a wide range of 
substrates, from single AMP or UMP residues to the addition of the trinucleotide 
CCA to tRNA aƚ  ? ?ĞŶĚƐ(Martin et al. 2008). Other members of this group mediate 
the addition of single to several residues of UMP, these are known as TUTases 
(terminal uridylyl transferases) (Martin and Keller 2007). The majority of PAPs are 
conserved among eukaryotes (Zhao et al. 1999). 
PAPs in general consist of three main domains: the catalytic domain found near the 
N terminal, followed by the central and the RNA binding domain near C-terminal 
NLS (nuclear localization signal), which overlaps with the RNA binding domain 
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(Balbo and Bohm 2007). All canonical PAPs share similar catalytic domains at the N 
terminal, which is connected to the RNA binding domain by the central domain. The 
nuclear localization signal (NLS) overlaps with the RNA binding domain. The              
C-terminal domain (residues 354 ?530) of canonical PAPs is responsible for binding 
the cleavage/polyadenylation subunit Fip1, in which three constant aspartate 
residues interact with two metals out of three metals of the active site, among 
which one interacts with the adenine ring. This interaction serves a crucial role in 
structural selection of ATP by poly(A) polymerase (Martin et al. 2000). Addition of 
ƌŝďŽŶƵĐůĞŽƐŝĚĞŵŽŶŽƉŚŽƐƉŚĂƚĞŽŶZE ? ?K,ŐƌŽƵƉďǇWWŝƐaccomplished by two 
metal ions in the active site. One binds to RNA while the other one interacts with 
the phosphate group of the incoming nucleotide and the  ? ? K, Őroup of a pre-
mRNA. PAPɲ is highly specific for ATP selection (Martin and Keller 2007). 
Identification of substrate and nucleotide selection by PAPɲ is due to the induced fit 
mechanism of enzyme (Martin and Keller 2007, Mandel et al. 2008).  
1.4.3 Types of PAPs 
The PAPs are classified into canonical and non canonical on a structural and 
functional basis in table 4. The eight identified PAP genes in mammals are PAPOLA 
 ?ƉĂƉ ɲ ? ? WWK>  ?ƉĂƉ ɴ ? ? WWK>'  ?ƉĂƉ ɶ ? ? WW ? ? WW ? ? WW ? ? WW ? ? ĂŶĚ
PAPD7 (PAP associated domain containing 1, 2, 4, 5, 7 respectively) (Wahle and 
Ruegsegger 1999, Kashiwabara et al. 2008). WWƐɲ ?ɴ ĂŶĚɶǁĞƌĞ first identified in 
mammals, are found in nucleus and are now called canonical PAPs. PAPD4 (GLD-2) 
(germline development gene), Trf-4/5, PAPD5, MtPAP and POLS were identified 
later so are known as non canonical rNTrs (Martin and Keller 2007).  
 
GLD-2, Trf-4/5 and other non-canonical PAPs contain a similar catalytic domain to 
canonical PAPs, but differ in their nucleotide recognition motifs. Non canonical PAPs 
lack the RRM-like RNA binding domain. TUTase and Mt PAP have different potential 
RNA binding domains in their N terminus, as indicated in figure 1.7. Most non-
canonical PAPs therefore require additional protein factors which recruit them to 
their target RNAs.  
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Figure 1.7: Structural organization of types of RNA specific nucleotidyl transferases: 
Three canonical and five non canonical PAPs are shown. Localizations in cells are indicated 
as C (cytoplasmic), N (nuclear), M (mitochondria) and No (nucleolar). Domains are indicated 
as: green for catalytic domain, Orange for central domain, pink for RNA binding domain, blue 
for nucleotide recognition motif in canonical PAPs (NRM type1), dark brown for NRM type 2 
in non canonical PAPs, light brown or Tan in U6 TUTase.  
 
Trf4 and Trf5 were initially identified in S.cerevisiae as being part of the TRAMP 
complex and are involved in transcript quality control and decay in the nucleus 
(Shcherbik et al. 2010). RNA oligoadenylated by the TRAMP complex becomes a 
substrate for degradation by the nuclear exosome. In addition to Trf4/5, the TRAMP 
complex consists of the RNA helicase (Mtr4p) along with RNA binding proteins Air1 
and Air2. Complete turnover of RNA requires multiple rounds of oligoadenylation 
(by the dZDW ĐŽŵƉůĞǆ ? ŽĨ ŝŶƚĞƌŵĞĚŝĂƚĞƐ ĚĞŐƌĂĚĞĚ ďǇ  ? ? ĞǆŽƐŽŵĞ (Martin et al. 
2008). 
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 Table 4: Types of mammalian poly (A) polymerases 
Types of PAPs Synonyms/homologs Characteristics 
PAP-alpha 
 ?WĂƉɲ ? 
PAPOLA, PAPII 
Found predominately in nucleus adds poly (A) tail to 
the end of an mRNA (Bardwell et al. 1990). Also 
involved in some cases of cytoplasmic 
polyadenylation (Hwang et al. 2001, Radford et al. 
2008). Different isoforms as a result of APA have 
been reported. PAP interacts with CPSF-1 and Fip1L 
by its C-terminal region (Martin and Keller 2007). 
PAP- beta 
 ?WĂƉɴ ? 
PAPOLB, TPAP or 
PAPT 
Testis-specific cytoplasmic PAP, mediates in 
polyadenylation of mRNA transcripts for 
spermatogenesis (Benoit et al. 2008, Kashiwabara et 
al. 2008) ? ƉĂƉɴis found in cytoplasm and nucleus 
both (Lee et al. 2000). 
PAP-gamma 
 ?WĂƉɶ ? 
PAPOLG, Neo-PAP, 
SRP RNA 3'-adenylating 
enzyme 
Involved in  ? ?ĞŶĚ ƉƌŽĐĞƐƐŝŶŐ ŽĨ ƉƌĞ-mRNA by 
polyadenylation, interacts with components cleavage 
and polyadenylation machinery (Martin and Keller 
2007). Found in nucleus, very similar to PAPɲ 
(Topalian et al. 2001). Is 60-75% homologous to 
amino termini region of PAPɲ ? Also mediates mono 
ĂĚĞŶǇůĂƚŝŽŶŽĨƐŵĂůůZEƐĂƚ ? ?ĞŶĚƐƵĐŚĂƐh ?ƐŵĂůů
nuclear RNA, signal recognition particle (SRP) RNA, 
ribosomal 5S RNA and nuclear 7SK RNA 
(Kyriakopoulou et al. 2001, Perumal et al. 2001). 
Gld2 
PAP associated domain 
containing 4 (PAPD4) 
Mediates cytoplasmic polyadenylation of CPE 
containing specific mRNAs upon oocytes maturation 
in Xenopus as well in Drosophila embryo and also in 
neurons (Radford et al. 2008). Regulate transition 
from mitosis to meiosis. Initially identified in C. 
Elegans (Stevenson and Norbury 2006), where it 
forms a complex with RNA binding protein Gld3 
which is recruited it to specific mRNAs              
(Martin and Keller 2007). Also stabilizes ŵŝZEƐďǇ ? ?
end monoadenylation (D'Ambrogio et al. 2012). 
Involved in spermatogenesis and oogenesis in frog 
and mice as well in cytoplasmic polyadenylation in 
somatic cells. XGLD2 an ortholog of GLD-2 in Xenopus 
found to localized in nucleus and cytoplasm. 
Drosophila GLD2 limited to cytoplasm only     
(Rouhana et al. 2005, Schmidt and Norbury 2010). 
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Papd5 
Gld4, Trf4 or 5p 
(topoisomerase-related 
function protein) 
Involves in RNA quality control, oligoadenylates RNA 
by targeting exosome mediated cryptic RNA 
degradation, component of TRAMP complex, 
ortholog of S. Cerevisiae, found in nucleus (Fasken et 
al. 2011, Schmidt et al. 2011). Also involves in 
polyadenylation of specific mRNAs (Ciais et al. 2008, 
Houseley and Tollervey 2009, Rammelt et al. 2011). 
Found to involved in cytoplasmic polyadenylation in 
the absence of GLD-2 in C. Elegans and expressed in 
germ cells (Schmid et al. 2009). Role in histone 
mRNAs uridylation and degradation also involves in 
turnover of pre-rRNA in nucleus (Schmidt and 
Norbury 2010, Schmidt et al. 2011). In human 
fibroblast, it is required for CPEB1 mediated 
polyadenylation of TP53 mRNA (D'Ambrogio et al. 
2013). 
Pols  
(DNA 
polymerase 
sigma) 
Trf4/PAP2/ 
PAPD7 
RNA quality control, oligoadenylates RNA by targeting 
exosome mediated cryptic RNA degradation, 
component of TRAMP complex, ortholog of S. 
Cerevisiae, found in nucleus (Stevenson and Norbury 
2006). Also involves in polyadenylation of specific 
mRNAs (Ciais et al. 2008, Rammelt et al. 2011).   
Starpap TUTase, Papd2 
Eukaryotic specific U6 snRNA TUTase (terminal RNA 
ƵƌŝĚǇůǇů ƚƌĂŶƐĨĞƌĂƐĞƐ ? ǁŚŝĐŚ ĂĚĚ h ƌĞƐŝĚƵĞƐ Ăƚ  ? ?ĞŶĚ
of an mRNA (Trippe et al. 2003, Trippe et al. 2006). 
Role in nuclear phosphoinositides mediated signalling 
pathways where it polyadenylates specific mRNAs 
(Schmidt and Norbury 2010). 
Mtpap 
(mitochondrial 
poly(A) 
polymerase) 
Mitopap, Papd1 
Involves in polyadenylation of transcripts encoded in 
mitochondria, localize in mitochondria (Nagaike et al. 
2008, Chang and Tong 2012). It also oligouridylate 
 ? ?ĞŶĚs and degrade histone mRNAs in cytoplasm  (Bai 
et al. 2011). 
 
1.5 Role of polyadenylation in cancer 
1.5.1 Polyadenylation in cancer 
Different factors of cleavage and polyadenylation machinery have been found to be 
elevated in cancer (Morris et al. 2012). High levels of the scaffold protein symplekin 
were observed in lung and colon cancer (Singh et al. 2009, Buchert et al. 2010, 
Cappell et al. 2010). High PAPOLA activity is correlated with cancer (including breast 
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cancer) (Scorilas et al. 2000) and high CPSF4 levels have been observed in lung 
cancer (Chen et al. 2013), indicating that changes in polyadenylation may play a role 
in tumorigenesis. 
In addition, high levels of CPEB4 have been linked with aggressive and highly 
malignant forms of cancer such as in prostate cancer and promote metastasis 
through EMT (epithelial ?mesenchymal transition) (Xu and Liu 2013). Upregulation 
of CPEB4 has also been observed in pancreatic ductal adenocarcinomas (Sosef and 
Dauby 2012). 
Reduced levels of polyadenylation factors under oxidative stress and DNA damage 
have been reported during cell cycle arrest (Mirkin et al. 2008, Kiefer et al. 2009).  
Upon DNA damage, BRCA1 (breast cancer 1) associated protein BARD1, ŝŶŚŝďŝƚƐ  ? ?
end processing of an mRNA by interacting with CstF-50, thus inhibiting 
polyadenylation (Kleiman and Manley 1999, Scorilas 2002, Mirkin et al. 2008, 
Cevher et al. 2010). A specific point mutation in BARDI found in tumours leads to 
disruption of its association with the polyadenylation machinery (Thai et al. 1998). 
1.5.1.1 Role of Poly (A) polymerases in cancer 
PAP mutations in humans lead to cell arrest in G0/G1 phase while overexpression is 
seen in human carcinomas such as breast, colon and ovary and in other 
haematological malignancies (Danckwardt et al. 2008). PAP gamma and PAP alpha 
are involved in nuclear polyadenylation and highly resemble each other. They were 
both found to be upregulated in tumour tissue (Topalian et al. 2001, Martin and 
Keller 2007). Hyperphosphorylation of PAP alpha by cyclin B1 during M phase leads 
to the inactivation of polyadenylation, which ultimately reduces the mRNA levels 
and protein production during mitosis (Colgan et al. 1996, Colgan et al. 1998). 
Therefore low levels of PAP result in cell cycle arrest and high levels of PAP correlate 
with less differentiated cells (Scorilas et al. 2000). Enhanced  levels of PAP have 
been found in actively proliferating lymphocytes (Scorilas et al. 2000) and in colon 
cancer (Pendurthi et al. 1997). PAP has also been used as a biomarker in chronic 
leukaemia (Trangas et al. 1984). Upregulation of PAP has been observed in rapidly 
proliferating cells, such as in aggressive types of cancer (Scorilas et al. 2000), 
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increasing the stability of oncogene mRNAs and resulting in increased rounds of 
translation (Pendurthi et al. 1997). 
1.5.2 Alternative polyadenylation  
As discussed above, an increase in the use of proximal polyadenylation sites has 
been observed in proliferating cells and during oncogenic transformation (Elkon et 
al. 2012, Tian and Manley 2013). Different breast cancer cell lines such as 
transformed MCF-7 cells, exhibit ƐŚŽƌƚĞŶŝŶŐ ŽĨ  ? ? hdZs compared to non-
transformed MCF10A, while MB231 shows lengthening of the  ? ?hdZ(Fu et al. 
2011). 
 
1.6 Role of the Poly(A) tail in the life of an mRNA 
Poly(A) tails play a major role in modulating the export, translation and stability of 
an mRNA (Kojima et al. 2012). The changes in the length of a poly(A) tail as a 
consequence of deadenylation is thought to be a determining factor of mRNA 
stability under different cellular and physiological conditions (Meyer et al. 2004, 
Zhang et al. 2010). 
1.6.1  Poly(A) tails in mRNA stability 
1.6.1.1 Deadenylation dependent decay of an mRNA 
The steady state levels of an mRNA are a balance between mRNA turnover and 
mRNA synthesis (Cevher et al. 2010, Ma et al. 2013). mRNA stability can vary 
depending upon the mRNA. For instance, in mammalian cells the c-fos transcript 
undergoes a rapid decay with a half life of only 10-15 minutes in cytoplasm 
compared to ɴ-globin transcript which is highly stable with a half life of several 
hours to 24 hours, depending on the species (Meyer et al. 2004). Two crucial 
modifications which mRNAs receive during their synthesis, are the  ? ?  ?-
methylguanosine cap and the poly( ?ƚĂŝůĂƚ ? ?ĞŶĚ ?&Žƌan mRNA to fully decay, both 
or either modification has to be removed. The removal of the cap and the poly(A) 
tail are believed to be rate determining steps in mRNA decay (Meyer et al. 2004).  
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 Poly(A) tails protect translationally active stable mRNAs from degradation, while 
aberrantly processed mRNAs are deadenylated leading to mRNA decay (Guhaniyogi 
and Brewer 2001, Goldstrohm and Wickens 2008, Eckmann et al. 2011, Chen and 
Shyu 2013). The decay of an mRNA is a biphasic process in nearly all eukaryotes and 
begins with a slow phase during deadenylation followed by rapid degradation of 
mRNA body, either by decapping or  ? ? ĂŶĚ  ? ? ĞǆŽŶƵĐůĞĂƐĞƐ (Garbarino-Pico et al. 
2007, Chen et al. 2008, Kuhn et al. 2009). Deadenylation is thought to be the rate 
determining and primary regulated step of mRNA degradation in mammalian cells. 
Pathways of mRNA decay via miRNA (microRNAs) or ARE (AU-rich elements) are 
also largely mediated through deadenylation (Chen et al. 2008, Chen and Shyu 
2011).  
The deadenylation of an mRNA begins with the initial shortening of the long poly(A) 
tail received in the nucleus by Pan2/Pan3 complex to  ๝30-60nts in mammals. This is 
followed by further reduction in length by aid of the cNOT complex to 8-10 nts 
depending upon the species, as shown in figure 1.8 (Chen and Shyu 2011). After 
deadenylation, the Lsm1-7 complex is recruited to the  ? ? ĞŶĚ ŽĨ ĂŶ ŵZE ǁŚŝĐŚ
induces decapping through DCP1/2 complex, in which DCP2 mediates cleavage of 
the  ? ?ĐĂƉƚŽŵ7GDP leaving an ŵZEĐŽŶƚĂŝŶŝŶŐĂ ? ?monophosphate, while DCP1 
initiates the hydrolysis of the cap followed by degradation of an mRNA body (Meyer 
et al. 2004). The degradation of an mRNA after deadenylation can be initiated in 
either direction. XRN1 degrades in the  ? ?- ? ?ĚŝƌĞĐƚŝŽŶand the exosome degrades in 
the  ? ?-  ? ?Ěirection, depending on the mRNA species (Schwede et al. 2009). 
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Figure 1.8: Schematic representation of deadenylation dependent decay of an mRNA: 
In mammalian cells, deadenylation is accomplished in two phases. First initial shortening of 
poly (A) tail (~30-60nts) by Pan2/Pan3, followed by further shortening of poly (A) tail by 
cNOT complex upto 8-10 nts depending upon species. Decapping enzyme (Dcp1/2) is 
stimulated by Lsm1- FRPSOH[ DWWDFKHG DW ¶ HQG RI DQ P51$ IROORZHG E\ decay of an 
P51$ ERG\ E\ ;51 LQ ¶-¶ GLUHFWLRQ $OWHUQDWLYHO\ ZKHQ ¶-¶ SDWKZD\ E\ ;51 LV
compromised, mRNA can be degraded by the cytoplasmic H[RVRPH¶-¶GHFD\SDWKZD\ 
 
1.6.2 Poly(A) tails in translation 
1.6.2.1 Translational regulation: 
1.6.2.1.1 Closed loop formation by the ·FDSDQG·SRO\(A) tail 
The co-operative association between the  ? ?ŵ7' ? ? ? ?WWW ? ? ? ?EĐĂƉ and the  ? ?poly (A) 
tail mediates translational initiation through the formation of the closed loop 
complex. This is the result of association of the translation initiation factor (eIF4F) 
complex through the  ? ? ĐĂƉ ƐƚƌƵĐƚƵƌĞ(Newbury 2006, Weill et al. 2012). The 
stability of the closed loop complex is a major determinant of translational 
regulation (Beilharz and Preiss 2009). 
Translational regulation plays a key role in controlling major cellular activities 
including development, cell proliferation to differentiation in association with 
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ƐĞǀĞƌĂůZEďŝŶĚŝŶŐƉƌŽƚĞŝŶƐƐƉĞĐŝĨŝĐĨŽƌǀĂƌŝŽƵƐĐŝƐĞůĞŵĞŶƚƐĨŽƵŶĚŽŶ ? ?Žƌ ? ?hdZ 
(Fukao et al. 2009). The process of translation is highly controlled and a rate 
determining step, which starts with the binding of translation initiation factors on 
the  ? ?ĐĂƉƐƚƌƵĐƚƵƌĞĨŽƵŶĚon all nuclear encoded mRNAs (D'Ambrogio et al. 2013). 
In translation initiation, the cap binding eukaryotic translation initiation factor 
(eIF4F) is composed of eIF4A (an RNA helicase involved in RNA unwinding), eIF4E 
(direcƚůǇ ďŝŶĚƐ ƚŽ  ? ? ĐĂƉ ? ĂŶĚ Ğ/& ?', a scaffold protein which interacts with eIF4E 
and binds to multisubunit factor eIF3. eIF3 mediates the recruitment of the 40S 
ribosomal subunit (43S upon association with other key factors in pre-initiation 
complex) to the  ? ?ĞŶĚŽĨĂŶŵZE (Fukao et al. 2009, D'Ambrogio et al. 2013). 
The poly(A) tail enhances the efficiency of translational initiation through the 
interaction of eIF4F complex and PABP (poly(A) binding protein) bound to the  ? ?ĐĂƉ
and the  ? ?ƉŽůǇ ? ?ƚĂŝůƌĞƐƉĞĐƚŝǀĞůǇ (Fukao et al. 2009, Burgess and Gray 2010). The 
poly(A) tail of nuclear polyadenylated mRNAs is bound to PABPN1, which before 
cytoplasmic export is replaced by PABPC1 (PABP1 or PAB1) (Afonina et al. 1998, 
Burgess and Gray 2012). It promotes translation initiation by interacting with eIF4G, 
a subunit of translation initiation complex, which in turn binds to eIF4E, mediating 
the formation of the so-called closed loop structure as shown in figure 1.9 (Fukao et 
al. 2009, Burgess and Gray 2010, Brook and Gray 2012, Kojima et al. 2012). The 
association of PABPC with a protein similar to eIF4G, PAIP1 (PABP interacting 
protein 1), stabilizes the closed loop structure by enhancing the recruitment of 
eIF4A and eIF3 (Craig et al. 1998). The interaction of PABPC1 with eIF4A co factor, 
eIF4B, enhances the helicase activity of eIF4A, however its exact role needs further 
investigation (Cheng and Gallie 2007, Burgess and Gray 2010).  
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Figure 1.9: Role of PABP1 in translation initiation:  
The poly(A) tail is bound by PABPC1 which connects the two ends of an mRNA by 
interacting with the eIF4F complex bound to the ¶FDS resulting in formation of the closed 
loop circular structure. The components of eukaryotic translation initiation factor complex 
(eIF4F) are recruited to ¶FDS 1, the scaffold protein eIF4G interacts with eIF4E and binds 
to eIF4A and eIF3 which ultimately recruits 40S small ribosomal subunit (43S upon 
DVVRFLDWLRQZLWKIDFWRUVLQ3,&DW¶HQGRI an mRNA.  
Abbreviation: ORF: open reading frame, PAIP1: PABP interacting protein 1.  
 
1.6.2.1.2 Role of cytoplasmic polyadenylation in translational reactivation 
The length of a poly(A) tail is also implicated in translational regulation, as 
cytoplasmic increases in poly(A) tail length correlate with translational activation of 
mRNAs. Upon specific stages of development, such as during oocyte maturation, 
the changes in poly(A) tail length and translational regulation of specific mRNAs are 
the consequence of deadenylation of long poly (A) tails made in the nucleus or the 
cytoplasmic polyadenylation of stored maternal mRNAs (Papin et al. 2008). 
Translational activation through cytoplasmic polyadenylation involves  recruitment 
of translation initiation machinery by poly(A) tails through PABP, which results in 
dissociation of inhibitory factors bound to an mRNA (Radford et al. 2008).  Freshly 
made mRNAs that have obtained a poly(A) tail in the nucleus are thought to 
translate more efficiently, while shorter poly (A) tails lead to poor translation of an 
mRNA (Kwak et al. 2008, Radford et al. 2008, Kuhn et al. 2009, Charlesworth et al. 
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2013). Therefore, length of a poly (A) tail is thought to be a major determinant of 
translation efficiency (Schmid et al. 2009, Weill et al. 2012), although a recent study 
indicates this may only hold true in early development. In any case, mRNAs  require 
at least 25 nt to permit PABP binding and stimulation of translation (Schwede et al. 
2009).  
1.6.2.2 Role of deadenylation: translational repression 
In general, poly(A) tail removal is the initial step in mRNA turnover or in silencing 
the cytoplasmic transcripts of specific mRNAs, but deadenylation does not always 
lead to mRNA decay. These stable deadenylated mRNAs  can remain translationally 
inactive and become reactivated upon  cytoplasmic polyadenylation (Weill et al. 
2012). Deadenylation may mediate mRNA decay and translational repression by 
disrupting the association between translational initiation factors bound to the cap 
and PABP (Goldstrohm and Wickens 2008). The interaction between PABP and the 
translation termination factor eRF3 also stimulates deadenylation (Goldstrohm and 
Wickens 2008, Zhang et al. 2010). mRNA specific translational regulation controlling 
the fate of an mRNA, depends upon the special regulatory elements mostly found in 
 ? ?hdZ ? dŚĞƐĞ ĐŝƐ-elements are bound by specific RNA binding proteins that 
assemble mRNAs into mRNPs (ribonucleoprotein complexes) (Schmid et al. 2009) 
and are involved in modulating the length of the poly(A) tail through recruitment of 
specific deadenylases (Goldstrohm and Wickens 2008, Weill et al. 2012). The 
interaction of translation components with the decay apparatus provides a 
mechanistic link with translational repression (Newbury 2006).  
1.6.2.2.1 AU-Rich elements (ARE) 
The AREs (AU-rich elements) are regulatory sequence elements in U-rich  ? ? hdZ
regions, which are recognised by various RNA binding proteins, which can prevent 
or promote decay as shown in figure 1.10. AREs are the best studied destabilizing 
elements and consist of penƚĂŵĞƌ ƌĞƉĞĂƚƐŽĨ  ? ?-AUUUA- ? ? ĨŽƵŶĚ ŝŶ the  ? ? hdZŽĨ
many unstable eukaryotic mRNAs (Chen et al. 2008, Weill et al. 2012). AREs regulate 
approximately 3000 genes (Meisner et al. 2004) through their interaction with 
almost 30 ARE-binding proteins identified so far (Weill et al. 2012). Cytokines, 
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proto-oncogenes, transcription factors encoding transcripts and growth regulatory 
genes are highly enriched for AREs (Garneau et al. 2007, Meijer et al. 2007). AREs 
promote deadenylation-mediated decay through ARE-binding proteins such as TTP 
(tristetraprolin), KHSRP (KH-type splicing regulatory protein), BRF1 (butyrate 
response factor 1), ELAV (embryonic lethal abnormal vision) and AUF1 (AU-rich 
binding factor 1), which recruit deadenylating enzymes (Garneau et al. 2007, Zhang 
et al. 2010). AREs can also mediate stabilization through the only identified 
stabilizing ARE-binding protein HuR (Hu protein R), a member of the ELAV family 
(Meisner et al. 2004, Garneau et al. 2007, Zhang et al. 2010). The ARE-binding 
proteins TTP (Zfp36) and KHSRP recruit deadenylases, the cNOT complex and PARN 
respectively (Garneau et al. 2007, Weill et al. 2012). 
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Figure 1.10: Regulation of deadenylation by AU-Rich elements: 
AREs mediate deadenylation regulation through the recognition of several ARE- binding 
proteins which stabilize or destabilize of mRNA.  AREs are recognized by many destabilizing 
factors such as AUF1, BRF1, KHSRP and TTP. KHSRP and TTP mediate recruitment of 
deadenylation enzymes such as the cNOT complex and PARN respectively. AREs 
containing mRNAs are stabilized through association of the ARE-binding protein HuR which 
acts as a positive regulator by preventing the interaction of destabilizing factors to AREs. 
HuR also stabilizes the interaction of PABPC with poly (A) tail.  
Abbreviations: ARE (AU-Rich element), TTP (tristetraprolin), KHSRP (KH-type splicing 
regulatory protein), BRF1 (butyrate response factor 1) and AUF1 (AU-rich binding factor 1).  
Adapted from: (Zhang et al. 2010). 
 
1.7 Cordycepin: highly prized traditional Chinese medicine 
1.7.1 History and habitat of the caterpillar fungi 
Cordyceps militaris and Ophiocordyceps sinensis (formerly Cordyceps sinsensis) 
infect caterpillars before producing fruiting bodies. O. sinensis has been used 
medicinally in China and Tibet for more than 300 years. . It is called  ‘ŽŶŐ- Chong 
yŝĂĂŽ ? (winter worm summer grass) and was first mentioned by Wang Ang in 1694 
in Ben-Cao-Bei-Yao (Yue et al. 2013). It is used for a large variety of diseases, 
including lung and kidney diseases and diseases of old age. Cordyceps militaris also 
parasitizes Lepidoptera larvae and is found throughout the Northern hemisphere, 
however fruiting bodies are very rare in all locations, in contrast to O. sinensis, 
which could be collected in quantity in Tibet (Cunningham et al. 1950, Kim et al. 
2006, Imesch et al. 2012).  
Collection of Ophiocordyceps sinensis is the source of 40% of cash income in rural 
Tibet. This is due to the high prices it fetches in China as the fungus is becoming rare 
in the wild (Winkler 2010). Ophiocordyceps sinensis does not form fruiting bodies in 
culture, and the level of cordycepin in cultivated samples is low (Utami, De Moor 
and Barrett, unpublished result). In contrast, Cordyceps militaris can be persuaded 
to form fruiting bodies in culture and strains with very high cordycepin production 
have been selected. All cordycepin currently on the market is isolated from 
cultivated C. militaris. 
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1.7.2 Structure of cordycepin 
Cordycepin  ? ? ?ĚĞŽǆǇĂĚĞŶŽƐŝŶĞ ?is an adenosine analogue that lacks the  ? ?ŚǇĚƌŽǆǇů
group at the ribose sugar, which is ŝŵƉŽƌƚĂŶƚĨŽƌ ? ?- ? ?ĞůŽŶŐĂƚŝŽŶ  (Cunningham et 
al. 1950) as shown in the figure 1.11.  
 
 
Figure 1.11: Chemical structures of adenosine, cordycepin and pentostatin.  
Taken from: (Tsai et al. 2010).  
 
1.7.3 Cordycepin as a cancer drug 
Cordycepin has been proposed as an anticancer drug acting by many different 
mechanisms such as inhibition of translation, induction of nucleic acid methylation, 
apoptosis induction, anti-angiogenesis, antioxidation and regulation of signalling 
pathways (Ng and Wang 2005). Other diversetherapeutic properties of cordycepin 
have been reported, ranging from anti-herpes activity (de Julian-Ortiz et al. 1999), 
anti-fungal (Sugar and McCaffrey 1998), antibacterial (Ahn et al. 2000), anti-malarial 
(Trigg et al. 1971), anti-viral (Panicali and Nair 1978), anti-atherosclerosis (Won et 
al. 2009) to anti-parasitic (Rottenberg et al. 2005) activities.  
1.7.3.1 Role of cordycepin in cancer cell survival and proliferation 
Anticancer activity of cordycepin through the induction of apoptosis has been 
reported in many papers (Buenz et al. 2005, Wehbe-Janek et al. 2007, Wu et al. 
2007, Chang et al. 2008, Chen et al. 2008, Thomadaki et al. 2008, Kitamura et al. 
2011) in many typer of cancer, such as leukemia (Wehbe-Janek et al. 2007), oral 
cancer cells (Wu et al. 2007), bladder (Lee et al. 2009), breast cancer cells 
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(Thomadaki et al. 2005), HELA cells  (He et al. 2009), mouse leydig tumor cells (Pan 
et al. 2011), human gallbladder (Wang et al. 2014) and lung cancerous cells 
(Nakamura et al. 2005, Nakamura et al. 2006). Cordycepin was reported to induce 
caspase-dependent apoptosis by activating reactive oxygen species (Thomadaki et 
al. 2008, Jeong et al. 2011) and caspase-independent apoptotic pathway by 
inhibiting RNA synthesis (Chen et al. 2010). Caspases are classed into upstream 
initiator caspases (caspases 2, 8, 9, 10) and effector caspases (caspases 3, 6, 7) 
which play crucial roles in inflammation and apoptosis (Earnshaw et al. 1999). 
Cordycepin has been reported in several papers to induce apoptosis by activating 
caspases (Park et al. 2005, Lee et al. 2006, Jin et al. 2008, Thomadaki et al. 2008, 
Park et al. 2009, Chen et al. 2010, He et al. 2010, Choi et al. 2011, Jen et al. 2011, 
Jeong et al. 2011). Activation of caspases leads to the disruption of crucial 
intracellular functional and structural proteins which results in apoptosis (He et al. 
2010). 
Deregulation of programmed cell death has been involved in increased cancer cell 
survival. Apoptosis is regulated by many intracellular signaling pathways, including 
the MAPK pathways. ERK (extracellular signal regulated protein kinase), c-jun N-
terminal kinase (JNK) and p38 MAPK pathway are among the three MAPK pathways 
kinases (Liu and Lin 2005). Cordycepin has been reported to induce apoptosis by 
increasing protein expression of Bcl-2 pro-apoptotic members (Bax, Bim, Bid and 
Puma) and activating MAPK pathways kinases (JNK and p38) (He et al. 2010). 
Several papers indicate that cordycepin inhibits cell proliferation (Nakamura et al. 
2005, Chang et al. 2008, Shi et al. 2008, Wang et al. 2014) including inhibiting the 
growth of HCT116 colon cancer cells by activating p21WAF1 expression (Lee et al. 
2010) and in B16 (Mouse melanoma cell line) by inhibiting cyclin D1 (Yoshikawa et 
al. 2008).  In addition, cordycepin has been reported to reduce protein synthesis by 
inducting the ƉŚŽƐƉŚŽƌǇůĂƚŝŽŶŽĨĞ/& ?ɲĂŶĚdephosphorylation of 4EBP (Wong et al. 
2010, Kitamura et al. 2011). Many of these studies claim to demonstrate the 
mechanism of action of cordycepin. However, a mechanism of action that 
demonstrates that the drug cordycepin directly affects the targeted process has not 
been identified in any of these cases. 
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As described previously, therapeutic agents have been selectively designed to 
target ER positive breast cancers, however these agents (ER modulators) are 
ineffective to ER negative breast cancers. In this regard, cordycepin has been 
investigated in treatment of breast cancer and found to be very effective in inducing 
apoptotic and autophagic cell death in MDA-MB-231 (basal like) cell and MCF-7 (ER 
positive) cells respectively. Thus cordycepin represses the in vitro growth of breast 
cancer cells irrespective to the presence of the ER. The exact mechanism of 
autophagic and apoptotic inducing cell death by cordycepin in breast cancer cells 
needs to be explored, but it may result from the inhibition of mTOR signalling that 
has been observed in other cell types (Wong et al. 2010). Cordycepin has been 
proposed as a potentially safe therapeutic agent for breast cancer treatment (Choi 
et al. 2011). The inhibition of cell proliferation by cordycepin in MCF-7 cells has also 
been reported by others (Ko et al. 2013). 
1.7.3.2 The effect of cordycepin on DNA damage repair 
Cordycepin has been reported to inhibit PARP (poly ADP-ribose polymerase) activity 
in BRCA1 mutated breast cancer MCF-7 cells. PARP is involved in repairing DNA 
single strand breaks (Kim et al. 2011). However, the inhibitor of PARP appears to be 
unmodified cordycepin, rather than cordycepin triphosphate, which is the 
predominant intracellular metabolite of cordycepin in MCF-7 cells (Utami, Khurshid, 
De Moor & Barrett. unpublished observation). 
Double strand breaks can be repaired  by protein complexes containing BRCA1 and 
BRCA2 (Jackson and Bartek 2009). In breast cancer with defective BRCA1 or BRCA2, 
PARP inhibition is considered as an effective mechanism to disable the DNA repair 
process (Weil and Chen 2011). Induction of the DNA double strand repair pathway 
was observed upon cordycepin treatment in breast cancer cells indicating the anti 
cancer effects of cordycepin may be through similar pathways as chemotherapy 
(Lee et al. 2012).  
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1.7.3.3 Cordycepin activates AMPK and inhibits PI3K/AKT and MAPK 
signaling pathways 
Cordycepin reduces AKT kinase and 4E-BP phosphorylation by inhibiting the 
activities of the mTORC1 and mTORC2 complexes in PI3K/AKT/mTOR signaling 
pathway, while cordycepin activates AMPK by an unknown mechanism that in turn 
inhibits mTORC2 activity leading to a double block of the mTOR signalling. Thus 
reduces total proten synthesis. Activation of AMPK appears to be upstream of 
downregulation of the mTOR pathway. Inactivation of AKT (Guo et al. 2010, Wong 
et al. 2010, Jeong et al. 2012, Takahashi et al. 2012, Wu et al. 2014, Zhang et al. 
2014) by cordycepin has also been reported. In one case, activation of AMPK by 
cordycepin also leads to reduction in ERK phosphorylation. This is thought to be 
through downregulation of BRAF, mediated by activated AMPK, thus suppressing 
the MAPK signaling cascade (Shen et al. 2013). 
1.7.4 Molecular functions of cordycepin 
Although there is some evidence for a direct interaction of cordycepin or its active 
metabolite cordycepin triphosphate with AMPK or PARP1 (Kim et al. 2011, Wu et al. 
2014), the best characterised direct effect of cordycepin is its termination of 
polyadenylation through chain termination and arrest of the cleavage complex. 
Cordycepin reduces mRNA synthesis and acts as a chain terminator for mRNA 
polyadenylation through poly(A) polymerases, without affecting pre-mRNA levels 
(Shigeura and Gordon 1965, Penman et al. 1970, Horowitz et al. 1976, Muller et al. 
1977, Rose et al. 1977, Glazer et al. 1978, Chen et al. 2010, Cheng et al. 2011). 
Cordycepin is definitely not a general transcription inhibitor (Kondrashov et al; 
2012).   
Cordycepin triphosphate has been widely used in in vitro polyadenylation reactions 
to elucidate the process of polyadenylation that is described in section 1.3. After 
chain termination, cordycepin arrests a complex of polyadenylation factors called 
the cleavage complex on the mRNA (Ryner and Manley 1987, Zarkower and 
Wickens 1987, Zarkower and Wickens 1987), which contains factors that are absent 
in other polyadenylation complexes (Shi et al. 2009), such as mRNA export factors. 
Normally, polyadenylation factors are released and the proto-oncoprotein 
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nucleophosmin is deposited on the mRNA before it is exported (Qu et al. 2009, 
Sagawa et al. 2011). In contrast, treatment of cells with cordycepin prevents the 
deposition of nucleophosmin on newly made mRNAs (Sagawa et al. 2011) as well as 
inhibiting polyadenylation (Kondrashov et al; 2012). Cordycepin specifically affects 
the expression of several inflammatory mRNAs in airway smooth muscle by a     
post-transcriptional route and their accumulation in the cytoplasm is prevented 
(Kondrashov et al; 2012).  If affects of cordycepin are mediated through the 
inhibition of polyadenylation, then inhibitors of cordycepin import and 
phosphorylation should abrogate them. In addition, early effects of cordycepin can 
be predicted to be post-transcriptional. Both of these predictions have been 
observed (Kondrashov et al; 2012).  In addition, transcription termination defects 
detected in cordycepin treated cells (Kondrashov et al; 2012), could account for the 
observation of DNA damage through the formation of R-loops (Hill et al. 2014, 
Skourti-Stathaki and Proudfoot 2014). These are hybrids that can form between 
transcribed RNA and DNA which can trigger a DNA damage response. 
1.7.5 Effect of cordycepin on adenosine receptors 
Adenosine and its receptors form a signaling pathway involved in the regulation of 
various tissue related functions. Low levels of adenosine are present in normal or 
unstressed cells compared to stressed or inflammatory states. In addition, genetic 
alterations which arise during cancer development enhance the amount of 
adenosine in the cell (Antonioli et al. 2014). In the extracellular environment high 
levels of adenosine stimulate adenosine receptors resulting in the activation of cell 
signaling cascades and the inductuon of anti-inflammatory and immune responses. 
In addition activation of adenosine receptors can lead to increased proliferation, 
apoptosis and metastasis of cancer cells (Antonioli et al. 2013, Virtanen et al. 2014). 
Four different G-protein coupled membrane receptors are responsible for action of 
extracellular adenosine. Activation either increases (A2A and A2B) or reduces (A1 and 
A3) intracellular levels of cAMP (Fredholm et al. 2001, Sorrentino et al. 2013).    
The strength of adenosine signalling relies on the amount of adenosine. Adenosine 
receptors interact with MAPK kinase pathway and adenosine also acst without its 
receptor through AMPK and adenosine kinase (Antonioli et al. 2013). Various papers 
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have been reported that stimulating an adenosine receptor, mainly A3, is
 
involved in 
suppressing cell proliferation in various cancers. This is thought to be through G0-G1 
cell cycle arrest by inhibiting the activity of cyclin D1, cyclin E1 and CDK4, which 
decreases the levels of AKT and downregulates the phosphorylation of ERK 
(Fishman et al. 2000, Fishman et al. 2002, Merighi et al. 2002, Madi et al. 2003, 
Morello et al. 2008, Aghaei et al. 2011). However, the role of other adenosine 
receptors in inhibiting cell proliferation needs further investigation (Antonioli et al. 
2013). Adenosine receptors can induce apoptosis in cancer cells by increasing the 
levels of CD95 (death receptor), TRAILR2 (tumour necrosis factor-related apoptosis-
inducing ligand receptor 2), FADD (FAS-associated death domain protein). This leads 
to activation of caspases 8 and 9 followed by caspase 3 and decreases the levels of 
anti-apoptotic protein such as BCL-2, in addition to the decrease of phosphorylation 
of AKT. It also increases the levels of BAX, BAD modulators of apoptosis (Kim et al. 
2002, Wen and Knowles 2003, Lee et al. 2005, Bar-Yehuda et al. 2008, Yasuda et al. 
2009, Yang et al. 2010, Cohen et al. 2011, Aghaei et al. 2012, Mlejnek et al. 2012, 
Tamura et al. 2012, Antonioli et al. 2013, Chen et al. 2014).  
Cordycepin also has been proposed to prevent tumor growth formation through 
activating adenosine Gi protein-coupled A3 receptors (Fishman et al. 2002, 
Nakamura et al. 2006, Yoshikawa et al. 2008, Kitamura et al. 2011).  It was reported 
previously that cordycepin acts through adenosine receptors (A1, A2A and A3) in 
stimulating steroidogenesis in mouse leydig cells, while it may act through A1, A2A, 
A2B and A3 receptors in MA-10 cells (Leu et al. 2011, Pan et al. 2011, Pao et al. 2012). 
Higher levels of mRNA expression of A3 adenosine receptors were reported in 
human breast and colon cancerous cells compared to non cancerous cells 
(Yoshikawa et al. 2008). The mechanism of action of cordycepin through activation 
of adenosine receptors predicts that adenosine and cordycepin should have similar 
activities and that inhibition of cordycepin import or phosphorylation should not 
prevent the activity of cordycepin. These predictions do not hold true in many cell 
types (Kondrashov et al; 2012; Wong et al; 2010). 
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1.7.6 Pharmacokinetics of adenosine and cordycepin 
Adenosine deaminase is a catabolic enzyme that plays an important role in purine 
metabolism. There are two isoenezymes ADA1 and ADA2. ADA1 is involved in the 
ĚĞĂŵŝŶĂƚŝŽŶ ƉƌŽĐĞƐƐ ŽĨ ĂĚĞŶŽƐŝŶĞ ĂŶĚ  ? ?ĚĞŽǆǇĂĚĞŶŽƐŝŶĞ(Kayhan et al. 2008). 
Normal endogenous levels of adenosine in plasma are 0.1-1µM. Adenosine and 
cordycepin are irreversibly deaminated by adenosine deaminase into 
hypoxanthinosine as shown in the figure 1.12 and to an inactive form 
 ? ?ĚĞŽǆǇŚǇƉŽǆĂŶƚŚŝŶŽƐŝŶĞ ŝŶ ƚŚĞ ƉůĂƐŵĂ respectively. The half life of adenosine in 
plasma is found to be 0.6-1.5 seconds (Tsai et al; 2010).  
 
Figure 1.12: Deamination of adenosine into hypoxanthinosine.  
Taken from: (Tsai et al. 2010). 
 
Nucleoside permeases are responsible for transporting adenosine into the cell 
where it is phosphorylated to form ATP by adenosine kinase, which also 
ƉŚŽƐƉŚŽƌǇůĂƚĞƐ ĐŽƌĚǇĐĞƉŝŶ ŝŶƚŽ  ? ?ĚĞŽǆǇĂĚĞŶŽƐŝŶĞ ƉŚŽƐƉŚĂƚĞ ĚĞƌŝǀĂƚŝǀĞƐ. Due to 
the instability of cordycepin it is usually administered in combination with another 
purine analog,  ? ?- deoxycoformycin (dCF), also known as pentostatin. However 
pentostatin has considerable adverse effects, including severe immune suppression. 
In contrast, cordycepin on its own has very few side effects. Co-administration of an 
ADA inhibitor eg. pentostatin increases cordycepin efficacy both in vivo and vitro, 
but it also results in gastrointestinal and bone marrow toxicity. (Rodman et al. 
1997). Combination of pentostatin with cordycepin cures Trypanosoma brucei 
infection in mice. The parasitic infection was found to be eliminated from the blood 
71 
 
and also from the brain parenchyma (Rottenberg et al. 2005, Vodnala et al. 2008). It 
was also reported that the combination of cordycepin and pentostatin effectively 
cures mice in vivo and vitro infected with Trypanosome evansi  (Dalla Rosa et al. 
2013).  
Pentostatin is an adenosine deaminase (ADA) inhibitor which inhibits the 
ĚĞĂŵŝŶĂƚŝŽŶ ŽĨ ďŽƚŚ ĂĚĞŶŽƐŝŶĞ ĂŶĚ  ?഻-deoxyadenosine to form inosine and 
 ?഻ĚĞŽǆǇ-inosine respectively. In addition, it has been reported to block DNA 
synthesis during the "S" phase of the cell cycle through inhibition of ribonucleotide 
reductase and through incorporation into DNA as a false purine base. Additional 
cytotoxic effects have been attributed to its incorporation into RNA (Tsai et al. 
2010).   
The exact mechanism of action of pentostatin is still unknown. However it is 
currently used to treat hairy cell leukemia and found to inhibit DNA repair, although 
toxicity issues have been reported (Airhart et al. 1996, Margolis and Grever 2000, 
Lauria and Forconi 2009, Robak and Robak 2012). Therefore due to a high rate of 
clearance and short half lives of adenosine and cordycepin, addition of pentostatin 
will reduce the degradation rate in plasma. Toxicity of cordycepin with pentostatin 
for acute lymphocytic leukemia was found to be tolerable in humans and further 
clinical trials are being coordinated by Oncovista (Foss 2000) (website reference 1).   
1.7.7 Mode of action of C-8 substituted adenosine analogues 
Modifications of cellular nucleosides are based on structural or conformational 
changes. They can be placed in the ribose sugar or the base such as 8-amino 
adenosine, 8-chloro adenosine etc as shown in figure 1.13. Such nucleoside 
homologs have been widely tested as a chemotherapeutic agent. In general, purine 
bases are studied more extensively for cancer therapy (Chen and Sheppard 2004). 
Adenosine analogues can decrease the endogenous levels of ATP by accumulating 
as triphoshate in the cell (Anders et al. 2010). The application of these C-8 
substituted adenosine analogues as an antineoplastic drug has been reported in 
many studies. The 8-amino adenosine and 8-chloro adenosine may induce 
apoptosis due to a decline in cellular ATP levels (Halgren et al. 1998, Gandhi et al. 
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2001, Chen et al. 2010).  8-chloro adenosine acts as a transcription inhibitor 
resulting in low levels of total cellular RNA due to an imbalance between RNA 
biosynthesis and the rate of its turnover, by slowing down the process of 
transcription and increasing mRNA degradation (Stellrecht et al. 2014). Addition of 
C-8 adenosine analogue disrupts chain extension during RNA transcription but also 
causes termination of the poly(A) tail, which results in inhibition of RNA transport or 
processing (Chen and Sheppard 2004). Adenosine analogues may exert their effects 
by disrupting other ATP dependent RNA polymerases, for example poly(A) 
polymerases that have a structural similarity to ATP (Chen and Sheppard 2004).  
 
Figure 1.13: Chemical structure of C-8 substituted adenosine analogue.  
Taken from: (Chen et al. 2010) 
 
C-8 substituted adenosine analogues cause conformational changes by changing the 
sugar equilibrium to the C- ? ? ĞŶĚŽ ĨŽƌŵ ůŝŬĞ E ŽǀĞƌ - ? ? ĞŶĚŽ ZE ůŝŬĞ
conformation. So far, among C-8 substituted adenosine analogues, 8-amino ado and 
8-azido ado have been reported to act similarly to cordycepin as chain terminators. 
They are thought to inhibit RNA polyadenylation by incorporating into nascent 
poly(A) tails. Differences in the polyadenylation inhibitory activities were also 
observed in vitro among these C-8 substituted adenosine analogues, depending 
upon the substitution. Nitrogenous substitution at C-8 position like 8-amino ado 
(adenosine), 8-aza ado and 8-azido ado resulted in a moderate inhibition of 
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polyadenylation compared to the halogen substitution at C-8 position. This is similar 
to 8-chloro ado and 8-bromo ado which markedly inhibited polyadenylation as they 
act as a weak substrate for PAP, decreasing the efficiency of transfer of AMP to the 
substrate from the enzyme. It was also proposed that the induction of glycosidic 
bond conformational changes in sugar play a role in these inhibitory effects. The 
main difference between preferred sugar conformations in ribonucleotides and 
deoxy ribonucleotides are due to the C- ? ?- endo for ribonucleotides and C- ? ?-endo 
for deoxy ribonucleotides (Chen and Sheppard 2004).  
1.7.7.1 8-Chloro adenosine analogue 
The cytotoxic effects of 8-chloro adenosine have been reported in several papers 
(Gandhi et al. 2002, Balakrishnan et al. 2005, Dennison et al. 2009) by suppressing 
transcription (Stellrecht et al. 2007) and PAPs (Chen and Sheppard 2004, Chen et al. 
2010) through incorporation into the mRNA (Stellrecht et al. 2003). 8-chloro 
adenosine has been reported to induce apoptosis in breast cancer by inhibiting the 
levels of cyclin E (Stellrecht et al. 2010) and like cordycepin by reducing the levels of 
cellular ATP. This in turns caused AMP and upstream kinases to activate AMPK in 
addition to downregulating levels of P-4EBP by inhibiting the PI3K/mTOR signaling 
cascade (Stellrecht et al. 2014). Currently 8-chloro adenosine is in phase I clinical 
trials (Pillai et al. 2012, Polotskaia et al. 2012). 8-chloro adenosine is the only purine 
analogue reported so far to be effective in multiple myeloma cell lines (Krett et al. 
1997, Halgren et al. 1998, Gandhi et al. 2001, Stellrecht et al. 2003) at inducing 
apoptosis by interfering with RNA synthesis, without exerting any effect on DNA 
synthesis. Like cordycepin, 8-chloroadenosine needs to be phosphorylated to exert 
its effects on cellular targets (Gandhi et al. 2001, Stellrecht et al. 2003). Unlike 
cladribine which gets phosphorylated by deoxycytidine kinase, 8-Cl-ado requires 
adenosine kinase to be metabolized intracellularly to 8-Cl-cAMP (Stellrecht et al. 
2003). In cells, inhibition of mRNA synthesis results from chain termination upon 
significant incorporation of 8-chloro adenosine by Pol II into the transcript, which 
might be due to the impaired base pairing between adenine and thymine. This 
results in a lack of hydrogen bonding between the DNA template and the newly 
formed transcript. In addition, Pol II may be more sensitive to the decreased levels 
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of ATP (Stellrecht et al. 2003). Degradation of 8 chloro adenosine also involves 
deamination by adenosine deaminases to 8-chloro-inosine monophosphate (Tsai et 
al. 2010).  
 
 
1.8 Aims of the project 
Cordycepin could interfere with many normal cell metabolic functions, as adenosine 
is used ubiquitously in the body and at least four direct targets have been proposed 
in the literature (adenosine receptors, AMPK, PARP1 and polyadenylation). The aim 
of my project is to investigate the mechanism of action of cordycepin and its 
potential as an anticancer drug by studying its effect on protein synthesis, cell 
proliferation and gene expression. I will be comparing the effects of cordycepin with 
those of other adenosine analogues and the knowckdown of poly(A) polymerase. A 
microarray study will be used to identify mRNAs that are affected by cordycepin 
treatment.  
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2 Materials and Methods: 
2.1  General reagents 
2.1.1 Reagent and equipment suppliers 
New England Biolabs (NEB) 75 - 77 Knowl Piece, Wilbury Way, Hitchin, Herts. SG4 
0TY 
Fisher-Scientific  Bishop Meadow Road, Loughborough, Leicestershire. LE11 5RG 
GE Healthcare (Amersham) GE Healthcare Life Sciences, Amersham Place, Little 
Chalfont, Buckinghamshire. HP7 9NA 
Invitrogen Ltd. 3 Fountain Drive, Inchinnan Business Park, Paisley, UK. PA4 9RF 
Sigma-Aldrich Company Ltd. The Old Brickyard, New Road, Gillingham, Dorset. SP8 
4XT 
Roche Products Limited.  6 Falcon Way, Shire Park, Welwyn Garden City. AL7 1TW 
       Promega, UK.  Delta House, Southampton Science Park, Southampton. SO16 7NS 
 
2.1.2 Chemicals 
CordycĞƉŝŶ  ? ? ?-Deoxyadenosine), 8- Bromoadenosine, DRB (5, 6-Dichloro-1-beta-D-
ribofuranosylbenzimidazole), Cladribine (2-Chloro- ? ?-deoxyadenosine) and  ? ?-Deoxy-
 ? ?-(methylthio) adenosine were purchased from Sigma. They were dissolved at a 
thousand fold concentration in DMSO to obtain the indicated final concentrations. 
Metformin (1, 1-Dimethylbiguanide hydrochloride) was also purchased from Sigma 
and dissolved upto 50mM in DMSO.  8- Azidoadenosine (8-N3-Ado) was purchased 
from Biolog. 8-Chloroadenosine and 8-aminoadenosine were purchased from 
Carbosynth and Santa Cruz respectively.  Pentostatin was purchased from Tocris. 
Se13 and Se15 confidential compounds were gifted by Dr Shudong Wang, Medicinal 
chemistry division, School of Pharmacy, University of Nottingham.  
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2.2 Tissue culture techniques 
2.2.1 Solutions and reagents 
Phosphate buffered saline (PBS): 4.3 mM Na2HPO4, 1.5 mM KH2PO4, 137 mM NaCl, 
2.7 mM KCl, pH 7.4. (OXOID) 
ƵůďĞĐĐŽ ?Ɛ DŽĚŝĨŝĞĚ ĂŐůĞƐ DĞĚŝƵŵ  ?DD ?  ?W ? with 4.5 g/L of glucose and 4 
mM glutamine 
McCoy's 5a Medium (Sigma) 
 Feotal Bovine Serum (FBS) and Foetal calf serum (FCS) heat-inactivated (PAA) 
Penicillin-Streptomycin, 10,000 ƵŶŝƚ ?Ɛ penicillin and 10 mg streptomycin/ml, sterile-
filtered (Sigma-Aldrich) 
2.2.2  Cell Lines 
Table 5: Decription of Cell lines 
Cell line Origins Description 
HELA 
Human cervical 
epithelial carcinoma 
Adherent cell line maintained in DMEM 
supplemented with 10% FBS and 4mM L-
glutamine 
MCF-7 
Human breast 
epithelia 
adenocarcinoma 
Adherent cell line maintained in DMEM 
supplemented with 10 % FBS, Penicillin-
Streptomycin 10ml/L and 4 mM L-
glutamine 
NIH3T3 
Mouse embryonic 
fibroblast cells 
Adherent cell line maintained in DMEM 
supplemented with 10 % FCS and 2 mM 
L-glutamine 
HT29 
Human colorectal 
adenocarcinoma 
cells 
Adherent cell line maintained in McCoy's 
5a Medium supplemented with 10 % 
FBS, and 4 mM L-glutamine 
HCT116 
Human colorectal 
adenocarcinoma 
cells 
Adherent cell line maintained in McCoy's 
5a Medium supplemented with 10 % 
FBS, and 4 mM L-glutamine 
A549 
Human lung 
adenocarcinoma 
cell line 
Adherent cell line maintained in DMEM 
supplemented with 10 % FBS, and 4 mM 
L-glutamine 
 
2.2.3 Culturing and Maintenance of cell lines 
All cell lines used were purchased from the European Collection of Cell Cultures 
(ECACC). Cells were cultured in gamma sterilized plasticware (TPP c/o Helena 
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Biosciences). NIH3T3 (Mouse fibroblast cell line) were cultured in calf serum while 
the rest of the cell lines were cultured ŝŶ &^ ? DĐŽǇ ?Ɛ  ? DĞĚŝƵŵ ǁĂƐ ƵƐĞĚto 
culture HCT116 and HT29 (Human colon carcinoma). 
For routine culture, cells grown to full confluence were washed with phosphate 
buffered saline (PBS) and treated with 1X Trypsin-0.5mM EDTA (PAA) for 5min at 
37
o
C. Once cells had detached, fresh medium was added to neutralise the trypsin 
and 20-40% seeded into a new flask and passaged every couple of days as required. 
Cells were maintained for no more than 20 passages. Where a specific seeding 
density was required, a haemocytometer was used to count cell density from a 
neutralised sample. For each experiment cells, were seeded at a required density 
one day before use or as indicated. Cells were washed with PBS, scraped and 
detached by trypsinization. All cells were cultured in gamma sterilised, tissue 
culture treated plasticware (TPP). 
2.2.4 Isolation and quantification of total RNA from Tissue culture cells 
Total RNA was isolated from tissue culture cells by using Total RNA Isolation kit 
(NucleoSpin
®
 RNA II) by MACHEREY-NAGEL (Germany) according to the 
ŵĂŶƵĨĂĐƚƵƌĞƌ ?Ɛ ŝŶƐƚƌƵĐƚŝŽŶƐ ďǇ ĂĨĨŝŶŝƚǇ ƉƵƌŝĨŝĐĂtion. RNA was quantified by 
nanodrop and the purity was assessed by a ratio of absorbance at 260 nm and 280 
nm (generally ~1.8 is accepted for RNA). Ratios lower than ~1.8 indicates the 
presence of contaminants such as protein or phenol that also absorbs strongly near 
280nm.  
 
2.3    Molecular Biology Techniques 
2.3.1 Buffers and solutions 
TE: 10 mM Tris-HCl, pH 7.5; 1 mM EDTA. 
1 x TBE: 89 mM Tris base; 89 mM boric acid; 2.5 mM EDTA; pH 8.0. 
RNA loading dye: 50 % (v/v) glycerol; 1 mM EDTA, pH 8.0; 0.25 % (w/v) 
bromophenol blue; 0.25 % (w/v) xylene cyanol. 
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UREA loading dye ĨŽƌ  ? ? ĞŶĚLabeling: 8 M Urea, 10mM EDTA, bromphenol blue 
(0.025%) w/v and Xylene cyanol (0.025%) w/v. 
2.3.2 Separation of Nuclear /Cytoplasmic fractions 
Nuclear and cytoplasmic fractions were separated according to (Felton-Edkins et al. 
2006), with minor changes. Cells were plated at a density of 2.5 million cells in  two 
15 cm plates the day before use for each treatment. Cells were treated for 2 hours 
with Cordycepin (50µM) at 37°C and washed and scraped in chilled PBS and cells 
pellet were collected by centrifugation at 2000 rpm for 5 minutes. The cell pellet for 
each treatment was lysed in 400µl of lysis buffer (Hepes 10mM pH 7.9, KCl  10mM, 
EDTA 0.1mM, EGTA  0.1mM, DTT 1mM, PMSF 0.5mM) (DTT and PMSF add freshly at 
time of use) followed by short incubation on ice for 15 minutes. The cells were 
vortexed and placed on ice for 3-5 minutes after the addition of 25 µl of 10% NP-40. 
Nuclei were collected by short spin at maximum speed for 40-45 seconds. For 
cytoplasmic fraction isolation, the supernatant was collected in a fresh tube and 
precipitated with 1 volume isopropanol for at least 30 minutes at -20° followed by 
centrifugation at 4°C for 20 minutes at maximum speed. The pellet was washed 
with 500 µl of 70% ethanol, then centrifuged at maximum speed at 4°C for 5 
minutes. The washed pellet was resuspended in 350 µl of lysis buffer (Total RNA 
Isolation kit) for RNA Isolation.  
 
For the nuclear fraction, the pellet (nuclei) was resuspended in lysis buffer (400µl), 
vortexed and placed on ice for 5 minutes, followed by centrifugation at maximum 
speed for 1-5 minutes. The nuclei pellet was lysed in a 350µl of lysis buffer (Total 
RNA Isolation kit) for RNA isolation.  
 
Cytoplasmic and nuclear RNA were isolated from individual fractions using Total 
RNA Isolation kit as described previously ĂĐĐŽƌĚŝŶŐƚŽŵĂŶƵĨĂĐƚƵƌĞƌ ?Ɛ ŝŶƐƚƌƵĐƚŝŽŶƐ. 
RNA was quantifyied by nanodrop and purity was assessed as described previously 
and used for RT-qPCR.                                                                           
79 
 
2.3.3 Quantitative PCR 
RNA was reverse transcribed using Superscript III (Invitrogen) and random 
hexamers (Invitrogen). Quantitative PCR was performed in triplicate on each sample 
using Go Taq qPCR Master Mix (Promega) ĂĐĐŽƌĚŝŶŐ ƚŽ ƚŚĞ ŵĂŶƵĨĂĐƚƵƌĞƌ ?Ɛ
instructions by using ROX as a reference dye. Primers were used in final 
concentrations of 0.5µM and 0.25 µM for test and control mRNAs respectively in a 
volume of 1µl each set of forward and reverse primer in a final reaction volume of 
20µl. Melting curves were observed for each reaction and RNA levels were 
expressed relative to GAPDH or 18S ribosomal mRNA levels. Untreated control 
values (no cordycepin or no SiRNA) were set at 1.  
2.3.3.1 Human primer sequences for RT-qPCR 
Table 6: Primers sequences for RT-qPCR: 
Name Sequence mRNA unspliced 
PTGS2- F TGAAACCCACTCCAAACACA x  
PTGS2-R GAGAAGGCTTCCCAGCTTTT x  
ACTB-F CCAACCGCGAGAAGATGA x  
ACTB-R CCAGAGGCGTACAGGGATAG x  
CCL2-F ACTGAAGCTCGCACTCTCGC x  
CCL2-R AGCCTCTGCACTGAGATCTTC x  
CXCL1-F GCAGACCCTGCAGGGAATTC x x 
CXCL1-R GCCACCAGTGAGCTTCCTCC x  
CXCL1 intron R AGGGAATCTCGTGAGGCAGG  x 
IL8-F CCAAGCTGGCCGTGGC x  
IL8-R GCTCTCTTCCATCAGAAAG x x 
un-IL8-FW GGACTTAGACTTTATGCCTGA  x 
GAPDH-F CATCGCTCAGACACCATGGG x  
GAPDH-R CGTTCTCAGCCTTGACGGTG x  
RPL10A-F TCTCTCGCGACACCCTGT x x 
RPL10A-R TTAGCCTCGTCACAGTGCTG x  
RPL10A Rev2 AGAGAGGAGGGGGGTTAAG  x 
PAPOLA -F GGGATCACAACAAACACAACC x  
PAPOLA -R TGCAGTTCCTCTTCCTCTTCA x  
PAPD4 -F CCACCCTTCACTCCAAATCA x  
PAPD4 -R CGAAATAATGGGGAAGCTGA x  
PAPOLG-F GCGGACTTCAATCCAAAAGA x  
PAPOLG-R CACTCAGTGGCTTCTCCACA x  
HIF1A -F CCGCTGGAGACACAATCATA x  
HIF1A -R AGCGGTGGGTAATGGAGAC x  
TWIST1 -F CTGGACTCCAAGATGGCAAG x  
TWIST1 -R TCCATTTTCTCCTTCTCTGGAA x  
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PIK3CA -F CCCCGAAATTCTACCCAAAT x  
PIK3CA -R GAACAGCAAAACCTCGAACC x  
PIK3CB -F TGGCCTCATTGAAGTTGTGA x  
PIK3CB -R GCCAGCACAGGACAGTGTAA x  
PIK3CD -F AAGATCGGCCACTTCCTTTT x  
PIK3CD -R TGAGAGCTCAGCTTGACGAA x  
IRS1 -F ACGTGCGCAAGGTGGGCTAC x  
IRS1 -R CGTTTGGGGGCGCTCGACTT x  
IRS2 -F CCACCCCGCCGCAACCTATC x  
IRS2 -R GGGGTTGTGGGCGAAGGACG x  
AKT1 -F AGAAGCAGGAGGAGGAGGAG x  
AKT1 -R TCTCCTTCACCAGGATCACC x  
AKT2 -F TCCTCCACGACTGAGGAGAT x  
AKT2 -R GCAGGATCTTCATGGCGTAG x  
AKT3 -F CAGTAGACTGGTGGGGCCTA x  
AKT3 -R ATCAAGAGCCCTGAAAGCAA x  
TP53 -F GTGGAAGGAAATTTGCGTGT x  
TP53 -R CCAGTGTGATGATGGTGAGG x  
RN18S -F GAAACTGCGAATGGCTCATTAA x  
RN18S -R GAATTACCACAGTTATCCAAGTAGGA x  
WEE1 (F) GGGGAATTGATTCCAGCTCT x  
WEE1 (R) CACTGGCTTCCATGTCTTCA x  
MED9 (F) CCCTCAAAAGCAAGTTCCAG x  
MED9 (R) GGGATTTCGAACATGCAGAG x  
LIF-F GCCACCCATGTCACAACAACC x  
LIF-R GCTTGGCCTTCTCCGTGC x  
c-JUN (F) ACA GAG CAT GAC CCT GAA CC x  
c-JUN (R) CCG TTG CTG GAC TGG ATT AT x  
FBXW7 (F) TTGGACCATGGTTCTGAGGT x  
FBXW7 (R) TGTAGGTGGCTGGACAGATG x  
PLK2 (F) AAAGGTGTTGACAGAGCCAGA x  
PLK2 (R) AGACCGAAGTCCCCAACTTT x  
ZFP36 -F ACTTCAGCGCTCCCACTCT x  
ZFP36 -R GACTCAGTCCCTCCATGGTC x  
SNAI1 (F) CTCTAGGCCCTGGCTGCTAC x  
SNAI1 (R) CTTGTGGAGCAGGGACATTC x  
ZFP36L1 (F) GTCTGCCACCATCTTCGACT x  
ZFP36L1 (R) GCTGGTTCTGGTGGAACTTG x  
NFKBIA (F) CTACACCTTGCCTGTGAGCA x  
NFKBIA (R) TCCTGAGCATTGACATCAGC x  
JUNB (F) AAGGGACACGCCTTCTGAAC x  
JUNB (R) AAACGTCGAGGTGGAAGGAC x  
EGR1  (F) CAGCACCTTCAACCCTCAG x  
EGR1 (R) AGCGGCCAGTATAGGTGATG x  
CSTF1 (F) GATCCTGGCTTCTGGTTCAA x  
CSTF1 (R) AGGCGAAGAGTAGGATGCTG x  
CNOT4 (F) TCCAAGTGCCAGTGCTTATG x  
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CNOT4 (R) TGCAGTCAGGTTTTGGACAC x  
BTG1 (F) CCATGCATCCCTTCTACACC x  
BTG1 (R) GCTTTTCTGGGAACCAGTGA x  
IL6 -F AAAGAGGCACTGGCAGAAAA x  
IL6 -R AGCTCTGGCTTGTTCCTCAC x  
NEK6 (F) ATCCCAACACGCTGTCTTTT x  
NEK6 (R) GCCGATCTCCTTGACACAGT x  
MCL1 (F) AGAAAGCTGCATCGAACCAT x  
MCL1 (R) CCAGCTCCTACTCCAGCAAC x  
MED13L (F) CACTTGGCAGCAGTTCCATA x  
MED13L (R) CAACAAGAGCCTCTCCCAAA x  
MED26 (F) CCAGCCTGGAGAAATACCCTA x  
MED26 (R) GGCTCGATGAGCTTCTGC x  
ATF4 (F) TCAAACCTCATGGGTTCTCC x  
ATF4 (R) GTGTCATCCAACGTGGTCAG x  
TFPI (F) GCCAGATTTCTGCTTTTTGG x  
TFPI (R) TGCGGAGTCAGGGAGTTATT x  
DCP1A (F) AAGACAGCAGCAGCAAGAGT x  
DCP1A (R) CGGGATGGCACTGGATAACA x  
CD68 (F) ACTGAACCCCAACAAAACCA x  
CD68 (R) TTGTACTCCACCGCCATGTA x  
SUN1 (F) AACAACAAAACAGCGCAGAA x  
SUN1 (R) TCCCTGAATGGCAGCTTTAT x  
CTSL1 (F) ACAGTGGACCAAGTGGAAGG x  
CTSL1 (R) TGGGCTTACGGTTTTGAAAG x  
CPE (F) TCTTGGCCCAGTACCTATGC x  
CPE (R) GTCTGGAAAGTTCCGGTTCA x  
GNAI3 (F) GCACCATTGTGAAACAGATGA x  
GNAI3 (R) CAGCTTCCCCAAAGTCAATC x  
CATSPER2 (F) ATCCTTTGGTTGTTGCTTGG x  
CATSPER2 (R) TGACGTCAGTGCTTCATGTG x  
 
 
2.3.4 siRNA Transfections 
Poly(A) polymerase mRNAs were knocked down by using the Smartpool siRNA (5 
nM) against indicated PAPs (Dharmacon) (in case of combination PAP knockdowns 
the concentration of each siPAP was adjusted to 5 nM), by using INTERFERin 
(Polyplus) in tissue culture cells according to the manufactƵƌĞƌ ?Ɛ ŝŶƐƚƌƵĐƚŝŽŶƐ ? Cells 
were seeded at a density of 0.075 million cells per well in a 12 well plate a day 
before first transfection followed by a medium changed at 24 hours and a second 
transfection was performed. Forty eight hours later, the cells were harvested and 
processed for total RNA isolation as described. 
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2.3.5 Protein synthesis assay by 35 S Methionine Incorporation 
To determine the protein synthesis rate in tissue culture cells, 50,000 cells were 
seeded one day before use in a 24-well plate in 1ml media in 4-6 replicates. The 
next day, cells were incubated with the required concentration of different 
adenosine analogues and incubated for 2 hours.  
The medium was then removed and the cells were washed twice with PBS and 5-15 
µCi/ml Tran
35
S-methionine label (Perkin Elmer) was added to pre-warmed cysteine 
and methionine-free DMEM, and returned to the incubator. After 10-15 minutes 
the cells were placed on ice, washed with PBS containing 1% (w/v) L-Methionine, 
ĂŶĚ ůǇƐĞĚ ǁŝƚŚ  ? ?ʅů  ?yWĂƐƐŝǀĞ ůǇƐŝƐ ďƵĨĨĞƌ  ?Promega) per well. Incorporation was 
measured by TCA precipitation on Whatman 3MM paper.  
10µl of lysate were used to be spotted on to Whatman 3MM filter paper and 10 µl 
were used for total protein quantification using Bradford reagent (Bio-Rad) in a 96 
well micro plate, according to the ŵĂŶƵĨĂĐƚƵƌĞƌ ?ƐŝŶƐƚƌƵĐƚŝŽŶƐ ?
Filters were incubated for a few minutes in 10% TCA with a pinch of methionine and 
cysteine at room temperature and then in 5% TCA for few a minutes. The filters 
were then washed twice with 98% industrial methylated spirits, and left to air dry. 
Radiolabeled protein was liberated using Ecoscint scintillation fluid (National 
Diagnostics) and quantified in a Wallac 1409 scintillation counter (Pegasus 
Scientific). Incorporation was corrected for protein content using the Bradford data. 
All incorporations were plotted as a percentage of the incorporation in the 
untreated control cells.  
2.3.6 In cell-enzyme linked immunosorbent assay (ELISA) for phospho 4E-
BP as a cordycepin bioassay 
Cells were seeded at a density of 20,000 cells per well in 4-5 wells for each 
treatment in 96 well plates in 100 µl medium the day before use. One set of 
replicates were the no primary antibody control, which were used as background. 
After the indicated treatments for 2 hours, cells were washed twice with PBS 
followed by incubation with 4% paraformaldehyde for 15 minutes. Cells were 
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washed again with PBS and incubated in 100µl of 0.1% Triton for 15 minutes. Cells 
were washed with PBS and incubated in 3% BSA for 30 minutes.  
In empty wells 40µl of anti phospho 4EBP is added at a concentration of 1:500 in 3% 
BSA, except for the background wells. After an overnight incubation at 4°C, cells 
were washed again with PBS and probed for 2 hours at RT with 40µl of anti-rabbit 
IgG-HRP in 1:1000 in 3% BSA followed by PBS washing. Cells were analyzed by using 
 ? ?  ?഻ ?  ? ?  ?഻-Tetramethylbenzidine (TMB) Liquid Substrate System substrate for 
horseradish peroxidise from sigma. The reaction was stopped by 1N sulphuric acid, 
forming a yellow reaction product that was read by plate reader Biotek at 450 nm 
and background values were subtracted from the readings. All values were plotted 
as a percentage of the average for the untreated control cells. 
2.3.7 ¶-End labeling of mRNA with 323S&S&\WLGLQH¶¶-bispKRVSKDWH¶-
32P)) 
RNA was prepared ĨŽƌ ? ?ĞŶĚůĂďĞling as described in detail by (Minvielle-Sebastia et 
al. 1991) with minor changes.  250ng of RNA was incubated in 7.5µl of reaction 
volume containing 50 mM N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid 
(HEPES; pH 8.1), 5uM ATP, 10 mM MgCl2, 3.3 mM dithiothreitol, 10% dimethyl 
sulfoxide, 300ug/ml of bovine serum albumin (BSA), 12.5 uCi/µl of Cytidine 3',5'-[5'-
32
P]biphosphate (
32
P-pCp; Perkin Elmer), and 3 U of T4 RNA ligase (New England 
BioLabs) overnight at 4°C. 
Next day the labelled RNAs were treated with RNase A (Sigma) and RNase T1 
(Fermentas) for 2 h at 37°C, to cleave everything except the poly (A) tail in a 12.5µl 
reaction mixture that contained the 7.5ul of initial reaction mixture, 0.8mg/ml of 
yeast tRNA (Ambion), 16 mM Tris (pH 7.5), 0.48 M NaCl, water and RNase cocktail 
(20 Units/µl of RNase T1, 50ng of RNase A in 50mM Tris (pH 7.5), 50% glycerol).  
Following this treatment, labelled RNA was subjected to Proteinase K treatment in 
7.5µl of initial reaction mixture containing proteinase K (2 mg/ml; NEB), 130 mM 
EDTA and 2.5% SDS for 30 min to 1 hour at 37 °C. Samples can be stored at -20 ° at 
this stage if required. 
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Labelled samples were processed for phenol-chloroform-isoamyl alcohol (25:24:1) 
extraction by adding equal volume of water in the sample. RNA was precipitated in 
absolute ethanol with 3M sodium acetate and 1.25µg glycogen as a carrier at -20°C. 
The pellet is resuspended in 8M urea gel loading buffer.  
The samples were denatured at 65 °C for 5-10 min and run on a 15% 
polyacrylamide-urea gel (acrylamide/bisacrylamide, 30:1; 7 M urea) in 0.5X TBE at 
20watts for 4 hours. The gels were autoradiographed overnight at -80°C and 
scanned the next day on phosphoimager STORM 825. Labelled RNA ladder was used 
as a marker where each band represents different sizes of poly(A) tail lengths in 
bases. 
2.3.8 Proliferation Assay 
Cells were counted using trypan blue staining (Sigma). The cells which exclude the 
dye are viable with intact cell membrane and retain as white. Cells were seeded in a 
6 well plate at a density of 0.15 million cells per well. After 24 hours, cells were 
processed for siRNA transfections (as described previously) or treated with 
indicated compounds for 72 hours. The cells were washed with PBS and collected by 
trypsinization and counted under the microscope using a haemocytometer. Each 
experiment was performed in four to five replicates. Data are represented as a 
relative number of cells by normalizing to its original seeding density. 
2.3.9 Immunohistochemistry of MCF-7 cells 
In order to observe focal adhesion changes by immunohistochemistry, MCF-7 cells 
were seeded in a 24 well plate at a density to 15,000 cells per well on round glass 
coverslips of 13 mm, thickness 1, borosilicate glass (VWR 631-0149).  Cells were 
treated after 48 hours with indicated concentration of cordycepin for 3 hours.  
After treatment, cells are washed carefully with PBS and fixed with 4% 
paraformaldehyde. After a couple of washes with PBS, cells were incubated in 0.1% 
Triton X100 in PBS for 10 minutes then washed again with PBS and followed by an 
hour incubation at room temperature with 3% bovine serum albumin in PBS. Cells 
were incubated with primary antibody (Vinculin from sigma) in 0.25 ml 3% BSA in 
PBS, incubated O/N at 4°C at 1:200. PBS was used to wash the cells followed by 1 hr 
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incubation at room temperature in secondary antibody of anti-mouse-coupled to 
Alexa 546 (Molecular Probes) at 1:200 in 3% bovine serum albumin in PBS. 
After a couple of washes with PBS, cover slips were mounted on slides with the help 
of mounting fluid. Imaging was performed on a Zeiss LSM510 Metaconfocal 
microscope at 63X magnification, and the images were processed using the 
ŵĂŶƵĨĂĐƚƵƌĞƌ ?ƐƐŽĨƚǁĂƌĞ ? 
 
2.4 Microarray profiling 
Cells were seeded at a density of 2.3 million cells per 15 cm plate and incubated for 
24 hours. Cells were treated for 2 hours with DMSO and Cordycepin (50µM). Cells 
were washed gently with PBS to remove excess medium after the treatment and 
cells were scraped in 5ml of ice cold PBS followed by centrifugation. Collected cells 
were processed for total RNA isolation as described previously. Experiments were 
done in a four independent biological replicates.  
Microarray experiments were performed in quadruplicate in collaboration with 
Prof. Anne Willis, MRC Toxicology Unit University of Leicester using Agilent GE 60k 
human arrays. Each sample was hybridized in randomly assigned locations onto an 
individual microarray consisting of 8 on each slide.  
dŚĞ ƐĂŵƉůĞƐ ǁĞƌĞ ůĂďĞůůĞĚ ƵƐŝŶŐ ŐŝůĞŶƚ ?Ɛone-colour Low Input Quick Amp 
Labelling Kit i.e.the dye used was cy-3. The slides were scanned using an Agilent 
Microarray Scanner, model number G2505C, scan control version A.8.4.1. The data 
was extracted using the Agilent Feature Extraction software version 10.7.3.1. The 
platform used was: Human GE 8x60k v.2 microarrays. The R software package was 
used to analyse the data. 
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3 Characterizing the effects of cordycepin on 
different cell lines 
In this chapter I investigate whether different cell lines react in the same manner to 
cordycepin or not by examining its effects on protein synthesis via mTOR pathway, 
4-EBP phosphorylation and cell proliferation. To determine this, I have used cells 
treated with different doses of cordycepin and analysed them using various 
methods including 
35
S incorporation, in-cell ELISA and counting of cells using trypan 
blue dye. This work further elucidates to the sensitivity of different cell lines to 
cordycepin and gives a better understanding of the broad spectrum of its action 
among various cell lines. I further investigated the stability issue of cordycepin in 
growth medium due to its degradation by adenosine deaminase over time in HELA 
and MCF-7 cells, using the adenosine deaminases inhibitor pentostatin. Pentostatin 
has significant toxicity, therefore I investigated effects observed using the minimal 
effective dose of pentostatin in cordycepin sensitive cell lines. 
3.1 Dose response effect of cordycepin on protein synthesis by 
35S and ELISA on different cell lines 
In order to analyse the effects of cordycepin on protein synthesis and 4-EBP 
phosphorylation by 
35
S incorporation and in-cell ELISA, cells were treated with 
cordycepin at 10, 50 and 200µM for 2 hours. Our previous published work on 
NIH3T3 and HELA demonstrates dose response effects of cordycepin on the rate of 
protein synthesis (Wong et al. 2010) in figure 4 C and E. Previously, we had shown 
that sensitivity of the rate of protein synthesis to cordyepin increases with 
increasing dose of cordycepin. In Figure 3.1 A, the effect of cordycepin on cellular 
translation was measured by incorporation of radioactive amino acid for 10-15 min 
after a 2 hour cordycepin treatment. The rate of protein synthesis in NIH3T3 and 
HELA  cells declines with an increasing dose of cordycepin, which was consistent 
from the previous published data for NIH3T3 and HELA cells (Wong et al. 2010). 
However, the rate of protein synthesis in HT29 and MCF-7 cells was insensitive to 
cordycepin, while HCT116 cells and A549 are affected by cordycepin to a lesser 
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extent. Statistical significance is shown as: * for P<0.05, ** for P<0.01 and *** for 
P<0.001. 
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Figure 3.1: The sensitivity of cordycepin varies among different cell lines:   
Indicated cell lines were treated with cordycepin for 2 hours at indicated concentrations.       
A, Protein synthesis rates were measured by incorporation of 35S labeled amino acids into 
protein, corrected for total protein concentration and represented as a percent incorporation 
of the control. B, Levels of P- 4EBP were measured by in cell ELISA and expressed as 
percentages of the control. Experiments were performed in 4-5 technical replicates and the 
data are expressed as means ± S.D. For statistical significance unpaired T-test was 
performed in comparison with control (No cordycepin) indicated as * for P<0.05, ** for 
P<0.01 and *** for P<0.001.  
 
In previously published data from our laboratory, it was shown that cordycepin 
inhibits protein synthesis in NIH3T3 cells by reducing 4EBP phosphorylation (Wong 
et al., 2010). To confirm the effects of cordycepin on the mTOR pathway levels of 
the mTORC1 product phospho- 4EBP were investigated by in cell ELISA. Levels of P-
4EBP were examined in figure 3.1, B in different cell lines, which showed that P-
4EBP levels decrease with an increasing dose of cordycepin in NIH3T3 cells in a 2 
hour treatment, although a high variability makes this effect this only significant at 
the highest doses.  Levels of P-4EBP in HELA cells are more sensitive to cordycepin. 
Surprisingly, HT29 and MCF-7 show marked decreases in the levels of P-4EBP with 
increasing doses of cordycepin, although their rate of protein synthesis remains 
insensitive. Levels of P-4EBP in HCT116 +/+ and A549 also remain unaffected. The 
effect of cordycepin on protein synthesis and phospho-4EBP levels varies therefore 
0
20
40
60
80
100
120
140
160
DMSO Cordycepin    
10µM
Cordycepin     
50µM
Cordycepin     
200µM
--------------------------------------------
A549
HCT116+/+
0
20
40
60
80
100
120
140
160
DMSO Cor10µM Cor50µM Cor200µM
- - - - - - - - - - - - - - - - - - - - - - - - - -
0
20
40
60
80
100
120
DMSO Cor10µM Cor50µM Cor200µM
- - - - - - - - - - - - - - - - - - - - - - - -
0.0
20.0
40.0
60.0
80.0
100.0
120.0
140.0
160.0
DMSO Cor10 µM Cor50 µM Cor200 µM
- - - - - - - - - - - - - - - - - - - - - - - - - -
%
 o
f 
in
co
rp
o
ra
ti
on
 o
f c
o
nt
ro
l
%
  o
f 
co
n
tr
o
l v
al
u
e
s
*
**
89 
 
among different cell lines, in some cases there is a strong correlation between the 
effect on phospho-4EBP levels and protein synthesis, but in others the effect is 
more subtle or absent. The validation of ELISA method for phospho-4EBP levels by 
western blotting is necessary, but this could not be achieved due to technical 
reasons. The data for the rate of protein synthesis and levels of P-4EBP are 
summarized in table 7.  
Table 7: Summary of rate of protein synthesis and levels of P-4EBP by in cell ELISA 
on various cell lines: 
Cell Line 
Dose of 
cordycepin 
µM 
Decline in rate of 
protein synthesis 
(%) 
Reduction in 
P-4EBP levels 
(%) 
 
NIH3T3 
10 78 88 
50 62 78 
200 36 60 
 
HCT116 
10 78 110 
50 78 110 
200 48 78 
 
MCF-7 
10 82 74 
50 100 40 
200 100 4 
 
HELA 
10 32 100 
50 22 58 
200 2 22 
 
HT29 
10 110 80 
50 110 50 
200 98 18 
 
A549 
10 110 98 
50 98 88 
200 78 82 
 
Summarized data expressed as percentages of the control values calculated from technical 
replicates. 
 
3.2 The effects overtime of combining cordycepin with a 
stabilizing drug in MCF-7 cells 
The effects of cordycepin on protein synthesis and phospho-4EBP levels may be 
limited by high levels of the cordycepin degrading enzyme adenosine deaminase in 
these cell lines. We examined the effects of Pentostatin (deoxycoformycin), an 
adenosine analogue which act as an adenosine deaminase inhibitor which 
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administered in combination with cordycepin may make it effective over longer 
time periods. MCF-7 cells were seeded a day before use, followed by a medium 
change and then treated with cordycepin (50µM) in absence or presence of 
pentostatin (1µM) for 2, 8 and 24 hours. As can be seen in figure 3.2, the relative 
rate of protein synthesis in comparison with untreated (no cordycepin, no 
pentostatin) was markedly decreased at 8 and 24 hours in combination with 
cordycepin with pentostatin as compared to the 2 hour time point. However the 
relative rate of protein synthesis with cordycepin in absence of pentostatin shows 
much less reduction at all indicated time points. There is also not much effect of 
pentostatin on its own compared to untreated cells. These data shows that 
pentostatin increases the effect of cordycepin over time in MCF-7 cells, presumably 
by inhibiting its degradation. 
                                        
 
 
Figure 3.2: Effects of cordycepin and pentostatin on the rate of protein synthesis over 
time: 
MCF-7 cells were treated with cordycepin (50µM) in absence or presence of pentostatin 
(1µM) for 2, 8 and 24 hours. Protein synthesis rates were measured by incorporation of 35S 
labeled amino acids into protein, corrected for total protein concentration and represent as a 
relative incorporation. Error bar shows standard deviations over independent biological 
triplicates. For statistical significance Paired T-test was performed in comparison with control 
indicated as * for P<0.05, ** for P<0.01 and *** for P<0.001. 
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The data showed in figure 3.3 represents cordycepin levels in the culture medium of 
MCF-7 cells (unpublished data, obatained in collaboration with Prof. Dave Barrete 
by Wahy Utami). MCF-7 cells were treated with cordycepin (50µM) in absence or 
presence of pentostatin (1µM) for 2, 8 and 24 hours. As can be seen in figure 3.3 
that pentostatin stabilizes the concentration of cordycepin by slowly decreasing the 
level of cordycepin over time. The cordycepin disappears completely from the 
culture medium at 8 and 24 hours in the absence of pentostatin. 
 
 
Figure 3.3: Pentostatin stabilizes cordycepin levels over time in MCF-7 cells: 
Concentrations of cordycepin were determined in the culture medium of MCF-7 cells. The 
cells were treated with cordycepin (50µM) in absence or presence of pentostatin (1µM) for 2, 
8 and 24 hours. Each bar represents the mean ± SEM. (Work done by PhD student Wahyu 
Utami). 
 
3.3 Pentostatin stabilizes cordycepin in HELA cells over time 
Next, I investigated the long term effects of cordycepin on the cellular rate of 
translation and levels of P-4EBP in combination with pentostatin in HELA cells. HELA 
cells were treated with cordycepin with 10 and 50µM in presence or absence of 
pentostatin (1µM) for 2, 16 and 24 hours. It can be observed from figure 3.4A,  that 
the rate of protein synthesis, represented in percentage incorporation of untreated 
(no cordycepin, no pentostatin), shows much more reduction at 2 hours with 
cordycepin (50µM) in presence of pentostatin compared with cordycepin alone. 
Cordycepin (50µM) decreases the rate of protein synthesis significantly at 16 and 24 
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hours in combination with pentostatin compared to on its own or at lower dose 
(10µM). These data demonstrate that pentostatin enhances the effects of 
cordycepin on the cellular rate of translation over time. 
To assess whether the decline in rate of protein synthesis correlates with the levels 
of P-4EBP, we examined the HELA cells by in-cell ELISA for this effect, treated with 
cordycepin in combination with pentostatin (1µM) for 2, 16 and 24 hours. The levels 
of P-4EBP, represented as a percentage of the control values as seen in figure 3.4B,   
show clearly that pentostatin enhances the effect of cordycepin on 4EBP 
phosphorylation at all timepoints, although P-4EBP levels appear to recover 
somewhat in the later timepoints. Validation of the ELISA method for phospho-4EBP 
levels by western blotting is necessary but this could not achieve due to technical 
reasons. 
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Figure 3.4: Pentostatin increases the effect of Cordycepin in HELA: 
HELA cells were treated with cordycepin in absence or presence of pentostatin at indicated 
concentrations for 2, 16 and 24 hours. A, Protein synthesis rates were measured by 
incorporation of 35S labeled amino acids into protein, corrected for total protein concentration 
and represented as a of percent incorporation of control. All error bars represents standard 
deviations over three independent biological replicates. A paired T-test was performed and 
stars indicate significance: * for P<0.05, ** for P<0.01 and *** for P<0.001. B, Level of P- 
4EBP was measured by in cell ELISA for 2, 16 and 24 hours. Reduction in levels of P-4EBP 
without pentostatin seems to be much less compared with in presence of pentostatin. Values 
are expressed as percentages of the control. Error bars are representative of results 
obtained from four technical replicates.  Unpaired T-test was performed to show statistical 
differences among treatment represents as * for P<0.05, ** for P<0.01 and *** for P<0.001. 
 
3.4 A minimal dose of pentostatin is still effective 
As we have seen that co-administration of pentostatin with cordycepin stabilizes 
and improves its efficacy, there is a need to investigate any undesirable side effects 
of pentostatin that have been recorded both in patients and in animal models  
(Airhart et al. 1996, Lauria and Forconi 2009, Tadmor 2011).  In order to reduce its 
toxicity we investigated the minimal effective concentration of pentostatin in 
NIH3T3 cells by its effects on cellular rate of protein synthesis. NIH3T3 cells were 
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titrated with different concentrations of pentostatin from 1000nM - 1.25nM in 
presence or absence of cordycepin (50µM) for 16 hours. 
 
Figure 3.5: Concentration titration of pentostatin in combination with cordycepin: 
A & B, NIH3T3 cells were treated with different concentrations of pentostatin as indicated in 
presence or absence of cordycepin (50µM) for 16 hours. Protein synthesis rates were 
measured by incorporation of 35S labeled amino acids into protein, corrected for total protein 
concentration and represent as a percent incorporation of control. All error bars represents 
standard deviations over four to five technical replicates. Unpaired T-test for a statistical 
significance in comparison with control (No cordycepin) indicated as * for P<0.05 and ** for 
P<0.01. 
 
Rate of protein synthesis with different doses of pentostatin (1000nM - 1.25nM) in 
combination with cordycepin seems to be sensitive as shown in figure 3.5A and 
3.5B, compared with pentostatin alone which seems to be insensitive with effects 
on cellular rate of translation. For a significant statistical difference, effects of 
protein synthesis need to be examined on more biological replicates. We can 
conclude that doses of pentostatin of 1.25 nM are still very active in combination 
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with cordycepin and are likely to reduce its undesirable effects in vivo to a greater 
extent. 
 
3.5 Cell proliferation and survival are affected by cordycepin in 
different cell lines 
In a few cell lines we have seen effects on protein synthesis with changes in levels 
of P-4EBP while in most cell lines we observed that cordycepin is affecting either 
one of these. Now we need to investigate whether the sensitivity of cordycepin for 
cellular rate of protein synthesis combined with levels of P-4EBP is related to its 
effects on cell proliferation and survival. NIH3T3, HELA, MCF-7 and A549 cells were 
treated a day after seeding with cordycepin at 10µM and 50µM while HCT116+/+ 
was treated only at 50µM in absence or presence of pentostatin (1.25nM) for 72 
hours and undergo cell counting by using trypan blue dye as (dead) blue and (live) 
white cells. As shown in figure 3.6, cell numbers were decreased by treatment with 
cordycepin (50µM), and this was enhanced in the presence of pentostatin (1.25nM) 
in NIH3T3, HELA, MCF-7, HCT116+/+ and A549 cells. Cell proliferation is also 
reduced with a lower concentration of cordycepin (10µM) but to a lesser extent 
than with higher concentrations (50µM) in these cell lines, although it is not always 
statistically significant. In HCT116 and MCF-7 cells cordycepin and pentostatin 
appear to primarily inhibit cell division. Pentostatin alone also inhibits cell 
proliferation in NIH3T3. However pentostatin does not inhibit cell proliferation in 
HCT116 and MCF-7. This indicates that different cell lines have different sensitivities 
to pentostatin. The sensitivity of NIH3T3 cells for cell proliferation by cordycepin is 
consistent with the previous published work (Wong et al., 2010) shown in figure 1D 
for NIH3T3 cells. These results indicate that co-administration of pentostatin with 
cordycepin increases the anti proliferative effects over longer period of times. 
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Figure 3.6: Pentostatin enhances the long-term effects of cordycepin: 
Indicated cells were treated with cordycepin with indicated concentrations in absence or 
presence of pentostatin (1.25nM) for 72 hours and cell counts were done by counting (dead) 
blue and (live) white cells using trypan blue dye under microscope. Pentostatin co-
administration stabilized and improved the anti-proliferative effect of cordycepin. Results are 
presented as a relative number of cells and data represents standard deviations over two 
independent biological replicates for each treatment.  
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3.6 Effects of low dose of pentostatin on cell proliferation 
After observing effects on the cellular rate of translation at low doses of pentostatin 
in presence of cordycepin (50µM), we further titrated down the dose of pentostatin 
to determine the least minimal effective dose of pentostatin on cell proliferation in 
NIH3T3 cells in combination with cordycepin (5µM). NIH3T3 cells were treated with 
different doses of pentostatin (1nM - 0.025nM) in combination with cordycepin 
(5µM) for 72 hours followed by counting the cells in trypan blue dye under the 
microscope. As can be seen from figure 3.7, cell numbers declined to a much 
greater extent at all low doses of pentostatin in the presence of cordycepin 
compared to cordycepin (5µM) alone, which only has a small effect on cell 
proliferation. Therefore pentostatin seems to be significantly effective at very low 
doses and combination of pentostatin with cordycepin not only stabilizes its activity 
but also increases its anti-proliferative properties. 
 
 
 
 Figure 3.7: Dose response effects of pentostatin with cordycepin on cell proliferation: 
NIH3T3 cells were treated with indicated concentration of pentostatin in presence of 
cordycepin (5µM) for 72 hours and cell counts were done by counting (dead) blue and (live) 
white cells using trypan blue dye under microscope. Results are presented as a relative 
number of cells and experiments were performed in four to five technical replicate expressed 
as means ±S.D. Unpaired T-test was performed to show statistical significance compared to 
untreated control represents as * for P<0.05 and ** for P<0.01.  
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3.7 Minimal doses of pentostatin are still effective at lower doses 
of cordycepin  
We next want to examine the minimal effective dose of cordycepin in combination 
with lowest active dose of pentostatin in MCF-7 cells in order to reduce the 
possibility of any undesirable effects due to any of these drugs. Cells were treated 
with different low doses of cordycepin (2µM- 8µM) in combination with pentostatin 
at 1.25nM for 72 hours. The cells were counted using trypan blue dye and cell 
numbers are shown relative to the seeding density of the cells. It can be observed 
from figure 3.8 that cell numbers seem to be reduced by half at the lowest tested 
dose of cordycepin in presence of pentostatin compared to higher dose of 
cordycepin at 4µM and 8µM, which shows a bigger decline in cell numbers in a dose 
dependent manner. Effects on cell proliferation on live and dead cells were 
significantly different indicated as * for P<0.05 and ** for P<0.01 performed by 
unpaired t- test. 
Therefore, it can be concluded that cordycepin is still very active and stable at its 
lowest dose, as it is reducing cell numbers in combination with low dose of 
pentostatin. The addition of pentostatin also improves its efficacy by reducing its 
toxicity over time in medium. We conclude that its instability reduces the biological 
activity of cordycepin significantly and that this is likely to affect its usefulness for 
cancer therapy. The data indicate that when administrated in combination, much 
lower doses of cordycepin and pentostatin can be used than previously reported. 
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Figure 3.8: Effects of low doses of cordycepin and pentostatin on cell proliferation in 
MCF-7: 
MCF-7 cells were treated with indicated concentrations of cordycepin in presence of 
pentostatin (1.25nM) for 72 hours and cell counts were done by counting (dead) blue and 
(live) white cells using trypan blue dye. Results are presented as relative numbers of cells. 
Measurements were performed in 4-5 technical replicate expressed as means ±S.D. 
Statistical significance in comparison with control (No cordycepin) were determined by 
unpaired T-test indicated as * for P<0.05 and ** for P<0.01. 
 
3.8 Discussion 
So far we have seen that effects of cordycepin are cell type specific and that the 
sensitivity of cordycepin towards protein synthesis and changes in levels of P-4EBP 
varies among different cell lines. Except MCF-7 and HT29 cells, all examined cell 
lines are sensitive to cordycepin in their rate of protein synthesis while HCT116 is 
affected to a much lesser extent. However, A549 does not show much change in the 
rate of protein synthesis or changes in levels of P-4EBP ELISA. The dose response 
effects on protein synthesis in NIH3T3 and HELA cells are similar to those observed 
previously (Wong et al., 2010). However levels of P-4EBP are sensitive to cordycepin 
in HELA, HT29 and MCF-7 cells and to a lesser extent in NIH3T3 cells. Cordycepin 
does not significantly change the levels of P-4EBP in HCT116+/+ and A549 cells.  In 
NIH3T3 and HELA cells, the rate of protein synthesis and levels of P-4EBP are 
sensitive to cordycepin. The data on 4EBP phosphorylation for MCF-7 cells are 
puzzling as they indicate that protein synthesis was unaffected in these cells, 
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however there is still a prominent reduction in 4EBP phosphorylation. This could be 
due to a reduction in total 4EBP levels in MCF7 cells in response to cordycepin, 
however it was not possible to measure changes in total 4EBP levels by western 
blotting due to technical reasons. Such an effect has been observed by Western blot 
in NIH3T3 cells (Wong et al, 2010). To check this it would be necessary to measure 
total 4EBP levels as well as phospho-4EBP levels. Another potential cause of the 
differences between cell types could lie in the decay rates of the drug in absence of 
pentostatin. We have seen complete disappearance of cordycepin levels in the 
medium at 8 and 24 hours on its own with only a small amount of cordycepin left at 
2 hours. However, a gradual drop in the level of cordycepin has been observed 
when cordycepin (50µM) is used in combination with pentostatin (1µM) 
(unpublished data, obtained in collaboration with Prof. Barrett by Wahyu Utami). A 
similar pattern was observed for the levels of cordycepin triphosphate inside the 
cell, which persist longer in the presence of pentostatin. Previously (Wong et al., 
2010), it was demonstrated that cordycepin reduced AKT kinase and 4E- BP 
phosphorylation by the mTORC1 and mTORC2 complexes and activates AMP 
activated kinase (AMPK) by an unidentified mechanism. Factors which the make 
sensitivity of cordycepin variable among different cell lines need to be investigated 
in future.  
Protein synthesis is strongly affected by cordycepin with pentostatin at later time 
points in HELA and MCF7 cells. This is likely to be through its effects on cell survival, 
as subsequent work has demonstrated that the combination of cordycepin with 
pentostatin induces apoptosis within 8 hours (Richa Singhania, unpublished result). I 
have shown that pentostatin potentiates the effects of cordycepin, even with very 
low doses of both. Given the known immune suppressive effects of pentostatin in 
vivo, it is likely that optimal therapy will need to employ its lowest active dose, 
which appears to be nearly a thousand fold lower than the doses commonly used in 
the clinic.  
We have seen that cordycepin inhibits proliferation in all cell lines, regardless of its 
effects on 4EBP phosphorylation and protein synthesis. Therefore, we can conclude 
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that effects on protein synthesis via inhibition of mTOR are not always responsible 
for the effects of cordycepin on cell proliferation. 
  
4 Effects of cordycepin on gene expression, 
polyadenylation and cell adhesion in MCF7 cells 
In order to be able to design and validate more stable analogues or formulations of 
cordycepin, we first have to understand the mechanism of action of the drug. As 
outlined in the introduction, cordycepin is certainly a polyadenylation inhibitor, but 
other mechanisms of action have also been proposed to contribute to the 
therapeutic properties of cordycepin. In this chapter we study the effects of 
cordycepin observed previously in other cell lines, in more detail in MCF-7 cells. We 
examined the MCF-7 cells in detail because they were found to be insensitive at the 
level of protein synthesis but exhibit significant sensitivity on cell proliferation. We 
can therefore discount any indirect effects due to reduced protein synthesis at the 
earlier timepoints, where the primary effects must be taking place. We examined 
the effects of cordycepin on gene expression, cell adhesion and polyadenylation.  
4.1 Inflammatory mRNAs affected by cordycepin  
In order to narrow down the events leading to the reduction in proliferation that is 
induced by cordycepin, I decided to try to identify the earliest effects on gene 
expression. In the first instance, I pursued a candidate gene approach. The TWIST1 
mRNA was selected as it is regulated by CPEB and found to be upregulated in 
epithelial-mesenchymal transition in MCF-10A and it shows sensitivity towards 
cordycepin (Nairismagi et al. 2012). I was further interested in investigating the 
sensitivity of inflammatory mRNAs to cordycepin (PTGS2, CCL2, CXCL1 and IL8) in 
MCF-7 cells, because we have previously shown they are sensitive in primary airway 
smooth muscle cells (Kondrashov et al; 2012). Cells were treated 24 hours after 
seeding for 2 hours with cordycepin (50µM). The cells were harvested and total RNA 
was isolated as described previously. RNA was reverse transcribed and subjected to 
RT-qPCR.  As a control, the housekeeping mRNAs encoding ribosomal protein 
(RPL10A) and ɴ actin (ACTB) were used. Normalization was performed to GAPDH, a 
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well characterised house-keeping gene. It can be observed from figure 4.1 that 
cordycepin reduces the expression of IL8 and CXCL1. Other inflammatory mRNAs 
e.g PTGS2 and CCL2 were not significantly affected. The expression of TWIST1 
mRNA was also greatly reduced by cordycepin in MCF-7 cells.  
 
Figure 4.1: Levels of inflammatory mRNAs affected by cordycepin: 
Total RNA was isolated from MCF-7 cells treated with cordycepin (50µM) for 2 hours. RT-
qPCR was performed for mature mRNAs and the mRNA levels were expressed as 
normalised to GAPDH mRNA. Untreated control values (no cordycepin) were set at 1. All 
error bars are standard deviations over three independent biological replicates. Statistical 
significance compared to control (No cordycepin) were determined by Paired T-test indicated 
but none of the examined mRNA found to be statistically different from the untreated. 
 
4.2 Cordycepin acts as a polyadenylation inhibitor   
After examining the effects of cordycepin on protein synthesis, levels of P-4EBP and 
on cell proliferation in MCF-7 cells, we investigated whether cordycepin acts as a 
polyadenylation inhibitor in MCF-7 cells. To examine this MCF-7 cells were treated 
with increasing concentrations of cordycepin 10µM and 50µM to study the effects 
on total poly(A) tail length. MCF-7 cells were treated for 2 hours with cordycepin 
followed by total RNA isolation. RNA was subjected to  ? ?ĞŶĚůĂďĞůŝŶŐĂŶĚnon-poly 
adenylated RNA was degraded with RNAses A and T1 followed by electrophoresis 
on urea polyacrylamide gel. It can be observed from figure 4.2 that 10 µM and 50 
µM cordycepin equally reduce the total poly(A) tail length in the cell. 
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Figure 4.2: Dose response effect of cordycepin on total poly (A) tail length in MCF-7:  
MCF-7 cells were treated for 2 hours with cordycepin at indicated concentrations. Total RNA 
was prepared and labelled at 3´ end with 32P-pCp along with other necessary components 
and non-polyadenylated RNA degraded, resulting in a smear representing the total poly (A) 
mRNAs in the cell. The reaction products were analyzed by urea (7M) 15% Polyacrylamide 
gel electrophoresis. Labelled RNA ladder was used as a marker where each size 
corresponds to different poly(A) tail lengths in bases.  
L     1     2    3    
660
349
262
163
117
93
135
6 0
349
262
163
135
1 7
93
105 
 
4.3 Polyadenylation is affected by cordycepin over time  
As we demonstrated that cordycepin at both 10 and 50 µM reduces the length of 
total poly(A) tails in MCF-7 cells after 2 hours, we next examined whether 
pentostatin mediated stabilization of cordycepin, resulting in the inhibition of 
polyadenylation for a longer time period.  MCF-7 cells were treated with cordycepin 
in the absence or presence of pentostatin for 2, 8 and 24 hours followed by total 
RNA isolation. RNA was subjected to  ? ? ĞŶĚ ůĂďĞůŝŶŐfollowed by degradation of 
non-polyadenylated RNA with RNAses A and T1 and electrophoresis on urea 
polyacrylamide gel. It can be observed from figure 4.3 that total poly(A) tail length is 
reduced equally by cordycepin (50µM) and cordycepin with pentostatin (1 µM) at 2 
hours and the same effects were also observed at the 8 hour time point. However 
at 24 hours the total poly(A) tail size is recovered in the presence of cordycepin 
alone.  
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Figure 4.3: Effects of cordycepin on total poly (A) tail length over time in MCF-7: 
MCF-7 cells were treated with cordycepin (50µM) in absence or presence of pentostatin 
(1µM) for indicated time points. Total RNA was prepared and labelled at the 3´ end with 32P-
pCp along with other necessary components and non-polyadenylated RNA degraded which 
results in a smear presenting the total poly(A) mRNAs in the cell. The reaction products were 
analyzed by urea (7M) 15% Polyacrylamide gel electrophoresis.  A labelled RNA ladder was 
used as a marker where each size corresponds to different poly(A) tail lengths in bases. 
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4.4 Effects on cell adhesion by cordycepin in MCF-7 cells 
It was demonstrated previously in NIH3T3 cells that cells lost focal adhesions upon 
treatment with cordycepin at 50µM (Wong et al., 2010). As we had already seen 
effects of cordycepin on polyadenylation and cell proliferation we next examined 
the effects cordycepin had on cell shape. In order to study changes in cell shape in 
detail, immunohistochemistry was performed using the focal adhesion marker 
vinculin. MCF-7 cells were seeded on cover slips and were treated after 24 hours 
with cordycepin 50µM for 3 hours. As observed in figure 4.4, no changes were 
observed in focal adhesions in MCF-7 cells after treatment with cordycepin 50µM. 
 
Figure 4.4: Immunohistochemistry of MCF-7 cells treated with cordycepin: 
On coverslips MCF-7 cells were seeded the day before treatment. Next day cells were 
treated for 3 hours with cordycepin (50µM). The cells were fixed and stained with an 
antibody against vinculin (red) to detect focal adhesions. Images were taken at 63X 
magnification. 
 
4.5 Discussion 
In this chapter we have shown that like in ASM cells, gene expression of 
inflammatory mRNAs (CXCL1 and IL8) in MCF-7 cells are sensitive to cordycepin. 
However control mRNAs which are more abundant and stable (RPL10A and ACTB) 
remain unchanged. This indicates that effects on inflammatory mRNAs by 
cordycepin are not cell type specific but seem to be gene type specific. Cordycepin 
Control Cordycepin 50µM
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10µM already inhibits polyadenylation compared to 50µM which clearly indicates 
that cordycepin represses polyadenylation in MCF7 cells. Therefore it can be 
concluded that as in ASM cells, cordycepin also inhibits the gene expression of 
several inflammatory mRNAs in MCF-7 cells. TWIST1 was also found to be 
downregulated in MCF-7 cells, same as previously observed in MCF-10A cells. 
Pentostatin, an adenosine deaminases inhibitor, enhances the potency of 
cordycepin, presumably by preventing its degradation and improves its efficacy over 
time. We demonstrate that at the 2 and 8 hour time points Polyadenylation is 
equally affected by cordycepin in the absence or presence of pentostatin however     
poly(A) tail size recovers after 24 hours in the absence of pentostatin. The lack of 
recovery in the cells treated with cordycepin and pentostatin is likely to be due to 
the death of the cells by apoptosis (Richa Singhania, personal communication).  
We have previously seen effects on cell adhesion in NIH3T3 cells, but in MCF-7 cells 
no changes in focal adhesions were detected by immunohistochemistry. We did 
observe changes in cell shape under the microscope in tissue culture dishes, but 
these changes seem to have vanished when we plated the cells on glass coverslips 
to perform immunohistochemistry in detail. This might be due to the difference in 
the adhesion surface, the seeding density or the time in culture after seeding. These 
parameters may have to be re-examined in the future.  
 
5 Investigating the mechanism of action of 
cordycepin in MCF-7 
In this chapter I will examine the mode of action of cordycepin in detail in MCF-7 
cells. As observed previously, the stability of cordycepin improves when used in 
combination with pentostatin over time, however adverse effects of pentostatin 
have been reported. Other adenosine analogues which inhibit polyadenylation 
might therefore be better drugs than cordycepin. Adenosine analogues with their 
mode of action and further details were listed in table 8. However, we will have to 
determine if such compounds have similar mechanisms of action to cordycepin by 
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also examining their effects on protein synthesis, 4EBP phosphorylation and effects 
on inflammatory mRNAs and polyadenylation, which could be more stable than 
cordycepin.   
 
Table 8: Description of adenosine analogues and related compounds:  
Chemical structure, mode of action and biological effects were summarized for all examined 
adenosine (ado) analogues and related compounds (Metformin). 
Adenosine 
analogues 
Chemical Structures Biological effects Mode of action 
 
 
 
 
 
 
 
 
 
Cordycepin 
 
 
 
 
 
 
Medicinal properties of 
cordycepin range from anti-
bacterial and anti-fungal to 
anti-malarial, antivirus, anti-
harpes, anti-leukemic and anti-
diabetic (Shin et al. 2009). 
Pharmacological activities such 
as anti-metastatic, anti-oxidant 
and immunomodulatory effects 
by suppression of over 
expressed inflammation (Jeong 
et al. 2010). Antiapoptotic 
reduces cell proliferation and 
metastasis, inhibits cell 
signalling, pathways (He et al. 
2010) and have anti-tumor 
activity in colon, leukemia, 
bladder, and lung carcinoma 
cells (Yoshikawa et al. 2008).  
Lipid peroxide formation 
inhibition (Buenz et al. 2005). 
 
Premature 
termination of 
chain by inhibiting 
polyadenylation 
(Kondrashov et al; 
2012) 
 
8 Bromo ado 
 
In multiple myeloma cells, 
mantle cell lymphoma, breast 
cancer cell lines  and in primary 
CLL lymphocytes decline in ATP 
pool observed (Dennison et al. 
2009)  
Polyadenylation 
inhibitor, chain 
termination leads 
to inhibition of 
RNA synthesis 
(Chen et al. 2010) 
 
 
 
 
 
 
 
8 Chloro ado 
8 Amino ado 
 
 
 
8 Azido ado 
   C8  Ado
X=Br,Cl,NH2,N3
110 
 
 
 DRB  
or 5,6-Dichloro-
1-ɴ-D-
ribofuranosyl 
benzimidazole 
 
 
Induce DNA damage pathway 
leads to arrest at G1 phase in 
cancer cells (Turinetto et al. 
2009).  
Affects 
polyadenylation by 
reducing the 
recruitment of 
polyadenylation 
factors to RNA 
polymerase 
II(Glover-Cutter et 
al. 2008) , act as 
inhibitors of 
transcriptional 
CDK7 and CDK9 the 
kinases involves in 
phosphorylation of 
C-terminal domain 
(CTD) of RNA 
polymerase II 
(Chen et al. 2009, 
Turinetto et al. 
2009, Mapendano 
et al. 2010).  
Se13 and Se15 Unknown (gifted) May act same as DRB cdk9 inhibitor 
could interfere in 
polyadenylation 
 
 
 
Cladribine 
or 
2-Chloro- ? ?-
deoxyadenosin
e 
 
Used in hairy cell leukemia, cell 
cycle arrest and induces 
apoptosis 
Inhibits DNA 
repair, DNA 
synthesis and 
aggregation of 
DNA strand breaks 
(Robak and Robak 
2012). Interferes in 
RNA synthesis, also 
inhibits a poly(A) 
polymerase activity 
(Chen et al. 2008) 
 
 
 
 
 ? ?-Deoxy- ? ?-
(methylthio) 
ado 
 
 
 
Act as an anticancer agent 
(Christopher et al. 2002, Avila et 
al. 2004), inhibitor of cell 
proliferation (Christa et al. 
1984) 
By-product of 
polyamine 
metabolism, 5'-
methylthioadenosi
ne phosphorylase 
(MTAP) a tumor 
suppressor gene 
involved in purine 
salvage pathway. 
(Christopher et al. 
2002, Bertino et al. 
2011) 
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Metformin  
or 
1,1-Dimethylbi 
guanide 
hydrochloride 
 
Anticancer drug in animals used 
in bowel cancer, anti diabetic, 
lower the chance of cancer in 
patients suffering with type 2 
diabetics (Libby et al. 2009, 
Martin-Castillo et al. 2010, 
Loubiere et al. 2013). 
AMPK activator 
(Dowling et al. 
2007), similar 
cellular effects to 
cordycepin. 
 
If cordycepin affects cells primarily by its properties as a polyadenylation inhibitor, 
unrelated compounds that affect polyadenylation should have similar effects. We 
therefore also investigated the effect of siRNA knockdown of different PAPs on total 
poly(A) content, in cell proliferation, polyadenylation and effects on gene 
expression of inflammatory mRNAs.   
5.1 The effects of adenosine analogues on polyadenylation  
To examine which of the adenosine analogues are polyadenylation inhibitors, 
investigated the consequences of adenosine analogues on polyadenylation. MCF-7 
and NIH3T3 cells were examined for the effects of adenosine analogues on 
ƉŽůǇĂĚĞŶǇůĂƚŝŽŶďǇ ? ?ĞŶĚůĂďĞůŝŶŐ ?ĞůůƐǁĞƌĞƚƌĞĂƚĞĚǁŝƚŚ individual analogues for 
2 hours at an indicated concentration. It can be observed from figure 5.1 that 8 
amino adenosine showed reduction in length of total poly (A) tail like cordycepin in 
NIH3T3 cells which was also observed previously in ASM cells (Kondrashov et al; 
2012). As observed before, polyadenylation was readily affected by cordycepin 
(10µM and 50µM). 8 aminoadenosine also showed a reduction but to a lesser 
extent. Surprisingly, other reputed polyadenylation inhibitors such as 8-chloro 
adenosine did not affect the total poly(A) length in the cell. 
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Figure 5.1: The effects of Adenosine analogues at 50µM on total poly (A) tail length: 
Indicated cell lines were treated for 2 hours with indicated analogues at 50µM. Total RNA 
was prepared and labelled at the 3´ end with 32P-pCp along with other necessary 
components and non-polyadenylated RNA was degraded, which results in a smear which 
presents the total poly (A) in the cell. The reaction products were analyzed by urea (7M) 15% 
Polyacrylamide gel electrophoresis. Labelled RNA ladder was used as a marker where each 
size corresponds to different poly(A) tail lengths in bases. 
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5.2 Other adenosine analogues as alternative polyadenylation 
inhibitors 
We investigated the effects of the adenosine analogues on the cellular rate of 
protein synthesis and the levels of P-4EBP in MCF-7 and HELA cells. Both cell lines 
were treated with indicated adenosine analogues for 2 hours at 50µM and the rate 
of protein synthesis was determined by S
35
, while the levels of P-4EBP were 
determined by ELISA. As shown in figure 5.2. HELA cells show a decline in rate of 
protein synthesis and in levels of P-4EBP upon treatment with 8-amino adenosine, 
which has been previously shown to also inhibit polyadenylation by chain 
termination (Chen et al. 2010). The rate of protein synthesis remains insensitive 
upon treatment with 8 aminoadenosine in MCF-7 cells but shows greater sensitivity 
towards levels of P-4EBP, similar to the effects of cordycepin in these cells. 8-amino 
adenosine also behaves similarly to cordycepin in HeLa cells.  All the other 
adenosine analogues have effects that are distinct from those of cordycepin on the 
levels of P-4EBP and protein synthesis in HeLa and MCF7 cells, with some affecting 
protein synthesis in MCF 7 cells (8-azidoadenosine and Se15) and all except Se15 
not reducing P-4EBP levels in HeLa cells.Therefore 8-amino adenosine is the only 
analogue tested that is similar to cordycepin in its effects on protein synthesis and 
phosphorylation of P-4EBP in different cell lines. The validation of the ELISA method 
for measuring phospho-4EBP levels by western blotting is necessary, but this could 
not achieve due to technical reasons. 
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Figure 5.2: The effects of adenosine analogues on MCF-7 and HELA cells: 
Indicated cell lines were treated for 2 hours with indicated analogues at 50µM. A, Protein 
synthesis rates were measured by incorporation of 35S labeled amino acids into protein, 
corrected for total protein concentration and represented as a percent of incorporation of the 
control. B, Levels of P4EBP were determined by in cell ELISA for respective cell lines upon 
treatment with analogues. Levels of P-4EBP in different cell lines were corrected with total 
protein concentration. Values are expressed as percentages of the control. The data are 
shown as the means ±S.D of 4-5 technical replicates for each treatment. Unpaired T-test 
was performed to show statistical significance compared to untreated control represented as 
* for P<0.05 and ** for P<0.01.  
 
5.3 The effects of adenosine analogues on cell proliferation  
After examining the effects of adenosine analogues on protein synthesis and 
phosphorylation of P-4EBP, I investigated its effects on cell proliferation in MCF-7 
cells. MCF-7 cells were treated for 72 hours with specified compounds and at 
indicated concentrations and used for cell counting with the trypan blue dye. Cells 
numbers are represented relative to the seeding density. As shown in figure 5.3 the 
number of live cells is markedly decreased by cordycepin, 8-azidoadenosine, 
cladribine and 8-aminoadenosine, while reduction with DRB and 8-bromoadenosine 
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were also observed. The decline in number of live cells is observed to a much lesser 
extent after treatment with 8-chloroadenosine, MTA (methylthio ado) and 
Metformin. Some of the samples that were treated with the adenosine analogues 
and counted for live and dead cells, were significantly different compared to the 
untreated samples indicated as * for P<0.05 and ** for P<0.01. This experiment 
illustrates that many adenosine analogues can affect cell proliferation, but their 
mechanisms of action are likely to be diverse. Cell proliferation and survival assays 
are not very useful for elucidating the mechanism of action of a drug. 
 
Figure 5.3: The effects on MCF-7 cells by different compounds on cell proliferation: 
MCF-7 cells were treated with different compounds and adenosine analogues with indicated 
concentration for 72 hours and cell counts were done for (dead) blue and (live) white cells 
using trypan blue dye under the microscope. Results are presented as a relative number of 
cells. Error bars show standard deviations over 4-5 technical replicates. Statistical 
significance compared to untreated control was performed by unpaired T-test represented as   
* for P<0.05 and ** for P<0.01. 
 
5.4 PAP knockdown by SiRNAs 
Our data show that cordycepin is certainly a polyadenylation inhibitor in MCF7 cells, 
but its effects on protein synthesis, 4EBP phosphorylation and cell proliferation 
could conceivably be mediated by other cellular targets. It is unknown if cordycepin 
affects the polyadenylation by all PAPs, and what the roles of different PAPs in cell 
proliferation are. We therefore performed siRNA knockdown experiments. As 
shown in figure 5.4, knockdown of PAPOLA, PAPOLG and PAPD4 by siRNA 
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transfection reduced the mRNA levels for each targeted PAP. I then examined the 
effects of PAP knockdown on cell proliferation. Knockdown of PAPOLA and PAPD4 
resulted in a small decline in the number of live cells. The small effect was probably 
due to the cells reaching confluency early in the experiment, therefore in 
subsequent experiments lower numbers of cells were seeded (data not shown). 
 
 
Figure 5.4: PAP knockdown by SiRNAs: 
MCF-7 cells were transfected twice with indicated siRNAs for PAPOLA, PAPOLG and 
PAPD4 as described. mRNA isolation was done after 72 hours of the first transfection at the 
same time point. A, Levels of spliced mRNA were determined by RT-qPCR and expressed 
relative to GAPDH mRNA levels. Values for control SiRNA were set at 1. Error bars are 
standard deviations over two independent biological replicates.  
 
5.5 Combination PAP knockdowns affects cell proliferation 
As we observed the effects of individual PAPs knocked down on cell proliferation, 
we next examined the effects of combination PAP knockdown in MCF-7. Cells were 
seeded at a density of 0.075 million cells per well and transfected the next day and 
the day after as described previously and used for cell counting after 72 hours of 
the first transfection. It can be observed from figure 5.5 that the reduction in cell 
numbers is similar upon knock down of individual PAPs and this is not increased in 
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the combination of siPAPOLA with siPAPOLG. However by knocking down different 
in combinations such as siPAPOLA with siPAPD4, siPAPOLG with siPAPD4 and all 
three PAPs (siPAPOLA, siPAPOLG, siPAPD4), a much greater decline in cell numbers 
is observed. As shown in the figure, most of the samples for live cells were 
statistical significant indicated as * for P<0.05, ** for P<0.01 and *** for P<0.001. 
These data clearly indicate that all three poly(A) polymerases we examined are 
required for cell proliferation. As we saw effects on cell proliferation we next 
examined the changes in total poly (A) tail length by knocking down either of these 
PAPs. 
 
 
 
Figure 5.5: Cell proliferation is affected by combination PAP knockdowns in MCF-7 
cells: 
Cells were transfected twice in combination with indicated siPAPs for PAPOLA, PAPOLG 
and PAPD4 as described. Cell counts were done after 72 hours of first transfection by 
counting (dead) blue and (live) white cells using trypan blue dye under microscope. Results 
are presented as relative numbers of cells and measurements were independent biological 
triplicates expressed as the mean ±S.D. Statistical significance compared to control               
(No cordycepin) were determined by Paired T-test indicated as * for P<0.05, ** for P<0.01 
and   *** for P<0.001. 
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5.6 The effects of PAP knockdowns on polyadenylation  
To examine the effects on polyadenylation on the knock down of individual PAPs we 
performed another  ? ? ĞŶĚ ůĂďĞůŝŶŐ ĞǆƉĞƌŝŵĞŶƚ ? dŚĞ ĐĞůůƐ ǁĞƌĞ transfected as 
described previously followed by total RNA isolation. RNA was labeled and 
processed for degradation of non-polyadenylated RNA by RNase T1 and RNase A 
and electrophoresis on urea polyacrylamide gel. As shown in figure 5.6 the length of 
total poly(A) tail was not affected by the knocking down of any indicated PAPs. It 
indicates that bulk polyadenylation is not dependent on any of the individual PAPs 
we tested and that there is probably some redundancy in the function of different 
PAPs. 
119 
 
 
120 
 
Figure 5.6: The effects of PAP knockdowns on total poly (A) tail length in MCF-7: 
MCF-7 cells were transfected twice with indicated siPAPs for PAPOLA, PAPOLG and 
PAPD4 within 72 hours. Total RNA was prepared and labelled at the 3´ end with 32P-pCp 
along with other necessary components and non-polyadenylated RNA degraded which 
results in a smear presenting the total poly(A) in the cell. The reaction products were 
analyzed by urea (7M) 15% Polyacrylamide gel electrophoresis. Labelled RNA ladder was 
used as a marker where each size corresponds to different poly(A) tail lengths in bases.  
 
5.7 The effects of PAP knock down on the level of selected 
mRNAs 
We determined the effects on polyadenylation on gene expression of inflammatory 
and cordycepin potentially targeted mRNAs by siPAP knocked down. MCF-7 cells 
were transfected as described previously followed by total RNA isolation. RT-qPCR 
was performed on each mRNA and values were expressed relative to untreated 
(sictrl), which was set at 1. GAPDH was used as a control for normalization. 
Unexpectedly, siRNA transfection induced the inflammatory mRNAs. We found that 
this was due to the Interferin transfection reagent, as this effect occurred even in 
the absence of any siRNAs (data not shown). We therefore compared the mRNA 
levels only to the control siRNA treated samples. As shown in figure 5.7 not much 
effect was observed on CXCL1 expression, while for IL8 lower levels were observed 
in PAPD4 knockdown only. No effects were observed on expression of TWIST1 and 
ACTB mRNAs. So, in contrast to in ASM cells (Kondrashov et al; 2012), the effects of 
PAP knockdown did not mimic that of cordycepin in MCF7 cells.  
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Figure 5.7: The effects of PAP knockdown on MCF-7 cells: 
MCF-7 cells were transfected twice with indicated siPAP for PAPOLA, PAPOLG and PAPD4 
within 72 hours as described. Total RNA was isolated and RT-qPCR was performed as 
described. For a control housekeeping mRNAs Ǻ-actin (ACTB) and RPL10A were used. The 
mRNA levels are expressed relative to GAPDH mRNA and untreated values for control 
siRNA were set at 1. Error bars are standard deviations over three independent biological 
replicates. Statistical significance compared to sicontrol was determined by Paired T-test but 
none of them found to be statistically different from the sicontrol. 
 
In these experiments, knockdown of poly(A) polymerases does not appear to have 
similar cellular effects to cordycepin. It is possible that this is due to the longer 
duration of knockdown compared to drug treatment or to the redundant functions 
of the poly(A) polymerases. It may also be because the effect of cordycepin is not 
similar to the removal of an RNA polymerase, but has dominant effects through its 
stabilization of the cleavage complex. An alternative approach could be using 
dominant negative mutants of the relevant PAPs to study the effects of 
polyadenylation on levels of cordycepin sensitive genes. 
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5.8 Effects of adenosine analogues on inflammatory mRNAs 
We next evaluated the effects of adenosine analogues on levels of inflammatory 
mRNAs in MCF-7 cells.  Cells were treated with adenosine analogues at 50µM for 2 
hours followed by total RNA isolation. RT-qPCR was done on inflammatory mRNAs 
normalized to GAPDH and values for untreated were set as 1. It can be observed 
from figure 5.8 that CXCL1 is sensitive to both cordycepin 50µM and                          
8-aminoadenosine treatments. However 8 azidoadenosine also shows a small 
reduction in levels of CXCL1.  Cordycepin at both dosages, 8 aminoadenosine and 8 
azido adenosine all reduced the levels of IL8 mRNA. The RPL10A and ACTB 
housekeeping mRNAs remained unchanged. We previously observed the reduction 
in induction of inflammatory mRNAs such as CXCL1 and IL8 by cordycepin and 8 
amino adenosine treatments in ASM cells (Kondrashov et al; 2012). Therefore, it can 
be concluded that 8 amino adenosine is similar to cordycepin in its effects on 
polyadenylation, protein synthesis, 4EBP phosphorylation and gene expression in 
MCF-7 cells.  
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Figure 5.8: Adenosine analogues inhibit expression of inflammatory mRNAs in MCF-7: 
MCF-7 cells were treated with adenosine analogues (50µM) for 2 hours. Total RNA was 
isolated and RT-qPCR was performed as described. Housekeeping mRNAs encoding ȕ-
actin (ACTB) and a ribosomal protein (RPL10A) were used as a control. The mRNA levels 
are expressed relative to GAPDH mRNA and untreated control values (no cordycepin) were 
set at 1. Experiments were independent biological triplicates and data are expressed as 
means ±S.D. Statistical significance compared to control was determined by Paired T-test 
but none of the examined mRNAs were found to be sensitive. 
. 
 
5.9 Effects on cordycepin sensitive mRNAs are post-
transcriptional 
In order to examine whether cordycepin affects mRNA synthesis or stability, we 
evaluated the effects of cordycepin on nuclear and cytoplasmic fractions. Cells were 
treated for 2 hours with cordycepin followed by separation of nuclear and 
cytoplasmic fractions. RT-qPCR was done on each fraction and normalized to 
GAPDH. As shown in figure 5.9A, the levels of CXCL1, IL8 and TWIST1 mRNA were 
markedly reduced in cytoplasmic fractions by cordycepin, while less effect was 
observed in the nuclear fraction, indicating that effects of cordycepin were post-
transcriptional in MCF-7 cells. The data suggest that cordycepin induces 
degradation of sensitive mRNAs soon after they are exported from the nucleus. In 
figure 5.9 B, the levels of unspliced pre-mRNAs in nuclear RNA were determined. 
Un-CXCL1 shows a small reduction in mRNA levels, while un-IL8 remains unchanged. 
We previously demonstrated that cordycepin increases the levels of unspliced     
pre-mRNA for CXCL1 compared to CCL2, which remain unchanged. Meanwhile, 
levels of unspliced pre-mRNA of IL8 were reduced in ASM cells (Kondrashov et al; 
2012). Nascent and mature RPL10A mRNA levels were used as controls, which 
remain unchanged by cordycepin treatment. Figure 5.9 C, shows the ratio of 
unspliced over spliced RPL10A for each sample in the nuclear and cytoplasmic 
fractions, demonstrating successful fractionation. All experiments were performed 
in three independent biological replicates and statistical significance was calculated 
by a paired T test compared to untreated controls for each mRNA. 
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Figure 5.9: Nascent and mature inflammatory mRNAs affected by cordycepin: 
MCF-7 cells were treated with cordycepin (50µM) for 2 hours and nuclear and cytoplasmic 
fractions were separated as described. A, Total RNA was isolated and RT-qPCR for mature 
mRNA (spliced) was performed on nuclear and cytoplasmic fractions. The mRNA levels 
were expressed relative to GAPDH mRNA and control values of untreated (no cordycepin) 
were set at 1. Error bars represent standard deviations over independent biological 
triplicates. B, RT-qPCR for unspliced pre-mRNA was performed on the nuclear fraction. The 
mRNA levels are expressed relative to GAPDH mRNA and control values of untreated (no 
cordycepin) were set at 1. Error bars represent standard deviations over independent 
biological triplicates. C, RNA fractions were separated followed by RT-qPCR for spliced and 
unspliced RPL10A mRNA. The ratio of unspliced over spliced for each sample was divided 
by this ratio in the nuclear and cytoplasmic fraction. Error bars are standard deviations over 
independent biological triplicates. Statistical significance compared to control (No 
cordycepin) was determined by a paired T-test for A, B and C, but none of them were found 
to be statistically different from the control. 
 
 
fractions 
fractions 
A
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
un-CXCL1 un-IL8 un-RPL10A
m
R
N
A
 le
v
e
ls
 r
e
la
ti
v
e
 
to
 u
n
tr
e
a
te
d
C50
- - - - - - - - - - - - - - - - - - - - - - - - -
B
0.000
0.002
0.004
0.006
0.008
0.010
0.012
Ctrl C50 Ctrl C50
Nuclear Cytoplasm
F
o
ld
  
e
n
ri
c
h
m
e
n
t
C
125 
 
5.10  Investigation of the cordycepin sensitivity of mRNAs in 
cancer and mTOR related pathways 
It is known that cordycepin affects mTOR signaling and components of the 
upstream PI3K pathway have been reported to be subject to regulation by the 
cytoplasmic polyadenylation element binding protein (Wong et al. 2010). We 
therefore decided to investigate the mRNAs involved in mTOR signalling and other 
candidates for regulation by CPEB like TWIST1 (Nairismagi et al. 2012) in an attempt 
to identify more target mRNAs for comparison of cordycepin with other treatments 
in MCF-7 cells. Cells were treated with cordycepin 50µM for 2 hours followed by 
total RNA isolation. RT-qPCR was performed normalized to GAPDH and untreated 
values were set at 1. The key players of mTOR pathway including cancer related and 
control mRNAs were investigated as shown in figure 5.10 as separated by a space. 
None of the tested mRNAs were sensitive to cordycepin except TWIST1 and to a 
lesser extent PIK3CB mRNA. Housekeeping mRNAs ACTB and RPL10A remain 
unchanged. Experiments were done in three independent biological replicates and 
none of the examined mRNAs were found to be significantly different from the 
untreated by paired T-test. 
We also examined the cordycepin sensitivity of several mRNAs that were linked to 
the machinery of polyadenylation complexes. This was on the argument that there 
might be autoregulation, however we were unable to find any other sensitive 
mRNAs. Therefore in order to find cordycepin targeted mRNAs there is a need to 
create high throughput data in order to identify more target mRNAs of cordycepin, 
such as by microarray analysis. 
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Figure 5.10: Cordycepin does not affect expression levels of mTOR and cancer 
mRNAs: 
Total RNA was isolated from MCF-7 cells treated with cordycepin (50µM) for 2 hours. RT-
qPCR was performed and the mRNA levels were expressed relative to GAPDH mRNA. 
Control values of untreated (no cordycepin) were set at 1. Error bars represent standard 
deviations of independent biological triplicates. Statistical significance compared to control 
(No cordycepin) was determined by paired T-test but none of the examined mRNAs were 
found to be significant. 
 
5.11  Discussion 
The half life of the cordycepin is very short due to its degradation in the blood by an 
enzyme called adenosine deaminase. To counteract this effect, cordycepin is usually 
administered in combination with the adenosine deaminases inhibitor 
deoxycoformycin or pentostatin, however there is some limitation in using these 
drugs due to their toxicity. To design more stable cordycepin analogues, we first 
need to firmly establish its mechanism of action. If cordycepin works by inhibiting 
polyadenylation, which PAPs is it targeting? Therefore other adenosine analogues 
were investigated which could be stable and could have different specificity for 
individual PAPs. Like cordycepin, other adenosine analogues also show different 
activities towards various cell lines. 8 amino adenosine, 8 azido adenosine and Se15 
inhibit cellular rates of protein synthesis, perhaps by reducing the phosphorylation 
of 4EBP. In MCF-7 cells Se15 reduces the rate of protein synthesis by exerting its 
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effects on P-4EBP. In MCF-7 cells cell proliferation was found to be sensitive to 8 
aminoadenosine, 8 azidoadenosine and cladribine. Therefore, among all tested 
analogues 8 azidoadenosine may reduce cell proliferation by affecting the rate of 
protein synthesis and phosphorylation of 4EBP. 
We also evaluated the effects on cell proliferation of poly(A) polymerase (PAP) 
alpha, gamma and Papd4 knockdowns and found all PAPs are necessary for cell 
proliferation. However no significant difference has been observed by PAP knock 
downs on total polyadenylation and no changes in levels of gene expression were 
observed. However we previously published that knockdown of PAPOLA reduces 
inflammatory response in ASM cells. We also investigated of the level at which 
cordycepin affects mRNA abundance and we observed post-transcriptional effects 
on all mRNAs we examined (CXCL1, IL8 and TWIST1). To elucidate the cordycepin 
mode of action in MCF7 cells in detail we screened several mRNAs in order to find 
cordycepin sensitive mRNAs but we only found 2 mRNAs among all examined. We 
therefore proceeded to conduct a microarray in order to find more cordycepin 
targetted mRNAs. 
We therefore conclude that 8 aminoadenosine is the only compound that has 
similar cellular effects to cordycepin (protein synthesis, 4EBP level, proliferation and 
gene expression), as well as the only other compound that affects total poly(A) tail 
size. This indicates that the polyadenylation inhibition and the cellular effects are 
causally linked. Knockdown of 3 poly(A) polymerases in MCF-7 cell lines indicates 
that all are required for cell proliferation but that it does not have effects similar to 
cordycepin on gene expression. As both cordycepin and 8 aminoadenosine have 
been reported to act as chain terminators, it is possible that their effect is more due 
to a dominant negative effect mediated by an arrested complex. This would 
possibly be better mimicked by mutant PAPs, rather than by knockdown. 
Alternatively, there may be more redundancy in the PAPs in MCF7 cells, and 
multiple knockdowns should be tried. A genome wide study needs to be done to 
identify potential candidate mRNAs targeted by cordycepin. 
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6 Identifying cordycepin sensitive mRNAs in MCF7 
cells 
In this chapter we attempt to elucidate the mechanism of action of cordycepin in 
more detail by performing microarray analysis, which allows the study of the 
expression of thousand of genes simultaneously in one sample. This experiment 
was done in collaboration with Professor Anne Willis (MRC Toxicology unit, 
Leicester) on MCF-7 cells treated with cordycepin (50µM) for 2 hours in a four 
independent biological replicates. Enrichment of genes in functional groups was 
also investigated using the DAVID (Database for Annotation, Visualisation and 
Integrated Discovery). The lists of significantly expressed genes were sorted 
according to fold change and the P-value for the significance of the change. Some 
significantly changed candidates were selected for validation by RT-qPCR. We 
selected four cordycepin targeted mRNAs and examined the effects of adenosine 
analogues and PAP knockdowns. To elucidate the mode of action of cordycepin on 
these target mRNAs in detail we also investigate the stage in mRNA processing that 
is affected by cordycepin. 
6.1 Functional clustering of significant genes in microarray 
analysis 
The availability of different data analysis software makes it possible to analyze the 
data generated by high throughput genome wide screening to cluster the genes 
according to functional annotation on a wide range of criteria. Such types of tools 
are helpful in categorizing the genes in order to identify particular cellular functions 
affected by cordycepin. The list generated from microarray data analysis were 
categorized into two groups, firstly sorted according to a real fold change greater 
than 1.66 (up regulated by cordycepin) and with fold change less than 0.66 (down 
regulated by cordycepin), as calculated by Agilent software. Both these groups were 
filtered to only include P< 0.01 as shown in table 9 and table 10.   
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Table 9: List of significantly up regulated genes: 
'DWD RI PLFURDUUD\ DQDO\VLV ZHUH VRUWHG RQ WKH EDVLV RI IROG FKDQJH )& ޓ .66) with            
P-values (P< 0.01). 
Gene P.Value RealFC Gene P.Value RealFC 
LOC100652740 0.000 12.820 XLOC_008698 0.010 2.347 
LOC646719 0.001 6.306 CHRNA10 0.008 2.347 
LOC100507018 0.007 5.869 ENST00000450112 0.008 2.342 
FAM90A7 0.000 5.575 GLB1L 0.002 2.337 
AK025118 0.001 5.476 PTPRK 0.008 2.337 
MGC11082 0.001 4.904 C16orf55 0.003 2.304 
LRRC66 0.000 4.861 ENST00000535853 0.004 2.301 
FAM83E 0.002 4.734 XLOC_000377 0.004 2.294 
LOC100506262 0.000 4.667 SART1 0.006 2.273 
ZNF865 0.001 4.658 LOC340335 0.007 2.271 
A_33_P3223860 0.001 4.578 CRTC1 0.003 2.256 
ARPC4-TTLL3 0.000 4.490 THC2565581 0.005 2.252 
KIAA1875 0.003 4.463 FHL2 0.008 2.244 
PRPF40A 0.001 4.447 LOC100128563 0.007 2.243 
DENR 0.003 4.441 ARL9 0.002 2.240 
TMED6 0.002 4.310 APOE 0.004 2.235 
LOC100132006 0.000 4.184 ENST00000518331 0.007 2.217 
CDRT1 0.001 4.115 XLOC_l2_001091 0.005 2.206 
XLOC_014513 0.007 4.115 LOC100147773 0.008 2.204 
FOXD4 0.005 4.074 CENPN 0.009 2.202 
XLOC_000153 0.003 3.944 FOXP1-IT1 0.006 2.192 
XLOC_000152 0.000 3.936 LOC100132356 0.006 2.189 
KCNJ14 0.001 3.921 HCG18 0.008 2.174 
AMY1C 0.005 3.910 PNPLA7 0.004 2.166 
THC2767054 0.004 3.857 TAL2 0.004 2.136 
DQ272581 0.002 3.854 PRRT2 0.004 2.122 
ENST00000326348 0.002 3.818 XLOC_008828 0.003 2.122 
C1orf162 0.002 3.736 RASL10A 0.003 2.118 
FBXW10 0.003 3.733 A_33_P3381305 0.010 2.107 
A_24_P203814 0.001 3.663 LOC285178 0.008 2.088 
XLOC_003522 0.003 3.642 SPRED3 0.003 2.087 
C20orf106 0.002 3.634 MCART1 0.007 2.083 
FAM90A1 0.001 3.630 THC2725851 0.003 2.079 
FLJ38717 0.001 3.573 LOC100130285 0.003 2.077 
PP12719 0.002 3.517 XLOC_l2_013873 0.007 2.077 
FES 0.001 3.516 XLOC_l2_015213 0.008 2.065 
XLOC_007942 0.001 3.475 LOC100499221 0.005 2.058 
SCARNA15 0.006 3.432 FLJ31662 0.008 2.057 
ENST00000355500 0.003 3.396 LOC100131825 0.005 2.055 
P39195 0.002 3.369 AK074630 0.004 2.054 
XLOC_l2_008221 0.005 3.321 C21orf58 0.006 2.046 
XLOC_002517 0.003 3.310 FLJ42627 0.006 2.039 
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XLOC_l2_013873 0.004 3.278 ZNF445 0.006 2.019 
LOC96610 0.001 3.276 TAS2R30 0.010 2.006 
AOC3 0.001 3.247 FLJ32224 0.010 1.988 
XLOC_004924 0.001 3.199 LOC644450 0.006 1.987 
XLOC_005244 0.010 3.193 AY129018 0.006 1.974 
RBM26-AS1 0.003 3.180 LOC143286 0.005 1.971 
XLOC_l2_013001 0.003 3.107 LOC100132356 0.005 1.967 
XLOC_012895 0.009 3.048 FAT3 0.005 1.964 
XLOC_012667 0.001 3.042 CARD9 0.006 1.963 
THC2539584 0.003 3.029 LOC100130000 0.009 1.963 
ALPK3 0.004 3.024 XLOC_014226 0.006 1.957 
XLOC_l2_010558 0.001 2.983 PIGL 0.009 1.954 
XLOC_001788 0.002 2.954 XLOC_012359 0.005 1.952 
XLOC_l2_009273 0.004 2.886 XLOC_l2_013846 0.010 1.942 
XLOC_l2_010558 0.003 2.878 ZSCAN12P1 0.008 1.935 
XLOC_004231 0.010 2.860 AK022609 0.007 1.935 
LOC100131792 0.006 2.849 XLOC_l2_011043 0.007 1.933 
LOC100216546 0.005 2.824 LOC203274 0.005 1.923 
KIAA1683 0.002 2.823 ENST00000411845 0.008 1.917 
LOC283693 0.003 2.822 WNK4 0.007 1.916 
MASP2 0.001 2.813 GALK1 0.008 1.914 
XLOC_009507 0.007 2.804 SNORD35B 0.007 1.906 
DNAJC30 0.009 2.786 PCDHGA2 0.009 1.902 
LOC100130887 0.001 2.759 CYTH1 0.008 1.902 
LOC100507410 0.010 2.756 P39194 0.009 1.877 
LOC145757 0.002 2.737 A_33_P3280502 0.007 1.869 
XLOC_l2_009273 0.001 2.735 LOC100505717 0.006 1.858 
LOC399900 0.003 2.723 LOC728537 0.008 1.857 
A_24_P170095 0.002 2.708 LOC100505648 0.010 1.855 
XLOC_002313 0.006 2.686 ENST00000439955 0.010 1.854 
HPS1 0.007 2.671 AF264629 0.008 1.854 
ENST00000378337 0.001 2.667 MACROD2 0.008 1.844 
HOXB9 0.006 2.627 FLJ37453 0.008 1.842 
XLOC_l2_012847 0.007 2.624 LOC100128811 0.008 1.841 
LEPROTL1 0.001 2.622 WDR78 0.007 1.837 
LOC100289230 0.009 2.621 LAG3 0.008 1.832 
XLOC_002996 0.001 2.603 LOC401320 0.008 1.827 
LOC100507501 0.004 2.599 SLC25A16 0.008 1.800 
DQ786257 0.002 2.595 FRMD4A 0.008 1.790 
XLOC_001942 0.005 2.571 LOC645261 0.010 1.782 
THC2674845 0.010 2.565 ENST00000367690 0.009 1.780 
XLOC_003405 0.002 2.559 C17orf76-AS1 0.009 1.780 
PAFAH1B2 0.004 2.558 TTC9C 0.009 1.778 
XLOC_002997 0.005 2.556 ENST00000354995 0.010 1.748 
KLRAP1 0.010 2.555 AK131313 0.010 1.746 
XLOC_002779 0.010 2.547 LOC338799 0.009 1.741 
FLJ45482 0.002 2.545 LOC100129387 0.010 1.733 
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BLZF1 0.009 2.542 ENST00000354995 0.010 1.748 
ZADH2 0.006 2.499    
XLOC_006973 0.002 2.477    
FLJ11710 0.006 2.473    
AVIL 0.003 2.469    
ENST00000535190 0.010 2.469    
XLOC_011248 0.005 2.448    
XLOC_011837 0.003 2.441    
ERVMER34-1 0.002 2.427    
THC2569478 0.004 2.415    
LOC100132352 0.004 2.393    
XLOC_l2_015038 0.002 2.373    
XLOC_l2_006578 0.010 2.358    
LOC338620 0.009 2.349    
 
Table 10: List of significantly down regulated genes: 
Data of microarray analysis were sorted on the basis of fold change (FC < 0.66) with values 
(P< 0.01). 
Gene P.Value RealFC Gene P.Value RealFC 
SNAR-A3 0.000 0.069 SPATA2L 0.002 0.412 
CYR61 0.001 0.077 MIR143HG 0.007 0.413 
SNAR-D 0.001 0.084 SNHG7 0.002 0.413 
SNAR-B2 0.001 0.084 HERPUD1 0.003 0.414 
SNAR-H 0.001 0.088 C7orf74 0.002 0.414 
SNAR-G2 0.001 0.095 GRPEL2 0.003 0.415 
CHAC1 0.000 0.098 SPSB1 0.005 0.416 
PLK3 0.000 0.108 NFKBIA 0.010 0.417 
VTRNA1-3 0.007 0.112 JUNB 0.003 0.417 
SNAR-F 0.001 0.115 ZNF283 0.006 0.417 
NAB2 0.001 0.117 PLEKHO2 0.007 0.419 
MYC 0.000 0.131 ZNF263 0.008 0.421 
TIPARP 0.001 0.133 ZNF8 0.004 0.421 
C15orf39 0.000 0.144 FOXL2 0.004 0.423 
PPP1R3C 0.007 0.170 EGR1 0.003 0.424 
MIRLET7BHG 0.001 0.178 GEM 0.009 0.424 
CITED2 0.001 0.191 SIK1 0.004 0.425 
SNAR-G1 0.001 0.192 STK40 0.004 0.428 
ID1 0.003 0.192 RNF216P1 0.004 0.429 
ERRFI1 0.002 0.194 SNORA70 0.010 0.431 
SERTAD1 0.001 0.195 FOXA1 0.004 0.432 
SLC25A25 0.002 0.196 C15orf42 0.003 0.434 
SGK1 0.001 0.197 MALAT1 0.007 0.434 
DUSP2 0.001 0.198 ZNF668 0.002 0.436 
ZNF134 0.009 0.204 CXCR4 0.010 0.437 
ADM 0.002 0.205 AEN 0.009 0.437 
ADRB2 0.002 0.207 HJURP 0.007 0.438 
TGIF1 0.001 0.210 C6orf145 0.007 0.438 
DDIT4 0.003 0.213 GPATCH3 0.002 0.438 
DLX2 0.003 0.213 NXT1 0.005 0.439 
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ARID5B 0.005 0.214 SNORA70E 0.009 0.439 
OBFC2A 0.000 0.217 ZNF165 0.009 0.440 
CTGF 0.005 0.217 RAPGEF2 0.002 0.441 
ID3 0.002 0.220 SNORA70G 0.008 0.442 
RND3 0.001 0.220 ZBTB45 0.003 0.442 
C3orf19 0.004 0.224 CYP1A1 0.004 0.443 
TRIB1 0.002 0.228 EFNA1 0.006 0.443 
WEE1 0.002 0.228 C8orf4 0.009 0.444 
MED9 0.004 0.229 ZNF629 0.002 0.444 
ATF3 0.002 0.237 PELO 0.004 0.446 
HILPDA 0.001 0.238 ZNF689 0.004 0.447 
DOK7 0.002 0.241 IL11 0.006 0.448 
DUSP1 0.001 0.243 SEMA4C 0.007 0.449 
CDC42EP2 0.001 0.246 PPRC1 0.003 0.449 
KCNK5 0.004 0.246 XKR8 0.007 0.450 
MAP3K14 0.001 0.246 SLC38A2 0.003 0.451 
KLHL21 0.001 0.247 CDR2 0.003 0.451 
SESN2 0.002 0.249 XLOC_006513 0.003 0.452 
ZBTB3 0.001 0.250 LRRC14 0.002 0.453 
PHF13 0.005 0.253 SCARNA9 0.009 0.454 
CSRNP1 0.001 0.257 ZNF646 0.004 0.454 
FOSL1 0.001 0.265 ATF3 0.005 0.460 
LIF 0.002 0.266 MID1IP1 0.007 0.460 
TGIF1 0.007 0.266 PLEKHG3 0.006 0.461 
LCMT2 0.002 0.267 RUSC2 0.004 0.461 
JUN 0.001 0.269 ZNF317 0.005 0.462 
BRF2 0.003 0.271 ZNF584 0.003 0.462 
DNAJB9 0.006 0.271 ZNF628 0.003 0.463 
F3 0.002 0.271 TICAM1 0.007 0.463 
MAD2L1BP 0.001 0.273 RPP38 0.006 0.464 
IER3 0.002 0.273 PHF23 0.003 0.465 
EIF1AD 0.001 0.275 SNORA70C 0.010 0.466 
IER3 0.001 0.277 NUAK1 0.004 0.466 
KTI12 0.010 0.278 PHF23 0.004 0.466 
FAM46A 0.005 0.278 FAM125B 0.008 0.466 
SOCS3 0.002 0.278 ND2 0.004 0.466 
AMOTL2 0.010 0.279 ZNF511 0.008 0.466 
FBXW7 0.003 0.279 NFIL3 0.007 0.467 
CLCF1 0.001 0.281 PLEKHF1 0.006 0.468 
RUNX1 0.002 0.282 ARMC7 0.004 0.469 
ZNF830 0.005 0.282 ZNF394 0.010 0.472 
DDX28 0.001 0.284 MIRLET7BHG 0.008 0.474 
NUAK2 0.003 0.284 EPHA2 0.008 0.475 
ITPRIP 0.001 0.287 NR4A3 0.009 0.475 
SNORA61 0.005 0.289 ZBTB5 0.008 0.475 
IER5 0.001 0.290 C5orf30 0.007 0.479 
PLK2 0.001 0.291 TLE4 0.003 0.479 
HPS6 0.003 0.293 KLF6 0.006 0.481 
PLAGL2 0.001 0.295 ZBED5 0.007 0.481 
ABL2 0.001 0.295 CSTF1 0.008 0.484 
TRIM13 0.004 0.300 BRD2 0.010 0.487 
C17orf51 0.002 0.300 DYRK1A 0.010 0.488 
KLHL25 0.001 0.305 ZNF394 0.010 0.488 
RHEBL1 0.004 0.306 RG9MTD1 0.007 0.488 
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PPP1R15A 0.001 0.307 FAM46A 0.005 0.489 
ZFP36 0.002 0.307 BTG1 0.010 0.490 
RHOB 0.007 0.311 AEN 0.010 0.490 
ZNF48 0.002 0.312 SIAH1 0.007 0.492 
BCAR3 0.001 0.313 NRG1 0.006 0.493 
CSRNP1 0.002 0.317 PILRB 0.005 0.493 
PPM1D 0.009 0.318 ZNF7 0.007 0.495 
TOB2 0.007 0.320 SIAH2 0.007 0.495 
BCDIN3D 0.003 0.321 PFKFB3 0.007 0.495 
KLF5 0.006 0.322 C18orf21 0.005 0.496 
C17orf51 0.001 0.322 C19orf48 0.006 0.497 
KLHL26 0.007 0.323 MLL5 0.010 0.497 
SNHG12 0.002 0.324 ETAA1 0.008 0.499 
TUFT1 0.009 0.325 ARL4A 0.005 0.500 
HBEGF 0.002 0.329 FAM83G 0.005 0.503 
C17orf51 0.001 0.332 PPP1R3B 0.005 0.506 
RELT 0.001 0.336 PABPC4L 0.007 0.506 
BAMBI 0.004 0.337 TRIM27 0.005 0.507 
FRAT2 0.007 0.339 POLR1C 0.005 0.509 
FOXQ1 0.002 0.342 FZD5 0.009 0.509 
E2F6 0.003 0.343 KIAA1826 0.005 0.510 
ING1 0.001 0.344 FBXO34 0.010 0.511 
C17orf51 0.001 0.344 FBXL5 0.008 0.511 
LDLR 0.002 0.348 MEX3C 0.008 0.512 
TIGD5 0.001 0.350 AIFM2 0.005 0.512 
TBCC 0.002 0.351 CDT1 0.007 0.513 
CBX8 0.003 0.352 SNX11 0.007 0.514 
ST3GAL1 0.002 0.352 ZKSCAN2 0.005 0.515 
ZNF574 0.002 0.353 PHLPP2 0.006 0.516 
SERTAD2 0.002 0.358 SNORD79 0.009 0.516 
MIER3 0.003 0.359 MYNN 0.005 0.516 
IER2 0.004 0.359 PGBD3 0.007 0.518 
PIM3 0.002 0.360 RASSF1 0.006 0.519 
C3orf52 0.001 0.361 ZNF581 0.009 0.520 
PLD6 0.002 0.361 GET4 0.008 0.520 
PTGER4 0.007 0.362 USP42 0.007 0.520 
ZNF134 0.001 0.363 HSF2 0.010 0.521 
SNAI1 0.003 0.364 GLIS2 0.010 0.521 
SPRY2 0.005 0.364 ZNF189 0.005 0.521 
TRIM11 0.004 0.367 CD86 0.008 0.521 
PPP1R15B 0.004 0.370 RARA 0.007 0.522 
CHAMP1 0.007 0.370 SMYD4 0.006 0.527 
RPUSD2 0.005 0.371 ADAT3 0.006 0.527 
MESDC1 0.002 0.371 MAFG 0.007 0.528 
MAFF 0.004 0.372 DHX35 0.009 0.530 
ZNF784 0.002 0.372 IL6 0.008 0.531 
SMAD6 0.001 0.374 NEDD9 0.009 0.532 
DDX20 0.002 0.375 INSIG1 0.009 0.533 
SPSB1 0.009 0.377 ZBTB43 0.007 0.536 
FUT1 0.009 0.377 DCP1A 0.006 0.536 
FOXC1 0.003 0.382 CYTB 0.006 0.536 
CENPBD1 0.002 0.384 PRR15L 0.007 0.540 
DLX1 0.005 0.387 C9orf156 0.008 0.540 
MIER2 0.003 0.388 USP35 0.008 0.540 
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ZNF555 0.002 0.389 BLOC1S3 0.006 0.540 
ZNF200 0.002 0.390 CBX2 0.008 0.544 
ZNF613 0.007 0.393 ABL1 0.008 0.545 
C8orf58 0.002 0.393 THAP3 0.007 0.545 
GATA6 0.004 0.395 ZNF503 0.010 0.546 
CDC25A 0.002 0.398 ZNF107 0.008 0.551 
SH3RF1 0.002 0.399 MEIS1 0.009 0.554 
PF4 0.006 0.400 MED13L 0.008 0.558 
C7orf40 0.003 0.401 SUZ12P 0.010 0.558 
YRDC 0.004 0.401 SH3BP4 0.009 0.559 
RPP38 0.002 0.402 C7orf49 0.010 0.559 
PLEKHF2 0.010 0.402 MID1 0.009 0.559 
CEBPB 0.006 0.403 GTF3C4 0.010 0.559 
CRY2 0.006 0.404 A_33_P3317460 0.009 0.560 
FADD 0.004 0.405 SETD1A 0.009 0.561 
RNF19A 0.004 0.405 USP36 0.010 0.562 
RLF 0.006 0.406 RSBN1L 0.008 0.563 
ZFP36L1 0.010 0.407 AMD1 0.009 0.566 
EPC2 0.003 0.407 TRAF2 0.008 0.568 
IRS2 0.002 0.408 SHB 0.009 0.569 
ZNF562 0.007 0.409 ZNF433 0.009 0.570 
SMAD7 0.002 0.410 CCNJL 0.009 0.571 
C1orf135 0.004 0.410 FAM110A 0.009 0.574 
   MKL1 0.010 0.586 
 
Functional clustering of significant genes was performed by the web-available 
program DAVID (Database for Annotation, Visualisation and Integrated Discovery) 
that clusters the genes into different categories such as tissue expression and 
function, according to the Gene-Ontology (GO) annotations (Dennis et al. 2003). 
As seen in the table 11 functional clustering of down regulated mRNAs was 
performed using the DAVID gene ontology software. Among all 289 significantly 
down regulated mRNAs 97 were found to be involved in regulation of transcription. 
In addition, significant enrichment was demonstrated for ontology terms linked to   
apoptosis, cell proliferation, cell cycle, cell migration and angiogenesis. The 97 
genes identified as being enriched in regulation of transcription included JUNB, 
MED9, MED13L, EGR1 and interleukin IL6. A transcription factor involved in cell 
migration, SNAI1, was absent from this category, which reflects defects in the 
annotation of genes in the ontology. We next validate the selected significantly 
expressed genes in the microarray by RT-qPCR. 
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Table 11: Functional clustering of 289 significantly down regulated genes:  
Significantly downregulated genes were functionally clustered by microarray analysis in 
breast cancer cell line MCF-7 treated with cordycepin and identified using DAVID gene 
ontology analysis. Out of 289 downregulated genes 97 were found to be involved in 
transcriptional regulation followed by roles in cell proliferation and in cell migration (Done by 
MSc project student:  Mangangcha Irengbam).  
 
 
 
6.2 Validation of selected candidates of microarray analysis 
The use of P values in microarray analysis is a difficult subject. Because so many 
measurements are made, often a corrected P value is calculated, which allows more 
stringent testing. However, in the experience of our collaborators at the MRC 
toxicology unit in Leicester, this often excludes real changes. We therefore decided 
to estimate the false discovery rate experimentally. We performed qPCR on 
selected candidates that were predicted to be downregulated or unchanged from 
the microarray analysis. One upregulated mRNA (CD68) was included, as listed in 
table 12. The mRNA levels were expressed relative to GAPDH mRNA. In total 33 
selected candidates from the microarray analysis proceeded for validation via RT-
qPCR of which 6 show a discrepancy (shown in yellow) between RT-qPCR and 
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microarray analysis as seen in figure 6.1A and B. The rest of the validated mRNAs 
are shown in blue. All the bars of mRNAs below the red dotted line were 
downregulated by cordycepin as shown in bar graph figure 6.1 A. In figure 6.1 B, the 
scatter plot represents 2logFC qPCR and 2logFC microarray values on x axis and y 
axis respectively. The co-efficient of determination (R
2
)
 
was calculated which 
measures the percentage of the data closest to the regression line. The R
2 
value of 
0.29 indicates that 29% of data variance in y can be explicated through linear 
relationship between y and X while 71% of variance in y remains undetermined. 
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Table 12: List of selected validated mRNAs:  
Fold change from RT-qPCR and fold change with P value from microarray data were shown 
for selected validated mRNAs. Standard deviation of the microarray data was calculated 
from the confidence interval (CI.025) by using POWER (2, (logFC-CI.025)).  The table was 
categorized into downregulated (in pink), unchanged (in blue) and upregulated (in green). 
 
mRNAs 
qPCR Microarray analysis 
Fold change Std. Dev Fold change P value 
WEE1 0.60 0.09 0.228 0.002 
MED9 2.00 0.60 0.229 0.004 
LIF 0.40 0.30 0.266 0.002 
c-Jun 0.98 0.47 0.269 0.001 
FBXW7 0.60 0.20 0.279 0.003 
PLK2 0.76 0.66 0.291 0.001 
ZFP36 0.43 0.06 0.307 0.002 
SNAI1 0.50 0.20 0.364 0.003 
ZFP36L1 0.40 0.20 0.407 0.010 
IRS2 1.25 0.64 0.408 0.002 
NFKBIA 0.80 0.30 0.417 0.010 
JUNB 0.30 0.20 0.417 0.003 
EGR1 0.60 0.40 0.424 0.003 
CSTF1 1.11 0.20 0.484 0.008 
CNOT4 0.50 0.20 0.484 0.012 
BTG1 1.16 0.45 0.490 0.010 
IL6 0.80 0.10 0.531 0.008 
NEK6 1.00 0.30 0.547 0.019 
MCL1 0.60 0.20 0.547 0.019 
MED13L 0.70 0.10 0.558 0.008 
MED26 0.60 0.30 0.570 0.019 
ATF4 0.70 0.20 0.665 0.027 
DCP1A 0.79 0.26 0.837 0.270 
AKT2 1.02 0.94 0.885 0.506 
RPL10A 1.74 0.60 0.982 0.887 
TP53 0.80 0.20 1.081 0.613 
SUN1 1.00 0.50 1.123 0.602 
TFPI 0.90 0.30 1.150 0.319 
CTSL1 1.60 0.90 1.182 0.252 
GNAI3 1.10 0.50 1.276 0.160 
CATSPER2 2.29 1.26 1.348 0.070 
CPE 1.30 1.00 1.526 0.033 
CD68 2.30 0.80 1.810 0.021 
 
Our data indicate that our method of analysis suggests that around 20% of mRNAs 
are differently classified in qPCR and microarray data. This is, when the P value cut-
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off is relaxed to 0.02 for the downregulated mRNAs and a fold change of 0.66 is 
considered biologically relevant, while for upregulated mRNAs a fold change of 1.66 
is used as a cut off. In fact, most of the discrepant mRNAs have low P values and a 
higher fold change.  This apparent error rate is probably a combination of false 
discovery due to the large number of mRNAs tested and cases in which the qPCR 
and the microarray are not detecting the same mRNA, e.g. due to alternative 
splicing. Among all validated mRNAs four of the most cordycepin sensitive mRNAs 
(WEE1, MCL1, JUNB and SNAI1) were selected to examine its effects on PAP 
knockdown, adenosine analogues and stage on mRNA processing. 
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Figure 6.1: Validation of candidates from microarray analysis: 
mRNAs were selected from microarray analysis on the basis of their real fold change and P 
values and proceed for validation via RT-qPCR. Total RNA was isolated from MCF-7 cells 
treated with cordycepin (50µM) for 2 hours. RT-qPCR was performed and the mRNA levels 
expressed relative to GAPDH mRNA. Among 33 tested mRNAs, 6 mRNAs shows 
discrepancy between RT-qPCR and microarray data represents in yellow bar while 
remaining 27 mRNAs in blue are validated. Control values of untreated (no cordycepin) were 
set at 1. Validation was performed on the same independent biological triplicates used for 
microarray analysis. A, Error bars show standard deviation over independent biological 
triplicates. Statistical significance compared to untreated (No cordycepin) were determined 
by paired T-test but none of them found to be statistically different from the untreated. B, 
Scatter plot showing 2logFCqPCR and 2logFCMicroarray on x axis and y axis respectively. 
Co efficient of determination R2   was calculated as 0.2916. 
 
6.3 The effect of adenosine analogues on four cordycepin 
targeted mRNAs  
We next examined the effects of adenosine analogues on four of the cordycepin 
target mRNAs validated by RT-qPCR. MCF-7 cells were treated for 2 hours with 
indicated adenosine analogues at 50µM or as indicated, followed by total RNA 
isolation. RT-qPCR was performed and normalized to GAPDH. Similar effects were 
observed by cordycepin 50µM on all examined mRNAs except JUNB as shown in 
figure 6.2 for which greater sensitivity was observed. 8 aminoadenosine affects 
these mRNAs in a very similar manner to cordycepin. However 8 azidoadenosine 
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affected MCL1 only. Changes in levels of MCL1 were found to be statistically 
significant in the cordycepin and 8-azidoadenosine samples. For JUNB, cordycepin 
and 8 amino adenosine were found have statistically significant effects compared to 
untreated as shown in the figure 6.2. 
It can be concluded that effects of adenosine analogues are also gene specific. 
Among all the mRNAs, JUNB is most affected by the polyadenylation inhibitors 
cordycepin and 8-aminoadenosine. Again, 8-aminoadenosine acts similarly to 
cordycepin. 
 
 
Figure 6.2: Effects of adenosine analogues treatment on selected mRNAs from 
microarray analysis: 
Cordycepin treated most-sensitive mRNAs were selected from microarray analysis after 
validation via RT-qPCR. MCF-7 cells were treated with adenosine analogues (50µM) or as 
indicated for 2 hours. Total RNA was isolated and RT-qPCR was performed as described. 
The mRNA levels expressed are relative to GAPDH mRNA and control values of untreated 
(no cordycepin) were set at 1. Measurements were independent biological triplicates and 
data are expressed as means ±S.D. Statistical significance compared to untreated (No 
cordycepin) were determined by paired T-test but none of them were found to be statistically 
different from the untreated. 
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6.4 The effects of PAP knockdowns on four cordycepin targeted 
mRNAs 
In order to investigate if specific PAPs are necessary for the expression of 
cordycepin target mRNAs we examined the effects on respective mRNAs by knock 
down experiments in MCF-7 cells. Cells were transfected twice, as described 
previously, and undergo total RNA isolation. RT-qPCR was performed and 
normalized to GAPDH. The untreated (sicontrol) control value is set as 1. It can be 
observed from figure 6.3 that none of the mRNAs were significantly affected by PAP 
knockdown.  
 
 
Figure 6.3: Effects of PAP knockdowns on selected mRNAs from microarray analysis: 
Cordycepin targeted mRNAs were selected from microarray analysis after validation via RT-
qPCR. MCF-7 cells were transfected twice with indicated siPAP for PAPOLA, PAPOLG and 
PAPD4 within 72 hours. Total RNA was isolated from MCF-7 and RT-qPCR was performed 
as described. The mRNA levels expressed relative to GAPDH mRNA and values for control 
siRNA were set at 1. Error bars shows standard deviations over independent biological 
triplicates. Statistical significance compared to sicontrol were determined by paired T-test but 
none of them found to be statistically different from the sicontrol. 
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6.5 Combination PAP knockdowns does not affect JUNB mRNA 
expression 
We next examined the effects of the combination PAP knockdowns on JUNB, 
because the combination knockdown was found to have a stronger effect on mRNA 
levels in the previous cordycepin and 8-aminoadenosine analogues sensitivity 
experiments. The MCF-7 cells were transfected with different combination of 
siRNAs against PAPs. As shown in figure 6.4A, knocked down reduced the levels of 
the corresponding PAP mRNAs. As can be seen in figure 6.4B, JUNB mRNA remains 
insensitive in the knock down experiments. It can be concluded that JunB 
expression is not dependent on these three PAPs and there is either redundancy 
with other PAPs or the residual expression of these PAPs after knockdown is 
sufficient for mRNA synthesis.  
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Figure 6.4: The effect of combination PAP knockdowns on JUNB expression: 
MCF-7 cells were transfected twice in combination with indicated SiPAP for PAPOLA, 
PAPOLG and PAPD4 as described. mRNA isolation was done after 72 hours of first 
transfection and RT-qPCR for JUNB was performed as described. The mRNA levels 
expressed relative to GAPDH mRNA and values for control siRNA were set at 1. Error bar 
shows standard deviations over independent biological triplicates. A, knockdown qPCR was 
performed for siPAPOLA, siPAPLOG and siPAPD4 with relevant PAP primer. Statistical 
significance compared to sicontrol was determined by Paired T-test indicated as ** for 
P<0.01. B, qPCR for JUNB was performed on combination PAP knockdown samples. 
Statistical significance compared to sicontrol was determined by Paired T-test but none of 
the treatments caused a change in JUNB mRNA levels. 
 
6.6 Post transcriptional effects of cordycepin on its target mRNAs 
In order to examine at which stage of mRNA processing the effects of cordycepin 
occur, we next investigated the effect of cordycepin on mRNA level changes in 
cytoplasmic and nuclear fractions. As shown in figure 6.5 the mRNA levels in the 
cytoplasmic fraction were markedly reduced upon cordycepin treatment compared 
to the nuclear fraction. This indicates that cordycepin has a post-transcriptional 
effect on all four examined cordycepin target mRNAs.  
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Figure 6.5: Post transcriptional effects of cordycepin: 
Cordycepin treated sensitive mRNAs were selected from microarray analysis after validation 
via RT-qPCR. MCF-7 cells were treated with cordycepin (50µM) for 2 hours and nuclear and 
cytoplasmic fractions were separated as described. Total RNA was isolated followed by RT-
qPCR for spliced mRNA. Four selected mRNAs were inhibited by cordycepin while RPL10A 
is insensitive. The mRNA levels are expressed relative to GAPDH mRNA and control values 
of untreated (no cordycepin) were set at 1. Error bars are standard deviations over 
independent biological triplicates. Statistical significance compared to untreated (No 
cordycepin) were determined by paired T-test but none of them found to be statistically 
different from the untreated.   
 
6.7 Discussion 
In this chapter we performed a genome wide study of gene profiling or microarray 
analysis in order to screen cordycepin sensitive mRNAs. From microarray analysis 
289 significantly downregulated genes by cordycepin has been found, which cluster 
on a functional basis, determined by the web based gene ontology software DAVID. 
The statistical relevance of clustered gene associations was determined by DAVID, 
which uses a modified version of the Fischer Exact test in order to investigate the 
enrichment of grouped genes in comparison to the total number of genes assigned 
to that particular group in the human genome. From the DAVID gene ontology 
analysis it can be observed that out of 289, 97 mRNAs were involved in the 
regulation of transcription. In addition, there is an enrichment of genes with crucial 
role in regulation of cell proliferation, apoptosis, cell cycle, angiogenesis and 
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migration. These data indicate that cordycepin induces a reprogramming of cancer 
cells in order to induce cell death or differentiation.  
We also found some genes involved in growth signalling and the small G-protein 
RHEBL1 (Ras homolog enriched in brain like 1 c), which is involved in promoting 
signal transduction via mTOR pathway (Tee et al. 2005). There are couple of 
significantly downregulated validated genes as found in figure 6.1 (A) which were 
not listed by DAVID such as SNAI1 (transcriptional repressor by downregulatig the 
expression of ectodermal genes within the mesoderm), MCL1 (a member of Bcnl-2 
anti-apoptotic protein), FBXW7 (involves in phosphorylation-dependent 
ubiquitination) and CNOT4 (transcriptional regulator). This indicates that the 
annotation in the gene ontology database is inadequate. We proceeded to validate 
mRNAs from the microarray analysis via RT-qPCR and found among 33 examined 
mRNAs only 6 showed a discrepancy between RT-qPCR and microarray analysis. 
Among all examined adenosine analogues, only 8-aminoadenosine acts similarly to 
cordycepin by affecting all cordycepin target mRNAs, especially JUNB. However a 
PAP knockdown does not show any effects on the examined cordycepin target 
mRNAs. All four target mRNAs were post transcriptionally affected by cordycepin. It 
might be useful to investigate RHEBL1, as its downregulation by cordycepin might 
explain the effects of cordycepin on mTOR signalling. 
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7 Discussion and Conclusion 
The main objective of this study is to characterize the effect of cordycepin on 
cellular proliferation, translation and gene expression. For this purpose several 
types of experiments were performed ranging from radioactive assays for the 
determination of rate of the protein synthesis and estimation of changes in total 
poly(A) tail length, to gene expression profiling. Several tested cell lines showed 
differences in their responses to cordycepin, but cordycepin inhibits cell 
proliferation in all cell lines as indicated in section 3. The variation in the cordycepin 
sensitivity of various cell lines may be due to differences in proliferation rates or in 
the levels of adenosine deaminase produced by the cells or present in the serum 
added to their media. The effects of cordycepin on protein synthesis and the levels 
of phosphorylated 4-EBP do not correlate with its effects on cell proliferation. The 
rate of cellular protein synthesis in cordycepin treated cells probably declines due 
to changes in translation initiation factors (Clemens 2004). 
It has been observed previously in NIH3T3 cells that cordycepin down regulates the 
mTOR kinase pathway and up regulates AMP activated kinase (Wong et al. 2010). 
The effect of cordycepin was attributed primarily to the dephosphorylation of 4EBP. 
Through effects on mTORC2, cordycepin affected the activation of the protein 
kinase Akt, which is required for cell survival, adhesion and proliferation (Wong et 
al. 2010). Over expression or upregulation of AKT is involved in many cancers and 
the PI3K pathway in general is often upregulated in a variety of malignancies. 
Indeed, the MCF7 breast cancer cell line used in this study has an activating 
mutation in a PI3K subunit (Wu et al. 2005, Liang et al. 2006) (COSMIC database). 
Therefore, there is a lot of interest in adenosine related drugs such as ATP 
competitive inhibitors for PI3K/AKT pathway or CDK inhibitors involved in targeting 
cell cycle kinases (Lindsley et al. 2008, Galons et al. 2010, Lindsley 2010).  Because 
ATP is required in many biological functions it might be possible that these drugs 
have multiple targets and some unknown targets result in toxicity of these drugs. 
Cordycepin, as a known inhibitor of the mTORC pathways, was therefore thought to 
be a good candidate for a novel type of cancer drug. Similarly, as a close adenosine 
analogue, cordycepin could interfere in a myriad of cellular processes, which 
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require adenosine or its nucleotides (Lee et al. 2012). However, a possible 
explanation is that in most situations, cordycepin triphosphate is either not 
recognized as a substrate by the relevant enzymes or that it is used in place of 
normal ATP as it contains the phosphate groups which could contribute normally to 
for instance, phosphorylation reactions. The cell type specific effects on protein 
synthesis and signal transduction indicate that not all effects of cordycepin are the 
same for all cell types. However, since all cell lines tested are inhibited in growth 
and show effects on polyadenylation, it is possible that the primary effects of 
cordycepin are more gene specific than cell type specific. One possibility is that 
cordycepin primarily affects rapidly transcribed genes, for instance because they 
need efficient transcription termination. As not all cell types transcribe the same 
genes, the effects would naturally be variable. This possibility is currently being 
tested in the De Moor laboratory. My work confirms that cordycepin affects the 
expression of specific mRNAs, including IL8, CXCL1, TWIST1 and the mRNAs 
identified in the microarray, which include JUNB, SNAI1, WEE1 and MCL1. The 
functional analysis does indeed indicate that the inhibited mRNAs are linked to cell 
proliferation, survival and migration. In addition, the high number of transcription 
factors shows that cordycepin is likely to cause secondary changes in gene 
expression in the longer term. 
Due to rapid clearance of cordycepin from the medium exposure is usually quite 
brief. Thus it has been administered with another potential drug such as 
pentostatin, an adenosine deaminase inhibitor, to increase its efficacy over longer 
time points (Tsai et al. 2010). An interesting observation detected in the present 
study is that a minimal dose of cordycepin and pentostatin together, increases its 
effectiveness by successfully stabilizing cordycepin over longer time points. This   
reduces the rate of protein synthesis and increases anti-proliferative activity. Thus 
degradation of cordycepin is also a factor in tissue culture experiments. Therefore 
pentostatin serves as a stabilising agent especially at longer time points. Indeed, 
pentostatin and another purine related analogue, cladribine, has been used in B-
chronic lymphocytic leukemia (Kay et al. 2007). My work indicates that lower doses 
of pentostatin may still be effective. 
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Consistent with the previously published data in ASM cells (Kondrashov et al; 2012) 
8-aminoadenosine affects polyadenylation in NIH3T3 to greater extent compared to 
MCF-7 cells. From section 5 it has been seen that in HELA 8-aminoadenosine effects 
similar to cordycepin by inhibiting the rate of protein synthesis through a decline in 
levels of P-4EBP. In MCF-7 cells it also acts similar to cordycepin by inhibiting the 
rate of protein synthesis, polyadenylation and cell proliferation. In most cases,         
8-aminoadenosine also affects gene expression in the same way as cordycepin. This 
is remarkable, since despite having their modifications in completely different parts 
of the adenosine moiety, both cordycepin and 8-aminoadenosine cause chain 
termination of polyadenylation (Zarkower and Wickens 1987, Chen et al. 2010), 
rather than inhibiting polyadenylation in any other way. This appears to indicate 
that the arrest of the cleavage complex on prematurely terminated poly(A) tails 
may play a large role in the mechanism of action of cordycepin. 
Like cordycepin, 8-aminoadenosine has been reported to mediate inhibition of the 
PI3K/AKT/mTOR and MAPK signaling pathway by decreasing the levels of p-AKT 
(Ghias et al. 2005), P-4EBP and p-ERK1/2 respectively (Dennison et al. 2010). It may 
also lead to inhibition of RNA transcription (Frey and Gandhi 2010). 8-amino 
adenosine has been shown to induce autophagic cell death (Shanmugam et al. 
2009) induce apoptosis and inhibits cell proliferation in MCF-7 cells (wild type p53) 
and T47-D cells (mutant p53) and estrogen receptor negative MDA-MB-231 or 
MDA-MB-468 (mutant p53) breast cancer cell lines (Polotskaia et al. 2012). 
Previously it has been shown that 8-aminoadenosine is highly cytotoxic to myeloma 
cancerous cells compared to normal lymphocytes (Krett et al. 2004, Dennison et al. 
2010). These data show that others also find that cordycepin and 8-amino 
adenosine are compounds with similar potentially therapeutic properties. 
In MCF-7 cells, cell proliferation is affected by 8-azidoadenosine and cladribine 
while DRB and 8-bromoadenosine affect cell proliferation to a lesser extent.  It 
could be interesting to explore other cell proliferation and cell cycle assays to 
elucidate the mode of action of these analogues, as they all appear to act 
differently. Among the examined adenosine analogues cladribine is known to 
interfere with DNA synthesis and RNA transcription while Metformin is an AMPK 
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activator used in type II diabetes and has been reported to have similar cellular 
effects to cordycepin (Zakikhani et al. 2008, Martin-Castillo et al. 2010).  DRB does 
not affect translation or the levels of P-4EBP in NIH3T3 cells (Fig 5.2), despite 
affecting polyadenylation (data not shown). DRB is known to affect polyadenylation 
by reducing the recruitment of polyadenylation factors to RNA polymerase II 
(Glover-Cutter et al. 2008). Like DRB, Se13 and Se15 are novel, highly specific CDK9 
inhibitors, but they do not inhibit polyadenylation. It indicates the possibility that 
different cdk-like kinases are involved in this process. A likely candidate is CKD12, 
which is sensitive to DRB, but perhaps not to Se13 and Se15. CDK12 was recently 
ƐŚŽǁŶƚŽďĞƚŚĞŵĂũŽƌZEƉŽů//ŬŝŶĂƐĞŝŶǀŽůǀĞĚŝŶ ? ?ŵZEƉƌŽĐĞƐƐŝŶŐ ?ĂǀŝĚƐŽŶ
et al., 2014).  
I observed that all three PAPs I examined are necessary for cell proliferation while 
knocking down of these PAPs does not affect the bulk polyadenylation in MCF-7 
cells. In airway smooth muscle cells, knockdown of PAPOLA affects the induction of 
inflammatory mRNAs (Kondrashov et al. 2012), but we did not observe effects of 
PAP knockdown on steady state mRNA levels for any of the cordycepin sensitive 
mRNAs.  The sensitivity of inflammatory mRNAs (CXCL1 and IL8) in MCF-7 cells to    
8-aminoadenosine and cordycepin was as reported previously in ASM cells 
(Kondrashov et al. 2012). 
In contrast to the observations in airway smooth muscle cells, where some 
cordycepin sensitive mRNAs were affected post-transcriptionally and others at the 
transcriptional level (Kondrashov et al., 2012), all cordycepin sensitive mRNAs that I 
examined in MCF7 cells were affected primarily at the post-transcriptional level. 
This is a strong indication that the effect of cordycepin on these genes is through its 
effect on polyadenylation, rather than on signal transduction, which would be 
expected to act primarily by affecting transcription. Given that so many 
transcription factor mRNAs are affected by cordycepin, one could expect secondary 
effects on transcription to follow soon.  
The microarray analysis discussed in section 6 provides wider a platform for the 
screening of cordycepin sensitive mRNAs in MCF-7 cells. Functional clustering of 
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down regulated mRNAs by DAVID gene ontology software reveals a high percentage 
of gene involvement in transcriptional regulation and apoptosis followed by cell 
proliferation, cell cycle and cell migration to angiogenesis. This implies the possible 
role of cordycepin in the attenuation of ERK signaling pathway in two ways. Firstly 
as the majority of downstream targets regulated by the ERK pathway are mostly 
affected by cordycepin such as transcription regulators (JunB, EGR1, MED13L, 
MED26, ZFP36, SNAI1, ZFP36L1, NFKBIA, FBXW7), cell proliferation regulators (LIF, 
ATF3, TOB2, MYC), cell cycle regulators (WEE1, DUSP1, PLK2), cell migration 
regulators (IL6) and regulators of angiogenesis (RUNX1). Secondly, AMPK activation 
has been previously reported upon cordycepin treatment (Wong et al. 2010), which 
leads to downregulation of BRAF through phoshorylation and inhibition of the ERK 
signaling cascade (Shen et al. 2013). It would therefore be important to examine the 
effect of cordycepin on the ERK signaling cascade in MCF7 cells. The fact that all 
cordycepin sensitive mRNAs (WEE1, MCL1, JUNB, SNAI1, IL8, CXCL1) are not 
affected by PAP knockdown, despite the post-transcriptional effect indicates that 
cordycepin does perhaps not work by inactivating poly(A) polymerases, but that the 
arrest of the cleavage complex may be the crucial mechanism.  It will be important 
to investigate the formation of the cleavage complex in vivo and to develop 
methods for arresting it independent of chain termination, for instance by the 
expression of inactivated poly(A) polymerases.  
Interestingly, the cytoplasmic polyadenylation factor CPEB4 has been shown to 
promote malignant transformation through inducing the EMT by positively 
regulating mesenchymal markers (such as SNAI1) (Xu and Liu 2013). By examining 
some other important mRNAs, such as RHEBL1 found in microarray analysis, will be 
useful in order to clarify the effects of cordycepin on the mTOR pathway. Our 
microarray analysis strongly indicates the potential of cordycepin as an anticancer 
drug as it has direct effects on key mRNAs involved in regulating cell proliferation, 
migration and survival. 
Proposed future work includes investigation of the effect on cell cycle specific 
stages of cordycepin and PAP knockdown using FACS analysis and transfection with 
mutant PAPs. Also, to investigate if the effect of cordycepin on Akt phosphorylation 
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is the major cause of its anti-proliferative effect, it will be useful to investigate if 
expression of a constitutively active Akt mutant mediates cordycepin resistance of 
signal transduction and cell proliferation. It will be necessary to investigate the 
effects of PAP knockdown and overexpression on signal transduction to test the 
hypothesis that the inhibition of polyadenylation is causing the effects of 
cordycepin on signal transduction. Polysome profiling of the effects of cordycepin 
on mRNA translation (Bushell et al. 2006) or poly(A) fractionation (Meijer et al. 
2007) may identify mRNAs with shortened poly(A) tails that are not reduced in 
abundance, but in translational efficiency. 
Taken together, my data indicate that cordycepin is a potential lead 
chemotherapeutic agent for the treatment of breast cancers and the main pathway 
is likely to be through effects on polyadenylation. This study provides some new 
insights into the mechanism of action of cordycepin, which will provide better 
understanding by enhancing the knowledge of the control of gene regulation of 
breast cancer cells, with consequences for the development of different cordycepin 
derivatives for breast cancer therapies. 
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